

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 20, 2005, 00:10:37 ; Search time 168 Seconds
(without alignments)
1258.861 Million cell updates/sec

Title: US-10-649-852-32

Perfect score: 2229

Sequence: 1 MDSTIFEIIDEFANGSLL.....SIPTSPTRISPHSIKQTAHV 413

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt 03:*

1: uniprot_sprot:*

2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2229	100.0	413	1	CRF2_XENLA
2	2051	92.0	411	2	Q68V60
3	1963.5	88.1	412	2	Q7ZZZ2
4	1904.5	85.4	414	2	Q8AWA1
5	1807	81.1	405	2	Q98UC1
6	1804	80.9	411	1	CRF2_HUMAN
7	1796.5	80.6	410	2	Q8WML9
8	1793	80.4	411	1	CRF2_RAT
9	1792	80.4	437	2	Q8WML8
10	1770.5	79.4	431	1	CRF2_MOUSE
11	1582.5	71.0	428	2	Q98UC0
12	1592	71.0	420	1	CRF1_CHICK
13	1578.5	70.8	445	2	Q98UC2
14	1566	70.3	415	2	Q76LL8
15	1564.5	70.2	415	1	CRF1_XENLA
16	1564.5	70.2	415	2	Q8K3R2
17	1561.5	70.1	434	2	Q7T3S9
18	1559.5	70.0	430	2	Q8AWA2
19	1559	69.9	415	2	Q8WMM0
20	1556.5	69.8	415	1	CRF1_MOUSE
21	1553	69.7	415	2	Q9BGU4
22	1551.5	69.6	415	1	CRF1_RAT
23	1541.5	69.2	444	1	CRF1_HUMAN
24	1541.5	69.2	447	2	Q8NG71
25	1539.5	69.1	416	2	Q8YV61
26	1523	68.3	415	1	CRF1_SHEEP
27	1409.5	63.2	329	2	Q70JV6
28	950	42.6	277	2	Q8BJD9
29	753	33.8	154	2	Q7TSA2
30	721.5	32.4	504	2	Q9V716
31	716.5	32.1	388	2	Q9V6C7

32	705	31.6	441	1	DIHR_ACHDO
33	704	31.6	188	2	Q7TSA1
34	649	29.1	465	2	Q7Q773
35	641.5	28.8	641	2	Q65AS2
36	636.5	28.6	631	2	Q65AS3
37	619.5	27.8	350	2	Q8MLL1
38	606	27.2	585	1	PTRR_DIDMA
39	597	26.8	585	1	PTRR_PIG
40	596	26.7	516	1	CALR_CAVPO
41	595.5	26.7	478	1	CALR_MOUSE
42	593	26.6	515	1	Q924D7
43	593	26.6	532	2	DIHR_MANSE
44	592.5	26.6	395	1	DIHR_MANSE
45	592.5	26.6	478	2	Q924D5

ALIGNMENTS

RESULT 1

CRF2_XENLA

ID CRF2_XENLA STANDARD; PRT; 413 AA.

AC O42603;

DT 15-JUL-1998 (Rel. 36, Last sequence update)

DT 15-JUL-1998 (Rel. 36, Last sequence update)

DT 25-OCT-2004 (Rel. 45, Last annotation update)

DE Corticotropin releasing factor receptor 2 precursor (CRF-R 2) (CRF2)

DE (Corticotropin-releasing hormone receptor 2) (CRH-R 2).

GN Name=CRF2;

OS Xenopus laevis (African clawed frog).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae;

OC Xenopodinae; Xenopus.

OX NCBI_TaxID=8355;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Brain, and Heart;

RX MEDLINE=97465573; PubMed=9326293;

RA Dautzenberg F.M., Dietrich K., Palchaudhuri M.R., Spiess J.;

RT "Identification of two corticotropin-releasing factor receptors from

RT Xenopus laevis with high ligand selectivity: unusual pharmacology of

RT the type 1 receptor."

RL J. Neurochem. 69:1640-1649(1997).

CC -!- FUNCTION: This is a receptor for corticotropin releasing factor.

CC Shows high-affinity binding for urotensin I. The activity of this

CC receptor is mediated by G proteins which activate adenylyl cyclase

CC (By similarity).

CC -!- SUBCELLULAR LOCATION: Integral membrane protein.

CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See http://www.isb-sib.ch/announce/

CC or send an email to license@isb-sib.ch).

CC EMBL; Y14037; CAA74364.1; -

CC InterPro; IPR000832; GPCR_secretin.

CC InterPro; IPR001879; hormn_receptor.

DR Pfam; PF00002; 7tm_2; 1.

DR Pfam; PF02793; HRM; 1.

DR PRINTS; PR00249; GPCRSECRETIN.

DR SMART; SM00008; Hormk; 1.

DR PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.

DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.

DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_3; 1.

DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_4; 1.

DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_5; 1.

DR G-protein coupled receptor; Glycoprotein; Signal; Transmembrane.

FT SIGNAL 1 ?

FT CHAIN ? 413

FT Corticotropin releasing factor receptor

FT 2.

Q16983 acheta dome
Q7tsal mesocricetu
Q7q773 anopheles g
Q65ae2 nilaparvata
Q65ae3 nilaparvata
Q8ml11 drosophila
P25107 didelphis m
P50133 sus scrofa
P32214 rattus norv
Q08893 cavia porce
Q60755 mus musculu
Q924d7 mus musculu
P35464 manduca sex
Q924d5 mus musculu

```
FT DOMAIN ? 120 Extracellular (Potential).
FT TRANSMEM 121 141 1 (Potential).
FT DOMAIN 142 150 Cytoplasmic (Potential).
FT TRANSMEM 151 170 2 (Potential).
FT DOMAIN 171 187 Extracellular (Potential).
FT TRANSMEM 188 211 3 (Potential).
FT DOMAIN 212 225 Cytoplasmic (Potential).
FT TRANSMEM 226 247 4 (Potential).
FT DOMAIN 248 266 Extracellular (Potential).
FT TRANSMEM 267 289 5 (Potential).
FT DOMAIN 290 312 Cytoplasmic (Potential).
FT TRANSMEM 313 332 6 (Potential).
FT DOMAIN 333 347 Extracellular (Potential).
FT TRANSMEM 348 367 7 (Potential).
FT DOMAIN 368 413 Cytoplasmic (Potential).
FT CARBOHYD 16 16 N-linked (GlcNAc. .) (Potential).
FT CARBOHYD 77 77 N-linked (GlcNAc. .) (Potential).
FT CARBOHYD 89 89 N-linked (GlcNAc. .) (Potential).
FT CARBOHYD 97 97 N-linked (GlcNAc. .) (Potential).
SQ SEQUENCE 413 AA; 48458 MW; DAD422F0A96C4626 CRC64;

Query Match 100.0%; Score 2229; DB 1; Length 413;
Best Local Similarity 100.0%; Pred. No. 1e-157;
Matches 413; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MDSTIFEIIDEFDANCSLLDAFQDSFLHSESSFFGFEQPGYCSATIDQIGTCWPRSLAG 60
Db 1 MDSTIFEIIDEFDANCSLLDAFQDSFLHSESSFFGFEQPGYCSATIDQIGTCWPRSLAG 60

Qy 61 ELVERPCDPSFNGIRYNTTRNVYRECENGFWASWNNYSQCVPLDNKRKYALHYKIALI 120
Db 61 ELVERPCDPSFNGIRYNTTRNVYRECENGFWASWNNYSQCVPLDNKRKYALHYKIALI 120

Qy 121 INYLGHCSISILALVIAFLFLCLRSIRCLRNIIHWNLIITFFILRNIMWFLQMDHNIHE 180
Db 121 INYLGHCSISILALVIAFLFLCLRSIRCLRNIIHWNLIITFFILRNIMWFLQMDHNIHE 180

Qy 181 SNEWCRCITTIYNYFVVTNFFWVVEGCVLHTAI VMTYSTDKLRKWVFLFICWCIPSP 240
Db 181 SNEWCRCITTIYNYFVVTNFFWVVEGCVLHTAI VMTYSTDKLRKWVFLFICWCIPSP 240

Qy 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVNI VRLMTKLRAST 300
Db 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVNI VRLMTKLRAST 300

Qy 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSFGQFFVSFV 360
Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSFGQFFVSFV 360

Qy 361 YCFLNGEVRSAARKRHWQDHHSLRVRVARAMS IPTSPTRISFHSIKQTA AV 413
Db 361 YCFLNGEVRSAARKRHWQDHHSLRVRVARAMS IPTSPTRISFHSIKQTA AV 413
```

```
RESULT 2
Q68Y60 PRELIMINARY; PRT; 411 AA.
AC Q68Y60;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Corticotropin releasing factor receptor type 2.
GN Name=CRFR-2;
OS Rana catesbeiana (Bull frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.
OX NCBI_TaxID=8400;
RN [1]
RP SEQUENCE FROM N.A.
RA Ito Y., Ogata D., Hasunuma I., Kikuyama S.;
RT "molecular cloning of two corticotropin releasing factor receptors
from bullfrog.";
RL Submitted (AUG-2004) to the EMBL/GenBank/DBJ databases.
```

```
DR EMBL; AB188111; BAD36784.1; -.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR003053; CRF2_receptor.
DR InterPro; IPR003051; CRF_receptor.
DR InterPro; IPR000832; GPCR_secretin.
DR InterPro; IPR001879; hormn_receptor.
DR Pfam; PF00002; 7tm_2; 1.
DR Pfam; PF02793; HRM; 1.
DR PRINTS; PR01279; CRFRECEPTOR.
DR PRINTS; PR01281; CRFRECEPTOR2.
DR PRINTS; PR00249; GPCRSECRETIN.
DR SMART; SM00008; Hormr; 1.
DR PROSITE; PS00649; G_PROTEIN_RECP_F2_1; 1.
DR PROSITE; PS00650; G_PROTEIN_RECP_F2_2; 1.
DR PROSITE; PS00227; G_PROTEIN_RECP_F2_3; 1.
DR PROSITE; PS00261; G_PROTEIN_RECP_F2_4; 1.
KW Receptor.
SQ SEQUENCE 411 AA; 48152 MW; 96D64ED8A24C179B CRC64;

Query Match 92.0%; Score 2051; DB 2; Length 411;
Best Local Similarity 92.3%; Pred. No. 1.8e-144;
Matches 381; Conservative 15; Mismatches 15; Indels 2; Gaps 2;

Qy 1 MDSTIFEIIDEFDANCSLLDAFQDSFLHSESSFFGFEQPGYCSATIDQIGTCWPRSLAG 60
Db 1 MESTIFEIIDEFDANCSLLDAFQDSFL-TINHTFLPFDGPHCIATIDQIGTCWPRSIAG 59

Qy 61 ELVERPCDPSFNGIRYNTTRNVYRECENGFWASWNNYSQCVPLDNKRKYALHYKIALI 120
Db 60 ELVERPCDPSFNGIKYNTTTRAVRECENGFWASWNNYSQCVPLD-KRKHDLYKIALI 118

Qy 121 INYLGHCSISILALVIAFLFLCLRSIRCLRNIIHWNLIITFFILRNIMWFLQMDHNIHE 180
Db 119 INYLGHCSISILALVIAFLFLCLRSIRCLRNIIHWNLIITFFILRNIMWFLQMDHNIHE 178

Qy 181 SNEWCRCITTIYNYFVVTNFFWVVEGCVLHTAI VMTYSTDKLRKWVFLFICWCIPSP 240
Db 179 KNEIWCRCITTIYNYFVVTNFFWVVEGCVLHTAI VMTYSTDKLRKWVFLFICWCIPCP 238

Qy 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVNI VRLMTKLRAST 300
Db 239 IIAWAIGKLYENECQWIGKEPGKYIDYIYQGPVILVLLINFLVNI VRLMTKLRAST 298

Qy 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSFGQFFVSFV 360
Db 299 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSFGQFFVSFV 358

Qy 361 YCFLNGEVRSAARKRHWQDHHSLRVRVARAMS IPTSPTRISFHSIKQTA AV 413
Db 359 YCFLNGEVRSAARKRHWQDHHSLRVRVARAMS IPTSPTRISFHSIKQTA AV 411

RESULT 3
Q7ZZZ2 PRELIMINARY; PRT; 412 AA.
ID Q7ZZZ2
AC Q7ZZZ2
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Putative corticotropin-releasing hormone receptor type 2.
GN Name=CRH-R2;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Cerebellum;
RX PubMed=12970166; DOI=10.1210/en.2003-0526;
RA De Groef B., Goris N., Arkens L., Kuhn E.R., Darras V.M.;
RT "Corticotropin-releasing hormone (CRH)-induced thyrotropin release is
directly mediated through CRH receptor type 2 on thyrotropes.";
```

Endocrinology 144:5537-5544 (2003).
 DR EMBL; AJ557031; CAD89534.2; -.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0004930; F:G-protein coupled receptor activity; IEA.
 DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro; IPR000832; GPCR_secretin.
 DR InterPro; IPR001879; hormn_receptor.
 DR Pfam; PF00002; 7tm_2; 1.
 DR Pfam; PF02793; HRM; 1.
 DR PRINTS; PRO0249; GPCRSECRETIN.
 DR SMART; SM00008; GPCRSECRETIN.
 DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
 DR PROSITE; PS0227; G_PROTEIN_RECEP_F2_3; 1.
 DR PROSITE; PS0261; G_PROTEIN_RECEP_F2_4; 1.
 KW Receptor.
 SQ SEQUENCE 412 AA; 48095 MW; 641B269460EC4041 CRC64;

Query Match 88.1%; Score 1963.5; DB 2; Length 412;
 Best Local Similarity 87.7%; Pred. No. 5.7e-138;
 Matches 362; Conservative 22; Mismatches 28; Indels 1; Gaps 1;
 QY 1 MDSTFEIILDFDANCSLLDAFQSFHSESSFFGEGPYCSATIDQIGTCWPRSLAG 60
 DB 1 MDVTISQFLEEDANRSLLD-LQETVLESFSISFLGFHGLYCNATTDQIGTCWPRASAG 59
 QY 61 ELVERPCDPSFNGIRYNTTRNVYRCFENGTCWASWNYSCVPILDNRKRYALHYKIALI 120
 DB 60 KLUVERPCPEFFNGIKNTTKNAYRCLNGTGWASKINISQCEPILDNRKRYALHYKIALI 119
 QY 121 INYLGHICISILAVIAFLFLCLRSIRCLRNIIHWNLTFTFLRNIMWFLQMDHNHIE 180
 DB 120 INYLGHICISVGLIIVAFMLFLCLRSIRCLRNIIHWNLTFTFLRNVMWFLQMDHNHIE 179
 QY 181 SNEVWCRCITTYINFTVNTFFWVFGCYLHTAIWMTYSTDKLRKWFVFLGWCIPSP 240
 DB 180 SNEVWCRCITTYINFTVNTFFWVFGCYLHTAIWMTYSTDKLRKWFVFLGWCIPCP 239
 QY 241 IYVTAICKLFYNEQCWIGKEPGKYIDYIQGRVILVLLINFLVFNIRILMTKLRAS 300
 DB 240 IYVTAICKLFYNEQCWIGKEPGKYIDYIQGRVILVLLINFLVFNIRILMTKLRAS 299
 QY 301 TSETIQYRKAVKATLVLLPLLGITMYLFFVNPGEDDVSQIVFIYFNSFLQSQGFVSVF 360
 DB 300 TSETIQYRKAVKATLVLLPLLGITMYLFFVNPGEDDISQIVFIYFNSFLQSQGFVSVF 359
 QY 361 YCFLNGEVSAAKRWQDHHSLRVVRVARAMSPTSPTRISFHSIKQTAAV 413
 DB 360 YCFLNGEVSAAKRWQDHHSLRVVRVARAMSPTSPTRISFHSIKQTAAV 412

RESULT 4

Q8AWA1 PRELIMINARY; PRT; 414 AA.
 AC Q8AWA1;
 DT 01-MAR-2003 (TrEMBLrel. 23, Created)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
 DE Corticotropin-releasing factor receptor type 2.
 GN Name=crfr2;
 OS Oncorhynchus keta (Chum salmon).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
 OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
 OX NCBI_TaxID=8018;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Heart;
 RA Pohl S., Darlison M.G., Lederis K., Richter D.;
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AJ277158; CAC81754.1; -.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0004930; F:G-protein coupled receptor activity; IEA.
 DR GO; GO:0004872; F:receptor activity; IEA.

InterPro; IPR003053; CRF2_receptor.
 DR InterPro; IPR003051; CRF_receptor.
 DR InterPro; IPR000832; GPCR_secretin.
 DR InterPro; IPR001879; hormn_receptor.
 DR Pfam; PF00002; 7tm_2; 1.
 DR Pfam; PF02793; HRM; 1.
 DR PRINTS; PRO1279; CRPRECEPTOR.
 DR PRINTS; PRO1281; CRPRECEPTOR2.
 DR PRINTS; PRO0249; GPCRSECRETIN.
 DR SMART; SM00008; Hormr; 1.
 DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
 DR PROSITE; PS0227; G_PROTEIN_RECEP_F2_3; 1.
 DR PROSITE; PS0261; G_PROTEIN_RECEP_F2_4; 1.
 KW Receptor.
 SQ SEQUENCE 414 AA; 48329 MW; 11FB2E9E4481CCC2 CRC64;

Query Match 85.4%; Score 1904.5; DB 2; Length 414;
 Best Local Similarity 83.8%; Pred. No. 1.4e-133;
 Matches 347; Conservative 30; Mismatches 36; Indels 1; Gaps 1;
 QY 1 MDSTFEIILDFDANCSLLDAFQSFHSESSFFGEGPYCSATIDQIGTCWPRSLA 59
 DB 1 MDATYQIIFGEGDPNCSVMSFQDSFYENASFSLMDFDGLYCNATTDQIGTCWPKSNT 60
 QY 60 GELVERPCDPSFNGIRYNTTRNVYRCFENGTCWASWNYSCVPILDNRKRYALHYKIAL 119
 DB 61 GRWVERPCPEYINGVKYNTTRSAVRECINDNGTALKSNYSCEPILEEKRYPMHYKIAL 120
 QY 120 IINYLGHICISILAVIAFLFLCLRSIRCLRNIIHWNLTFTFLRNIMWFLQMDHNH 179
 DB 121 IINYLGHICISVGLIIVAFMLFLCLRSIRCLRNIIHWNLTFTFLRNVMWFLQMDHNH 180
 QY 180 ESNEVWCRCITTYINFTVNTFFWVFGCYLHTAIWMTYSTDKLRKWFVFLGWCIPSP 239
 DB 181 ESNEVWCRCITTYINFTVNTFFWVFGCYLHTAIWMTYSTDKLRKWFVFLGWCIPCP 240
 QY 240 IYVTAICKLFYNEQCWIGKEPGKYIDYIQGRVILVLLINFLVFNIRILMTKLRAS 299
 DB 241 IYVTAICKLFYNEQCWIGKEPGKYIDYIQGRVILVLLINFLVFNIRILMTKLRAS 300
 QY 300 TSETIQYRKAVKATLVLLPLLGITMYLFFVNPGEDDVSQIVFIYFNSFLQSQGFVSVF 359
 DB 301 TSETIQYRKAVKATLVLLPLLGITMYLFFVNPGEDDISQIVFIYFNSFLQSQGFVSVF 360
 QY 360 YCFLNGEVSAAKRWQDHHSLRVVRVARAMSPTSPTRISFHSIKQTAAV 413
 DB 361 YCFLNGEVSAAKRWQDHHSLRVVRVARAMSPTSPTRISFHSIKQTAAV 414

RESULT 5

Q98UC1 PRELIMINARY; PRT; 405 AA.
 ID Q98UC1
 AC Q98UC1;
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
 DE Corticotropin-releasing factor receptor 2.
 OS Ameiurus nebulosus.
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Siluriformes;
 OC Ictaluridae; Ameiurus.
 OX NCBI_TaxID=27778;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21066341; PubMed=11145609; DOI=10.1210/en.142.1.446;
 RA Arai M., Arai I.O., Abou-Samra A.B.;
 RT "Characterization of three corticotropin-releasing factor receptors in
 RT catfish: a novel third receptor is predominantly expressed in
 RT pituitary and urophysis".
 RL Endocrinology 142:446-454(2001).
 DR EMBL; AF229360; AAK01069.1; -.
 DR GO; GO:0016020; C:membrane; IEA.
 DR GO; GO:0004930; F:G-protein coupled receptor activity; IEA.

356 VFYCFNCEVRSALRKRWHRQDHSLSRVPVARAMSIPTSPTRISFHSIKQTAHV 410

Db

RESULT 8

CRF2 RAT

ID CRF2 RAT STANDARD; PRT; 411 AA.

AC P47866;

DT 01-FEB-1996 (Rel. 33, Created)

DT 01-FEB-1996 (Rel. 33, Last sequence update)

DT 25-OCT-2004 (Rel. 45, Last annotation update)

DE Corticotropin releasing factor receptor 2 precursor (CRF-R 2) (CRF2)

DE (Corticotropin-releasing hormone receptor 2) (CRH-R 2).

GN Name=Crhr2; Synonyms=Crfr2;

OS Rattus norvegicus (Rat).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.

OX NCBI_TaxID=10116;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=Sprague-Dawley; TISSUE=Hypothalamus, and Lung;

RX MEDLINE=95148632; PubMed=7846062;

RA Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., de Souza E.B., Oltersdorf T.;

RA "Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain.";

RT Proc. Natl. Acad. Sci. U.S.A. 92:836-840(1995).

RL [2]

RN ERATUM.

RP Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., de Souza E.B., Oltersdorf T.;

RA Proc. Natl. Acad. Sci. U.S.A. 92:5759-5759(1995).

RL

CC -!- FUNCTION: This is a receptor for corticotropin releasing factor. Shows high-affinity CRF binding. Also binds to urocortin I, II and III. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.

CC -!- SUBCELLULAR LOCATION: Integral membrane protein.

CC -!- ALTERNATIVE PRODUCTS:

CC Event=Alternative splicing; Named isoforms=2;

CC Name=CRF2-alpha;

CC IsoId=P47866-1; Sequence=Displayed;

CC Note=Major isoform;

CC Name=CRF2-beta;

CC IsoId=P47866-2; Sequence=VSP 002001;

CC -!- TISSUE SPECIFICITY: Predominantly expressed in limbic regions of the brain such as the lateral septum, the entorhinal cortex, the hypothalamic ventromedial nucleus and several amygdaloid nuclei. Also detectable in lung, kidney and heart.

CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC -----

DR EMBL; U16253; AAC52159.1; -.

DR PIR; A55610; A55610.

DR RGD; 70547; Crhr2.

DR InterPro; IPR000832; GPCR_secretin.

DR InterPro; IPR001879; hormn_receptor.

DR Pfam; PF00002; 7tm_2; 1.

DR Pfam; PF02793; HRM; 1.

DR SMART; SM00249; GPCRSECRETIN.

DR SMART; SM00008; Hormr; 1.

DR PROSITE; PS00649; G_PROTEIN_RCEP_F2_1; 1.

DR PROSITE; PS00650; G_PROTEIN_RCEP_F2_2; 1.

DR PROSITE; PS02227; G_PROTEIN_RCEP_F2_3; 1.

DR PROSITE; PS02613; G_PROTEIN_RCEP_F2_4; 1.

DR Alternative splicing; G-PROTEIN coupled receptor; Glycoprotein; Signal; Transmembrane.

KW SIGNAL 1 17 Potential.

FT

PT CHAIN 18 411 Corticotropin releasing factor receptor 2.

FT DOMAIN 18 118 Extracellular (Potential).

FT TRANSMEM 119 139 1 (Potential).

FT DOMAIN 140 148 Cytoplasmic (Potential).

FT TRANSMEM 149 168 2 (Potential).

FT DOMAIN 169 185 Extracellular (Potential).

FT TRANSMEM 186 209 3 (Potential).

FT DOMAIN 210 223 Cytoplasmic (Potential).

FT TRANSMEM 224 245 4 (Potential).

FT DOMAIN 246 264 Extracellular (Potential).

FT TRANSMEM 265 287 5 (Potential).

FT DOMAIN 288 310 Cytoplasmic (Potential).

FT TRANSMEM 311 330 6 (Potential).

FT DOMAIN 331 345 Extracellular (Potential).

FT TRANSMEM 346 365 7 (Potential).

FT DOMAIN 366 411 N-linked (GLNAC. . .) (Potential).

FT CARBOHYD 41 41 N-linked (GLNAC. . .) (Potential).

FT CARBOHYD 74 74 N-linked (GLNAC. . .) (Potential).

FT CARBOHYD 86 86 N-linked (GLNAC. . .) (Potential).

FT CARBOHYD 94 94 N-linked (GLNAC. . .) (Potential).

FT VARSPLIC 1 34 MDALLSLLEAHCSLALAEELLDDGCEPDPFE -> MGH PGSLSAQALLCLLSLLPLQVAQPGRPLOQDPLWLEQY CHRTTRNFS (in isoform CRF2-beta).

FT /FTId=VSP 002001.

SQ SEQUENCE 411 AA; 47706 MW; 1C6B85801BC94469 CRC64;

Query Match 80.4%; Score 1793; DB 1; Length 411;

Best Local Similarity 80.0%; Pred. No. 2.7e-125;

Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

Qy 1 MDSTIFEIIDEFDANCSLLDAFQDSFLHSESSFFGEGP--YCSATIDQIGTCWPRSL 58

Db 1 MDAA---LLSLLEAHCSL--ALAEELLDDGCEPDPDPGPGSYCNLTLDQIGTCWQSA 55

Qy 59 AGEIVRPPCPDSPNGIRYNTRNVYRECFENGTSWMMYNSQCVPLDNK-RKYALHYKI 117

Db 56 PGALVERPCPEYFNGIKYNTNAYRECLENGTSWASRINYSHPCEILDQKQKYDLHYRI 115

Qy 118 ALIINYGHICISIALIVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMFWLLQMDHN 177

Db 116 ALIINYGHICSVVAVAAFLFLVLSIRCLRNIIHWNLTITFILRNITWFLQLDHE 175

Qy 178 IHESNEVWCRCITTYNYFVVTNFFWMFVBCVLYHTAIVMTYSTDKLRKVVFLFGWCIP 237

Db 176 VHGENVWCRCVITTYNYFVVTNFFWMFVBCVLYHTAIVMTYSTEHLRKKWFLFGWCIP 235

Qy 238 SPIITVMAICKLFYENEQWIGKEPGKYIDYIYQGRVILVLLINFLVFLNIVRLMTKLR 297

Db 236 CPIIWAAGVKLYYENEQWFGKEPGDLVDYIYQGPILVLLINFLVFLNIVRLMTKLR 295

Qy 298 ASTTSETIQRKAVKATLVLLPLLGITYMLFFNPGEDDVSQIVFYFNSFLOSFOGFFV 357

Db 296 ASTTSETIQRKAVKATLVLLPLLGITYMLFFNPGEDDLSQIVFYFNSFLOSFOGFFV 355

Qy 358 SVFYCFNLGVSRAARKRWHRQDHSLSRVPVARAMSIPTSPTRISFHSIKQTAHV 413

Db 356 SVFYCFNLGVSRAALKRWHRQDHSLSRVPVARAMSIPTSPTRISFHSIKQTAHV 411

RESULT 9

Q8WML8

ID Q8WML8 PRELIMINARY; PRT; 437 AA.

AC Q8WML8;

DT 01-MAR-2002 (TREMBLrel. 20, Created)

DT 01-MAR-2002 (TREMBLrel. 20, Last sequence update)

DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)

DE Corticotropin releasing factor type 2B receptor.

GN Name=crfb2b;

OS Tupia glis belangeri (Common tree shrew).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Scandentia; Tupaiidae; Tupia.

OX NCBI_TaxID=37347;

FT	SIGNAL	1	24	Potential.
FT	CHAIN	25	415	Corticotropin releasing factor receptor
FT				1.
FT	DOMAIN	25	121	Extracellular (Potential).
FT	TRANSMEM	122	142	1 (Potential).
FT	DOMAIN	143	151	Cytoplasmic (Potential).
FT	TRANSMEM	152	171	2 (Potential).
FT	DOMAIN	172	189	Extracellular (Potential).
FT	TRANSMEM	190	213	3 (Potential).
FT	DOMAIN	214	227	Cytoplasmic (Potential).
FT	TRANSMEM	228	249	4 (Potential).
FT	DOMAIN	250	268	Extracellular (Potential).
FT	TRANSMEM	269	291	5 (Potential).
FT	DOMAIN	292	314	Cytoplasmic (Potential).
FT	TRANSMEM	315	334	6 (Potential).
FT	DOMAIN	335	349	Extracellular (Potential).
FT	TRANSMEM	350	369	7 (Potential).
FT	DOMAIN	370	415	Cytoplasmic (Potential).
FT	DISULFID	30	54	By similarity.
FT	DISULFID	44	87	By similarity.
FT	DISULFID	68	102	By similarity.
FT	CARBOHYD	38	38	N-linked (GlcNac. . .) (Potential).
FT	CARBOHYD	45	45	N-linked (GlcNac. . .) (Potential).
FT	CARBOHYD	78	78	N-linked (GlcNac. . .) (Potential).
FT	CARBOHYD	90	90	N-linked (GlcNac. . .) (Potential).
SQ	SEQUENCE	415 AA;	47786 MW; 74ED24C17907B74D CRC64;	

Query Match

Best Local Similarity 70.2%; Score 1564.5; DB 1; Length 415;

Best Local Similarity 72.2%; Pred. No. 2.7e-108;

Matches 285; Conservative 49; Mismatches 58; Indels 3; Gaps 2;

Qy	20	LDAPDPSLHSSSFPGFEGYCSNATDQICWCPRLAGELVERPCDPSFNGIRYNTT	79
Db	23	LTSLDQCETLQHS--NFTGLACNASIDMIGTWPSTAAGQVAPCPFYFHGQYNTT	80
Qy	80	RNVYRECFENGWASWMYSCVPIIDNKRKYALHYKIALIINYLGHCISILALVIAFLL	139
Db	81	GNVYRECHLNGSWAGGDYACQOEILKQEKTKVHYHIAIVNLFGLHSISLCALAVAFIL	140
Qy	140	FLCLRSIRCLRNIIHWNLTITFILNIMWFLQM-IDNHIHESNEVWCRCITTYNYFV	198
Db	141	FLRLRSIRCLRNIIHWNLTITAFILRNVTWFMVQLTSLSHADSNVWVWCLVTAHNYFYV	200
Qy	199	TNFFWFMVEGCYLHTAIVMTYSTDKLRKWVLFIGWCIPSPLIIVTWAICKLFYNEQCWI	258
Db	201	TNFFWFMVEGCYLHTAIVLTYSTDKLRKWMFICIGWCIPPPPIIIVAWAIGKLYIDNEKWF	260
Qy	259	GKEPGKYIDYIYQGRVILVLLINFVLFNIVRLMTKLRASSTSETIOYRKAVKATLVLL	318
Db	261	GKKAGVYTDYIYQGPVILVLLINFVLFNIVRLMTKLRASSTSETIOYRKAVKATLVLL	320
Qy	319	PLLGITYMLFFVNPGEDDVSQIVFYFNSFLOSFGQFFVSVFYCFINGEVRSAARKRWH	378
Db	321	PLLGITYMLFFVTGDEISRIVFYFNSFLOSFGQFFVSVFYCFINSEVRSAVRKRWH	380
Qy	379	WQDHSIRVRARAMSIPSPTRISPHSIKQTAAV	413
Db	381	WQDKHSIRARARAMSIPSPTRISPHSIKQSSAI	415

Search completed: August 20, 2005, 00:28:25
Job time : 171 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 20, 2005, 00:18:48 ; Search time 40 Seconds
(without alignments)
993.438 Million cell updates/sec

Title: US-10-649-852-32
Perfect score: 2229
Sequence: 1 MDSITFEIIDEFDANCSSL.....SIPTSPTRISFHSIKQTA AV 413

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 79: *
1: PIR1: *
2: PIR2: *
3: PIR3: *
4: PIR4: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1793	80.4	411	2 A55610	corticotropin-rele
2	1770.5	79.4	431	2 I49149	CRF receptor - mou
3	1769	79.4	430	2 A56726	corticoliberin rec
4	1746.5	78.4	431	2 I49279	sauvagine/corticot
5	1556.5	69.8	415	2 S39535	corticotropin-rele
6	1551.5	69.6	415	2 I58144	corticotropin-rele
7	1541.5	69.2	444	2 A48260	corticoliberin rec
8	1408.5	63.2	375	2 I38879	corticotropin rele
9	612	27.5	585	2 A39286	parathyroid hormon
10	595.5	26.7	479	2 S33746	calcitonin recepto
11	593	26.6	515	2 I49154	calcitonin recepto
12	590	26.5	515	2 I60800	calcitonin recepto
13	589.5	26.4	478	2 A37430	parathyroid hormon
14	587.5	26.4	593	2 A49191	calcitonin recepto
15	587	26.3	474	2 I37217	calcitonin recepto
16	569	25.5	490	2 S34486	calcitonin recepto
17	567	25.4	591	2 I54195	parathyroid hormon
18	565.5	25.4	591	2 S44203	parathyroid hormon
19	564	25.3	482	2 A39285	calcitonin recepto
20	553.5	24.8	449	2 S16319	secretin receptor
21	553.5	24.8	449	2 I60194	calcitonin-like re
22	553	24.8	460	2 JC2532	secretin receptor
23	548.5	24.6	461	2 JC2477	calcitonin recepto
24	546	24.5	498	2 I47130	calcitonin recepto
25	545	24.5	589	2 I59297	parathyroid hormon
26	535.5	24.0	550	2 A70594	parathyroid hormon
27	516.5	23.2	459	2 JH0594	vasoactive intesti
28	506	22.7	460	2 JC2194	vasoactive intesti
29	506	22.7	495	2 JC2195	vasoactive intesti

pituitary adenylat
pituitary adenylat
glucagon receptor
glucagon receptor
somatoliberin rece
glucagon receptor
gastric inhibitory
gastric inhibitory
pituitary adenylat
glucagon-like pept
pituitary adenylat
pituitary adenylat
vasoactive intesti
glucagon-like pept
pituitary adenylat
gastric inhibitory
glucose-dependent

ALIGNMENTS

RESULT 1

A55610

corticotropin-releasing factor receptor subtype 2 - rat

C:Species: Rattus norvegicus (Norway rat)

C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004

C:Accession: A55610

R:Lovenberg, T.W.; Liaw, C.W.; Grigoriadis, D.E.; Clevenger, W.; Chalmers, D.T.; De Souza

Proc. Natl. Acad. Sci. U.S.A. 92, 836-840, 1995

A:Title: Cloning and characterization of a functionally distinct corticotropin-releasing

A:Reference number: A55610; MUID:95148632; PMID:7846062

A:Accession: A55610

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-411 <LOV>

A:Cross-references: UNIPROT:P47866; EMBL:U16253; NID:G644771; PIDN:AAC52159.1; PID:G6447

C:Genetics:

A:Gene: CRP2R

C:Superfamily: glucagon receptor

Query Match 80.4%; Score 1793; DB 2; Length 411;

Best Local Similarity 80.0%; Pred. No. 9.4e-143;

Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

Qy 1 MDSITFEIIDEFDANCSSLDAFODSFLHSSSSFFGEGP--YCSATIDQIGTCWPSRL 58

Db 1 MDAA---LLSLLEANCSL--ALAEELLDGWEPPDDEGYPYCNITLDDQIGTCWPSA 55

Qy 59 AGELVERPCDPSFNGIRYNTTRNVYRECFENGTSWASWNNYSQCVPILDNK-RKVALHYKI 117

Db 56 FGALVERPCPYFNGIKYNTTRNAYRECLENGTWSRINYSCHPEILDQKQKVDLHVRI 115

Qy 118 ALIINYLGHCTSIALVAFLLFLCLRSIRCLRNIIHWNLTITFILRNIMFLLQMDHN 177

Db 116 ALIINYLGHCVSVVALVAFLFLVLSIRCLRNIIHWNLTITFILRNITFLLQIDHE 175

Qy 178 IHESNEWCRCITTYNYFVVTNFWVEGCVLHTAIVMTYSTDKLRKWFVLTGWICIP 237

Db 176 VHEGNEWCRCVTTFYFNFFVVTNFWVEGCVLHTAIVMTYSTHEHLRKLFLFLGWICIP 235

Qy 238 SPIVTWAIKLFYENECWIGKEPGKYIDYIQORVILVLLINVFVLFNIVRIIMTKLR 297

Db 236 CPIIVAMAVGKLYENECWKEGPGDLVDYIYQGPILVLLINVFVLFNIVRIIMTKLR 295

Qy 298 ASTTSETIYQKAVKATLVLLPLLGITVYMLFFVNPGEDDVSGQIVFYFNFSFQSGFFV 357

Db 296 ASTTSETIYQKAVKATLVLLPLLGITVYMLFFVNPGEDDVSGQIVFYFNFSFQSGFFV 355

Qy 358 SVFYCFNLGVEVRSAAKRWKHHQDHSRVRVARAMSIPSPTRISFHSIKQTA AV 413

Db 356 SVFYCFNGEVRSALRKRWKHHQDHSRVRVARAMSIPSPTRISFHSIKQTA AV 411

RESULT 2

I49149
CRF receptor - mouse
C;Species: Mus musculus (house mouse)
C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C;Accession: I49149
R;Perrin, M.; Donaldson, C.; Chen, R.; Blount, A.; Berggren, T.; Bilesikjian, L.; Sawche
Proc. Natl. Acad. Sci. U.S.A. 92, 2969-2973, 1995
A;Title: Identification of a second corticotropin-releasing factor receptor gene and cha
A;Reference number: I49149; MUID:95224061; PMID:7708757
A;Accession: I49149
A;Status: preliminary; translated from GB/EMBL/DDBBJ
A;Molecule type: mRNA
A;Residues: 1-431 <RES>
A;Cross-references: UNIPROT:Q60748; EMBL:U17858; NID:g727254; PIDN:AAA68026.1; PID:g7272
C;Superfamily: glucagon receptor

Query Match 79.4%; Score 1770.5; DB 2; Length 431;
Best Local Similarity 84.7%; Pred. No. 7.6e-141;
Matches 321; Conservative 26; Mismatches 29; Indels 3; Gaps 2;

Qy 38 FEGP--YCSATIDQIGTCWPRSLAGELVERPCPSDFNGIRYNTRNVYRECENGWTASW 95
Db ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
53 FSGPYTYCNTLDQIGTCWFQSAPGALVERPCPEYFNGLIKNTNRAYRECLNGTWASR 112
Qy ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
96 MNYSSQCVPILDNK-RKYALHYKIALINYLGHCISILALVIAFLFLCLRISRCLRNIIH 154
Db ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
113 VNSHCEPILDQRKYDLYHRYALIWNYLGHCVSVVALVAAFLLFLVLRISICLRNVIH 172
Qy ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
155 WNLITPILRNIMWFLOMDIHNHSNEVCRCITTIYNYFVTTFNMVFEGCVLHTA 214
Db ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
173 WNLITPILRNAFWLLQLDHVEHGNEVCRCITTIENFYFVTTFNMVFEGCVLHTA 232
Qy ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
215 IVMTYSTDKLRKKVLFIFIGWCIPSPVIITWAI CKLVENEQCWIKEPGKY IDVIYQGRV 274
Db ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
233 IVMTYSTEHURKWLFLFIGWCIPCPIIAWAOKLYENEQCWFGEKAGDLVDYIIYQGPN 292
Qy ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
275 ILVLLINFFVLFIIVRLIMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPG 334
Db ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
293 MLVLLINFFVLFIIVRLIMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPG 352
Qy ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
335 DDVSQIVFIYFNFSFLSQFGQFFVSFCFLNGEVRSAARQWRHQDHSLSRVVARAMS 394
Db ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
353 DDLSQLIVFIYFNFSFLSQFGQFFVSFCFLNGEVRSAARQWRHQDHSLSRVVARAMS 412
Qy ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
395 IPTSPTRI SFHSIKQTAAV 413
Db ||| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :|| :||
413 IPTSPTRI SFHSIKQTAAV 431

RESULT 3

A56726
corticoliberin receptor precursor, cardiac - mouse
C;Species: Mus musculus (house mouse)
C;Date: 21-Jul-1995 #sequence_revision 28-Jul-1995 #text_change 09-Jul-2004
C;Accession: A56726
R;Stenzel, P.; Keeterson, R.; Yeung, W.; Cone, R.D.; Rittenberg, M.B.; Stenzel-Poore, M.
Mol. Endocrinol. 9, 637-645, 1995
A;Title: Identification of a novel murine receptor for corticotropin-releasing hormone e
A;Reference number: A56726; MUID:96015396; PMID:7565810
A;Accession: A56726
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-430 <STE>
A;Cross-references: UNIPROT:Q60748; GB:U19939; NID:g806763; PIDN:AAC52243.1; PID:g806764
C;Superfamily: glucagon receptor
C;Keywords: cardiac muscle; heart

Query Match 79.4%; Score 1769; DB 2; Length 430;
Best Local Similarity 84.4%; Pred. No. 1e-140;
Matches 319; Conservative 26; Mismatches 31; Indels 2; Gaps 1;

Qy 98 FEGP--YCSATIDQIGTCWPRSLAGELVERPCPSDFNGIRYNTRNVYRECENGWTASW 95

Qy 395 IPTSPTRISPHSIKQTAAY 413
|
Db 413 IPTSPTRISPHSIKQTAAY 431

RESULT 5
S39535 corticotropin-releasing hormone receptor - mouse
C:Species: Mus musculus (house mouse)
C>Date: 07-Oct-1994 #sequence_revision 10-Nov-1995 #text_change 09-Jul-2004
C:Accession: S39535
R:Vita, N.; Laurent, P.; Lefort, S.; Chalon, P.; Lelias, J.M.; Kaghad, M.; le Fur, G.; O
FEB8 Lett. 335, 1-5, 1993
A>Title: Primary structure and functional expression of mouse pituitary and human brain
A:Reference number: S39534; MUID:94063063; PMID:8243652
A:Accession: S39535
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-415 <VT>
A:Cross-references: UNIPROT:P35347; EMBL:X72305; NID:g436120; PIDN:CAA51053.1; PID:g43612
A>Note: the sequence from Fig. 1 is inconsistent with that from Fig. 3 in having an addi
C:Superfamily: glucagon receptor
C:Keywords: G protein-coupled receptor; transmembrane protein

Query Match	69.8%;	Score 1556.5;	DB 2;	Length 415;
Best Local Similarity	74.9%;	Pred. No. 6.4e-123;		
Matches 281;	Conservative 44;	Mismatches 49;	Indels 1;	Gaps 1;
Qy	40	GPYCSATDQIGTCWPSLACELVERPCDSFNGIRYNTNRNVYECFENGTSWAMNYS	99	
Db	41	GLQCNASVDLIGTCWPSRPAQGVVPCPAFYGVRYNTNNGYRECLANGSWARVNY	100	
Qy	100	QCVPIIDNRKXALHYKIALIINYLGHCISILALVAFLEFLCLRSIRCLRNIHWNLI	159	
Db	101	EQSILNEEKSXVHYHTAVIINYLGHCISLVALLVAFVFLRESIRCLRNIHWNLI	160	
Qy	160	TFILRNIMFWLLQ- IDRNIHESNEVWCRCITTIYNYFVFNPFMFVEGCVLHTAI	218	
Db	161	AFILRNATWVFWQLTVSPVEVHQSNVACRLVTAAYNYFVNTNPFMFVEGCVLHTAI	220	
Qy	219	YSTDKLRKWWFLFGWCITPSPIIVTWAICKLFYENECQWIGKEPKYIDYIQGRI	278	
Db	221	YSTDLRKMWFCVIGWGVPFPIIVAWATGKLYYDNKECWFGKRGPGVYDIYIQGRI	280	
Qy	279	LINFVFLPNIVRILMTKLRASTTSETIQYRKAVKATLVLLPLLGLITYMLFFVNP	338	
Db	281	LINFIFLNIIVRILMTKLRASTTSETIQYRKAVKATLVLLPLLGLITYMLFFVNP	340	
Qy	339	QIVFIYFNSTPQSGFQGVFSVFCYFLNGEVRSAARKWRHWDHSLRVRVARAMSI	398	
Db	341	PWVFIYFNSTPESFGFVFSVFCYFLNGEVRSAIRKWRWODKHSIRARVARAMSI	400	

RESULT 6
I58144
corticotropin-releasing factor receptor - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 26-Jul-1996 #sequence_revision 26-Jul-1996 #text_change 09-Jul-2004
C:Accession: I58144
R:Chang, C.P.; Pearce, R.V.; O'Connell, S.; Rosenfeld, M.G.
Neuron 11, 1187-1195, 1993
A:Title: Identification of a seven transmembrane helix receptor for corticotropin-releasing factor type 1
A:Reference number: I58144; MUID:94099969; PMID:8274282
A:Accession: I58144
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-415 <RES>
A:Cross-references: UNIPROT:P3353; GB:L25438; NID:g450298; PIDN:AAA16441.1; PID:g457615
C:Superfamily: glucagon receptor

	Query Match	69.6%	Score 1551.5	DB 2	Length 415
	Best Local Similarity	74.7%	Pred. No. 1.7e-122		
	Matches 280	Conservative 44	Mismatches 50	Indels 1	Gaps 1
Qy	40	GPYCSATIDIGTCWPRSLAGELVERPCDPSFNGIRYNTTNRVYRECFTNGTWSAMWYNS	99		
Db	41	GLQCNASVDLIGTCWPRSPAGQLVVRPCPAFFYGVRYNTTNNGYRECLANGSMAARVNYNS	100		
Qy	100	QCVPILDNKRKALHYKIALIINYGLGHCSISALUAVIAFLPLCLURSTRCLRNIIHWNLIIT	159		
Db	101	ECQEILNEEKSKVHYHVAVIINYGLGHCSISLVALLVAVFLRLURSTRCLRNIIHWNLIIS	160		
Qy	160	TFILRNIMFLLQW-IDHNHTSENVWCRCITTIYNYFVVTNPFMFWEGCYLHTAIVMT	218		
Db	161	AFILRNATWVFVQUTSPVEHQSNVACRLVTAAYNTFHVTFNPFMWEGCYLHTAIVLT	220		
Qy	219	YSTDKLRKWVLFIFGWCIPSPIIIVTWAICKLFYNEQCWIGKEPGKYIDIYIQGRVILVL	278		
Db	221	YSTDLRKWMFVCIGWGVPPFIIIVAWAIGKLHYDNEKWCWPKRPGVTDYIQGPMLIVL	280		
Qy	279	LINFVFLFNIVRIILMTKLRASTTSETIOYRKAVKATILVLLPLLGITWYMLFFVNPGEDDVS	338		
Db	281	LINFIFLFTNRIILMTKLRASTTSETIOYRKAVKATILVLLPLLGITWYMLFFVNPGEDEV	340		
Qy	339	QIVFIYNSFLQSFGQFVSFVFCFLNGEVRSAARKWRHWQDHSLSLRVVRARAMSIPTS	398		
Db	341	RVVFIYNSFLESFGQFVSFVFCFLNSEVRSAIRKWRWRQDKHSIRARVARAMSIPTS	400		
Qy	399	PTRISSHISIKOTAAV 413			
Db	401	PTRVSFHSIKOSTAV 415			

RESULT 7

A48260
corticotiberin receptor, long splice form - human
N:Alternate names: corticotiberin binding protein; corticotropin releasing factor receptor
C:Species: Homo sapiens (man)
C:Date: 31-May-1996 #sequence revision 11-Apr-1997 #text_change 09-Jul-2004
C:Accession: I60975; A48260; S39534
R:Chen, R.; Lewis, K.A.; Perrin, M.H.; Vale, W.W.
Proc. Natl. Acad. Sci. U.S.A. 90, 8967-8971, 1993
A:Title: Expression cloning of a human corticotropin-releasing factor (CRF) receptor.
A:Reference number: A48260; MUID:94022296; PMID:7692441
A:Accession: I60975
A:Status: translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-444 <RES>
A:Cross-references: UNIPROT:P34998; GB:L23333; NID:G408691; PIDN:AAA35719.1; PID:G408692
A:Experimental source: Cushing corticotropic cell tumor
A:Accession: A48260
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-145,175-444 <R2>
A:Cross-references: GB:L23332; NID:G408689; PIDN:AAA35718.1; PID:G408690
R:Vita, N.; Laurent, P.; Lefort, S.; Chalou, P.; Lelias, J.M.; Kaghad, M.; le Fur, G.; C
FEBS Lett. 335, 1-5, 1993
A:Title: Primary structure and functional expression of mouse pituitary and human brain
A:Reference number: S39534; MUID:94063063; PMID:8243652

A; Molecule type: mRNA
A; Residues: 1-145, 175-444 <VIT>
A; Cross-references: EMBL:X72304; NID:G436118; PIDN:CAA51052.1; PID:G436119

C;Genetics:
A;Gene: GDB:CRHR1; CRHR; CRF-R; CRF1
A;Cross-references: GDB:235922; OMIM:122561
A;Map position: 17q12-17q22
C;Superfamily: glucagon receptor
C;Keywords: alternative splicing; transmembrane protein

Query Match		69.2%;	Score 1541.5;	DB 2;	Length 444;
Best Local Similarity		67.8%;	Pred. No. 1.2e-121;		
Matches		287;	Conservative 46;	Mismatches 57;	Indels 33; Gaps 4;
Qy	22	AFQDSFLHSESSSF-FGFEFGYCSATIDQIGTCWPRSLAGELVERPCDPSFNGIRYNTNR	80		
Db	24	SLQDQ--HCESLSLASNISGLQCNASVDLIGTCWPRSPAGQLVVRPCPAFFYGVRYNTN	81		
Qy	81	NYRECFENGTSWAMNYSQCVPLDNKRKVALHYKIALINYLGHCISILALVIAFLF	140		
Db	82	NGYRECLANGSWAARVNYSECQEILNEEKKSVHYHVAIINYLGHCISILVALLVAFVLF	141		
Qy	141	LCL-----RSIRCLRNIHWNLTTFILRNIMWFL	171		
Db	142	LRLRPGTHWGQDQADGALEVCAPWSGAPFQVRRSIRCLRNIHWNLSAISILRNATWFFV	201		
Qy	172	QM-IDNHIESNEVWCRCITTIYNYFVVTFFMFWFGCVLHTAIVMYTSYTDKLRKWVFL	230		
Db	202	QLTWSPEVHQSNVGCRLVTAAYNYFHTVFFMFWFGCVLHTAIVLTYSTDLRKKWFI	261		
Qy	231	FIGWCIPSPITVTAICLKFYENQCWIGKEPGKYIDYIQGRVILVLLINFVLEFNIVR	290		
Db	262	CIGHGVFPITVAWAIGKLYYDNEKCFGKRGVYTDYIQGPMILVLLINFILFNIVR	321		
Qy	291	ILMTKLRASTTSETIQYRKAVKATLVLLPLIGITYMLFFVNPGBDDVSQIVFIYFNSFLQ	350		
Db	322	ILMTKLRASTTSETIQYRKAVKATLVLLPLIGITYMLFFVNPGBDESVRVFIYFNSFLE	381		
Qy	351	SFQGFVSVFYCFLNGEVSRAARKRHRWQDHHSLVRVARAMSIPTSPTRISPHSIKQT	410		
Db	382	SFQGFVSVFYCFLNSEVRSRAIRKRHRWQDKHSIRARVARAMSIPTSPTRVSPHSIKQS	441		
Qy	411	AAV 413			
Db	442	TAV 444			
RESULT 8					
corticotropin releasing hormone receptor variant - human					
C;Species: Homo sapiens (man)					
C;Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004					
C;Accession: I38879					
R;Ross, P.C.; Kostas, C.M.; Ramabhadran, T.V.					
Biochem. Biophys. Res. Commun. 205, 1836-1842, 1994					
A;Title: A variant of the human corticotropin-releasing factor (CRF) receptor: cloning,					
A;Reference number: I38879; MUID:95110332; PMID:7811272					
A;Accession: I38879					
A;Status: preliminary; translated from GB/EMBL/DBJ					
A;Molecule type: mRNA					
A;Cross-references: UNIPROT:P34998; EMBL:U16273; NID:g606973; PIDN:AAC50073.1; PID:g6069					
C;Superfamily: glucagon receptor					
Query Match		63.2%;	Score 1408.5;	DB 2;	Length 375;
Best Local Similarity		75.4%;	Pred. No. 1.5e-110;		
Matches		255;	Conservative 41;	Mismatches 41;	Indels 1; Gaps 1;
Qy	77	NTNRNVRECPENGTSWAMNYSQCVPLDNKRKVALHYKIALINYLGHCISILALVIA	136		
Db	38	NISDNGYRECLANGSWAARVNYSECQEILNEEKKSVHYHVAIINYLGHCISILVALLVA	97		
Qy	137	FLFLCLRISIRCLRNIHWNLTTFILRNIMWFLQM-IDNHIESNEVWCRCITTIYNY	195		
Db	98	FVLELRISIRCLRNIHWNLSAISILRNATWFFVQVLTMSPEVHQSNVGCRLVTAAYNY	157		
Qy	196	FVVTNFFMFWFGCVLHTAIVMYTSYTDKLRKWVLFYTCGICPSPITVTAICLKFYENQ	255		
Db	158	PHVTNFFMFWFGCVLHTAIVLTYSTDLRKKWFIICIGWGPFFIIVAWAIGKLYYDNEK	217		
Qy	256	CWIGKEPGKYIDYIQGRVILVLLINFVLEFNIVRLMTKLRASTTSETIQYRKAVKATL	315		
Db	218	CWFGKRGVYTDYIQGPMILVLLINFILFNIVRLMTKLRASTTSETIQYRKAVKATL	277		

Qy	316	VLLPLLGITVMLFFVNPGBDDVSQIVFIYFNSFLQSFGQFFSVFYCFLNGEVSRAARKR	375		
Db	278	VLLPLLGITVMLFFVNPGBDESVRVFIYFNSFLESFGQFFSVFYCFLNSEVRSIAIRKR	337		
Qy	376	WHRWQDHHSLVRVARAMSIPTSPTRISPHSIKQTAAV	413		
Db	338	WHRWQDKHSIRARVARAMSIPTSPTRVSPHSIKQSTAV	375		
RESULT 9					
A39286					
parathyroid hormone / parathyroid hormone-related peptide - North American opossum					
C;Species: Didelphis virginiana, Didelphis marsupialis virginiana (North American opossum					
C;Date: 24-Jan-1992 #sequence_revision 24-Jan-1992 #text_change 09-Jul-2004					
C;Accession: A39286					
R;Jueppner, H.; Abou-Samra, A.B.; Freeman, M.; Kong, X.F.; Schipani, E.; Richards, J.; K.					
Science 254, 1024-1026, 1991					
A;Title: A G protein-linked receptor for parathyroid hormone and parathyroid hormone-rela					
A;Reference number: A39286; MUID:92054592; PMID:1658941					
A;Accession: A39286					
A;Status: preliminary; not compared with conceptual translation					
A;Molecule type: mRNA					
A;Residues: 1-585 <JUE>					
A;Cross-references: UNIPROT:P25107; GB:M74445					
C;Superfamily: Glucagon receptor					
C;Keywords: G protein-coupled receptor; transmembrane protein					
Query Match		27.5%;	Score 612;	DB 2;	Length 585;
Best Local Similarity		33.3%;	Pred. No. 1.4e-43;		
Matches		125;	Conservative 72;	Mismatches 134;	Indels 44; Gaps 10;
Qy	42	YCSATIDQIGTCWPRSLAGELVERPCDPSFNGIRYNTNRNVRECFENGTV-----AS	94		
Db	104	FCLPEWDNI--VCPAGVPGKVAVPCPDYP--YDFNHKGRAYRRCDNSGWSWELVPGNNRT	160		
Qy	95	WMNYSQCVPILDNK-RKYALHYKIALIINYLGHCISILALVIAFLFLCLRISIRCLRNI	153		
Db	161	WANYSECVKFLTNETREREVEFDRLGMYT-VGYSISLGSITVAVLILGYFRRLHCTRNYI	219		
Qy	154	HNWLTITFILRNIMWFLQWIDNHIESNP-----VWCRCIT	190		
Db	220	HMFLVSVFMLRAVSIFIKOAVLYSGVSTDEIRITBEELRAFTTEPPPPADKAGFVGCRAV	279		
Qy	191	TIYNYFVTNFFMFWFGCVLHTAIVMYTSYTDKLRKWVLFYTCGICPSPITVTAICLKF	250		
Db	280	TVFLYFLTNYWILVEGLYLHSLIFMAFFSEKKYLWGFYLFNGWGLPAVFAVAVVTVRAT	339		
Qy	251	YENECQWIGKEPGKYIDYIQGRVILVLLINFVLEFNIVRLMTKLRL---ASTTSETIQY	307		
Db	340	LANTECWDLSSGNK--KWIIQVPIAAIVNVFILFINIENVLATKLRETNAGRCDTREQY	397		
Qy	308	RKAVKATLVLLPLLGITYMLFFVNPGBDDVSQIVF---IYFNSFLOSFGQFFSVFYCFL	364		
Db	398	RKLKSTLVLMPLFGVHYIVFMATP-YTEVSGILWQVMHYEMLFNSFQGFVVAIIYCF	456		
Qy	365	NGEVSRAARKRWERN	379		
Db	457	NGEVQAEIKKWSRW	471		
RESULT 10					
S33746					
calcitonin receptor cla precursor - rat					
C;Species: Rattus norvegicus (Norway rat)					
C;Date: 02-Dec-1993 #sequence_revision 10-Nov-1995 #text_change 09-Jul-2004					
C;Accession: S33746					
R;Albrandt, K.; Mull, E.; Brady, E.M.G.; Herich, J.; Moore, C.X.; Beaumont, K.					
FEBS Lett. 325, 225-232, 1993					
A;Title: Molecular cloning of two receptors from rat brain with high affinity for salmon					
A;Reference number: S33746; MUID:93307500; PMID:8391477					
A;Accession: S33746					
A;Molecule type: mRNA					


```
Qy 330 VNPGEEDVSQIVFIYENSFLQSFQGFVSVFCFLNGEVRSAARKRW-----HRW 379
Db 398 WRPSKNVLGKI-YDYLMSLHIFQGFVATYICFCNHEVQVTLKQKWAQFKIQWSHRW 454

RESULT 13
A37430
calcitonin receptor - rat
C:Species: Rattus norvegicus (Norway rat)
C>Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 24-Nov-1999
C:Accession: A37430
R:Sexton, P.M.; Housaami, S.; Hilton, J.M.; O'Keefe, L.M.; Center, R.J.; Gillespie, M.T.
Mol. Endocrinol. 7, 815-821, 1993
A:Title: Identification of brain isoforms of the rat calcitonin receptor.
A:Reference number: A37430; MUID:93368608; PMID:8395656
A:Accession: A37430
A:Molecule type: mRNA
A:Cross-references: translated from GB/EMBL/DBJ
A:Residues: 1-478 <RES>
A:Cross-references: GB:L13041; NID:G294530; PIDN:AAA03030.1; PID:G294531
C:Superfamily: glucagon receptor

Query Match 26.4%; Score 589.5; DB 2; Length 478;
Best Local Similarity 34.6%; Pred. No. 9e-42;
Matches 132; Conservative 75; Mismatches 142; Indels 33; Gaps 12;

Qy 19 LLDAFQDSFLHSESSPFGPGYCSATIDIGTCWPRSLAGELVERPCDPSFNGIRYNT 78
Db 48 LLDAQYCYDRIQQLPPYEGSGPCNRTWDG-WMCWDDTPAGVMSYQHCDFPD--FDP 104

Qy 79 TRNIVRECFENGW-----ASWNYSCQVPILDNRKKA-LHYKIALIINYLGHCISI 130
Db 105 TERVSKYKCDENGFRHPDSNRRTWSNYTLNCAFTPKLHNAYYSYLALV---GHSMSI 160

Qy 131 LALVIAFLFLCLASIRCLRIIHNLIITFLRNIMWFLQIMD---HNIHESNEVWC 186
Db 161 AALIASWGIFLFFKNLSQRTVLHKNMFLTYLINSII-IIHLVEVVPNGDLVRDPISC 219

Qy 187 RCITTIYNYVVTNFFNMVVEGCVLHTAIVM-TYSTDKLRKWPFLFTGWCIPSPITVWA 245
Db 220 KILHFFHQYMACNVFMWLCBGIVLHLYLTVMAVTEQDLRWYYL-LGWGPPIVPTIHA 278

Qy 246 ICKLFYENEQWIGKEPKYIDYIQGRVILVILNINFLNIVRIILMTKLRSSTSETI 305
Db 279 ITRAVYVNDNCWLSTE--THLLYIIHGFWMAALVQVNFLLNIVRVLTVMKQTHREAY 336

Qy 306 QYRKAVKATLVLLPLGLTYMLFFVNPGEEDVSQIVFIYENSFLQSFQGFVSVFCFLN 365
Db 337 MYLKAVKATVVLVPLGLTQVVFVFWPRPSNKVLGKI-YDYLMSLHIFQGFVATYICFN 395

Qy 366 GEVRSAAARKW-----HRW 379
Db 396 HEVQVTLKQKWAQFKIQWSHRW 417

RESULT 14
A49191
parathyroid hormone/PTH-related peptide receptor - human
N:Alternate names: parathyroid hormone/parathyroid hormone related peptide receptor
C:Species: Homo sapiens (man)
C>Date: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C:Accession: I38139; A49191; I38113; G01562; S29610
R:Schipani, E.; Weinstein, L.S.; Bergwitz, C.; Iida-Klein, A.; Kong, X.F.; Stuhmann, M.
Kronenberg, H.M.; Abou-Samra, A.B.; Segre, G.V.; Jueppner, H.
J. Clin. Endocrinol. Metab. 80, 1611-1621, 1995
A:Title: Pseudohypoparathyroidism type 1b is not caused by mutations in the coding exons
A:Reference number: I38139; MUID:95263723; PMID:7745008
A:Accession: I38139
A:Status: translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-593 <RES>
A:Cross-references: UNIPROT:Q03431; EMBL:U22409; NID:G897594; PIDN:AAB60657.1; PID:G8975
R:Schipani, E.; Karga, H.; Karaplis, A.C.; Potts Jr., J.T.; Kronenberg, H.M.; Segre, G.V.
```

```
Endocrinology 132, 2157-2165, 1993
A:Title: Identical complementary deoxyribonucleic acids encode a human renal and bone pa
A:Reference number: A49191; MUID:93238641; PMID:8386612
A:Accession: A49191
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-593 <SCH>
A:Cross-references: GB:L04308; NID:G190721; PIDN:AAA36525.1; PID:G190722
A>Note: Sequence extracted from NCBI backbone (NCBIN:130233, NCBIPI:130234)
R:Schneider, H.; Feyen, J.H.; Seuwen, K.; Movva, N.R.
Eur. J. Pharmacol. 246, 149-155, 1993
A:Title: Cloning and functional expression of a human parathyroid hormone receptor.
A:Reference number: I38113; MUID:93387403; PMID:8397094
A:Accession: I38113
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-593 <RE2>
A:Cross-references: EMBL:X68596; NID:G396812; PIDN:CAA48589.1; PID:G396813
R:Levine, M.
Submitted to the EMBL Data Library, November 1994
A:Reference number: G07787
A:Accession: G01562
A:Status: translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-593 <LEV>
A:Cross-references: EMBL:U17418; NID:G596129; PIDN:AAA56774.1; PID:G596130
C:Genetics:
A:Introns: 25/3; 60/1; 105/1; 142/1; 181/3; 213/2; 278/3; 330/1; 350/2; 372/3; 404/2; 45
C:Superfamily: glucagon receptor
C:Keywords: G protein-coupled receptor; transmembrane protein

Query Match 26.4%; Score 587.5; DB 2; Length 593;
Best Local Similarity 32.3%; Pred. No. 1.6e-41;
Matches 123; Conservative 69; Mismatches 144; Indels 45; Gaps 10;

Qy 38 FEGPYCSATIDIGTCWPRSLAGELVERPCDPSFNGIRYNTTRNIVRECFENGW----- 92
Db 103 YRGRCPLPEWDHI-LCWPLGAPGEVAVPCDYI--YDNHKGHAYRCDRNGSWELVPG 159

Qy 93 --ASWNYSCQVPILDNK-RKYALHYKIALIINYLGHCISILALVIAFLFLCLRSIRCL 149
Db 160 HNRTWANYSQVFLTNETREVERFORLGIYI-VGYSVSLASLITVAVLILAYFRLHCT 218

Qy 150 RNIHWNLIITFLRNIMWFLQIMDHN---IHESNEV----- 184
Db 219 RNTIHMFLFSLFPMRLAVSIFVKDAVLYSGATLDEASRLTEELRAIAQAPPPTAAAGY 278

Qy 185 -WRCITTIYNYVVTNFFNMVVEGCVLHTAIVM-TYSTDKLRKWPFLFTGWCIPSPITV 243
Db 279 AGCRVATVFLYFLATNYIWLVEGLYLSLIPWAFSEKKYLMGFTVFCGGLPAVFVAV 338

Qy 244 WAICKLFYENEQWIGKEPKYIDYIQGRVILVILNINFLNIVRIILMTKLRSSTSETI 300
Db 339 WVSVRATLANTGCWDLSSGNK--KWIIQVPIASIVLNFILNIVRVLTVMKRLRTNAGR 396

Qy 301 TSETIQYRKAVKATLVLLPLGLTYMLFFVNPGEEDVSQI--VFIFYNSFLQSFQGFVS 358
Db 397 CDTRQYRKLLKSTLVLMPLFGVHYIVFMATPYTEVSGTLQWQMHYEMLFNSFQGFVA 456

Qy 359 VFYCFNLNGEVRSAARKWHRW 379
Db 457 IIVCFNGEVOAIEKKKWSRW 477

RESULT 15
I37217
calcitonin receptor - human
C:Species: Homo sapiens (man)
C>Date: 12-Aug-1996 #sequence_revision 12-Aug-1996 #text_change 21-Jul-2000
C:Accession: I37217; S43673; S44209
R:Kuesner, R.E.; Elrod, R.D.; Grant, F.J.; Hagen, F.S.; Kuijper, J.L.; Matthews, S.L.;
n, P.M.; Moore, E.E.
Mol. Pharmacol. 46, 246-255, 1994
```

Search completed: August 20, 2005, 00:29:10
Job time : 41 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 20, 2005, 00:28:34 ; Search time 163 Seconds
(without alignments)
992.178 Million cell updates/sec

Title: US-10-649-852-32

Perfect score: 2229

Sequence: 1 MDSITFEIIDFDANCSSL.....SIPTSPTRISHSIKQTAUV 413

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1759131 seqs, 391586102 residues

Total number of hits satisfying chosen parameters: 1759131

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pcp.*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pcp.*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pcp.*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pcp.*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pcp.*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pcp.*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pcp.*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pcp.*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pcp.*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pcp.*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pcp.*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pcp.*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pcp.*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pcp.*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pcp.*
16: /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pcp.*
17: /cgn2_6/ptodata/2/pubpaa/US10E_PUBCOMB.pcp.*
18: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pcp.*
19: /cgn2_6/ptodata/2/pubpaa/US11A_PUBCOMB.pcp.*
20: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pcp.*
21: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pcp.*
22: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2229	100.0	413	10	US-09-799-978-32
2	2229	100.0	413	16	US-10-649-852-32
3	1807	81.1	405	10	US-09-799-978-38
4	1807	81.1	405	16	US-10-649-852-38
5	1804	80.9	411	15	US-10-292-798-636
6	1799	80.7	411	9	US-09-881-401-8
7	1799	80.7	411	10	US-09-799-978-10
8	1799	80.7	411	14	US-10-225-567A-96
9	1799	80.7	411	16	US-10-649-852-10
10	1799	80.7	411	16	US-10-821-502-8
11	1799	80.7	411	16	US-10-757-262-120

12	1793	80.4	411	9	US-09-881-401-4
13	1793	80.4	411	10	US-09-818-009-12
14	1793	80.4	411	10	US-09-799-978-18
15	1793	80.4	411	16	US-10-649-852-18
16	1793	80.4	411	16	US-10-821-502-4
17	1787.5	80.2	397	10	US-09-799-978-14
18	1787.5	80.2	397	16	US-10-649-852-14
19	1786	80.1	438	10	US-09-799-978-12
20	1786	80.1	438	16	US-10-649-852-12
21	1786	80.1	438	17	US-10-482-029-178
22	1784.5	80.1	431	9	US-09-881-401-2
23	1784.5	80.1	431	10	US-09-818-009-13
24	1784.5	80.1	431	16	US-10-821-502-2
25	1776.5	79.7	431	10	US-09-799-978-20
26	1776.5	79.7	431	16	US-10-649-852-20
27	1770.5	79.4	431	9	US-09-191-724-10
28	1770.5	79.4	431	10	US-09-818-009-11
29	1770.5	79.4	431	10	US-09-799-978-24
30	1770.5	79.4	431	15	US-10-649-193-10
31	1770.5	79.4	431	16	US-10-649-852-24
32	1769	79.4	430	9	US-09-853-386-140
33	1769	79.4	430	10	US-09-799-978-26
34	1769	79.4	430	16	US-10-649-852-26
35	1582.5	71.0	428	10	US-09-799-978-36
36	1582.5	71.0	428	16	US-10-649-852-36
37	1582	71.0	420	9	US-09-853-386-129
38	1582	71.0	420	10	US-09-799-978-42
39	1582	71.0	420	16	US-10-649-852-42
40	1578.5	70.8	445	10	US-09-799-978-34
41	1578.5	70.8	445	16	US-10-649-852-34
42	1566	70.3	415	9	US-09-191-724-2
43	1566	70.3	415	10	US-09-799-978-2
44	1566	70.3	415	10	US-09-799-978-4
45	1566	70.3	415	14	US-10-242-822B-1

ALIGNMENTS

RESULT 1

US-09-799-978-32
; Sequence 32, Application US/09799978
; Publication No. US20030165807A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or
; TITLE OF INVENTION: Function Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799,978
; CURRENT FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 32
; LENGTH: 413
; TYPE: PRT
; ORGANISM: Xenopus laevis
US-09-799-978-32

Query Match	100.0%	Score 2229;	DB 10;	Length 413;
Best Local Similarity	100.0%	Pred. No. 5.3e-199;		
Matches 413;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	MDSITFEIIDFDANCSSLDAFQSFHSESSSFFGEGPYCSATIDGICWPRSLAG	60	
Db	1	MDSITFEIIDFDANCSSLDAFQSFHSESSSFFGEGPYCSATIDGICWPRSLAG	60	
QY	61	ELVEPCDPSFNGIRYNTTRNVYRCFENGWASWNYSCQVCPILDNKKKYLHYKIALI	120	
Db	61	ELVEPCDPSFNGIRYNTTRNVYRCFENGWASWNYSCQVCPILDNKKKYLHYKIALI	120	
QY	121	INVLGHCSILAVIAFLFLCLRSIRCLRNLIHWNLIITFTILRNIMFWFLQMDHNIHE	180	

Db 121 INYLGHCSIALVIAFLFLCLRSICLRNIHWNLTITFILRNIMWFLQMDHNIHE 180
Qy 181 SNEVWCRCITTIYNYFVVTNFFWMEVGCYLHTAIVMTYSTDKLRKWVFLFIGWCIPSP 240
Db 181 SNEVWCRCITTIYNYFVVTNFFWMEVGCYLHTAIVMTYSTDKLRKWVFLFIGWCIPSP 240
Qy 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVFLNIVRILMTKLRAS 300
Db 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVFLNIVRILMTKLRAS 300
Qy 301 TSETIOYRKAVKATLVLLPLLGITTYMLFFVNPGEDDVSQIVFIYFNSFLOSFOGFFVSFV 360
Db 301 TSETIOYRKAVKATLVLLPLLGITTYMLFFVNPGEDDVSQIVFIYFNSFLOSFOGFFVSFV 360
Qy 361 YCFLNGEVRSAARKRWHRWQDHHSLRVRVARAMSIPSPTRISFHSIKQTAAV 413
Db 361 YCFLNGEVRSAARKRWHRWQDHHSLRVRVARAMSIPSPTRISFHSIKQTAAV 413

RESULT 2
US-10-649-852-32
; Sequence 32, Application US/10649852
; Publication No. US20040101911A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or F
; TITLE OF INVENTION: Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448R
; CURRENT APPLICATION NUMBER: US/10/649,852
; CURRENT FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: US 09/799,978
; PRIOR FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 32
; LENGTH: 413
; TYPE: PRT
; ORGANISM: Xenopus laevis
US-10-649-852-32

Query Match 100.0%; Score 2229; DB 16; Length 413;
Best Local Similarity 100.0%; Pred. No. 5.3e-199;
Matches 413; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MDSTIFEIIDEFDANGCSLLDAFQDSFLHSESSSFFGEGPYCSATIDQIGTCWPRSLAG 60
Db 1 MDSTIFEIIDEFDANGCSLLDAFQDSFLHSESSSFFGEGPYCSATIDQIGTCWPRSLAG 60
Qy 61 ELVERPCDPSFNGIRYNTNRVYRECENGFWASWNNYSQCVPILDNKRKYALHYKIALI 120
Db 61 ELVERPCDPSFNGIRYNTNRVYRECENGFWASWNNYSQCVPILDNKRKYALHYKIALI 120
Qy 121 INYLGHCSIALVIAFLFLCLRSICLRNIHWNLTITFILRNIMWFLQMDHNIHE 180
Db 121 INYLGHCSIALVIAFLFLCLRSICLRNIHWNLTITFILRNIMWFLQMDHNIHE 180
Qy 181 SNEVWCRCITTIYNYFVVTNFFWMEVGCYLHTAIVMTYSTDKLRKWVFLFIGWCIPSP 240
Db 181 SNEVWCRCITTIYNYFVVTNFFWMEVGCYLHTAIVMTYSTDKLRKWVFLFIGWCIPSP 240
Qy 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVFLNIVRILMTKLRAS 300
Db 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVFLNIVRILMTKLRAS 300
Qy 301 TSETIOYRKAVKATLVLLPLLGITTYMLFFVNPGEDDVSQIVFIYFNSFLOSFOGFFVSFV 360
Db 301 TSETIOYRKAVKATLVLLPLLGITTYMLFFVNPGEDDVSQIVFIYFNSFLOSFOGFFVSFV 360
Qy 361 YCFLNGEVRSAARKRWHRWQDHHSLRVRVARAMSIPSPTRISFHSIKQTAAV 413
Db 361 YCFLNGEVRSAARKRWHRWQDHHSLRVRVARAMSIPSPTRISFHSIKQTAAV 413

Db 361 YCFLNGEVRSAARKRWHRWQDHHSLRVRVARAMSIPSPTRISFHSIKQTAAV 413
RESULT 3
US-09-799-978-38
; Sequence 38, Application US/09799978
; Publication No. US2003010165807A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or F
; TITLE OF INVENTION: Function Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799,978
; CURRENT FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 38
; LENGTH: 405
; TYPE: PRT
; ORGANISM: Ameiurus nebulosus
US-09-799-978-38
Query Match 81.1%; Score 1807; DB 10; Length 405;
Best Local Similarity 79.9%; Pred. No. 1.1e-159;
Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;
Qy 1 MDSTIFEIIDEFDANGCSLLDAFQDSFLHSESSSFFGEGPYCSATIDQIGTCWPRSLAG 60
Db 1 MEVSLLELL--SVEVNCSLADAFGDPAYGNASDAL-----YCNATADEIGTCWPRSGAG 52
Qy 61 ELVERPCDPSFNGIRYNTNRVYRECENGFWASWNNYSQCVPILDNKRKYALHYKIALI 120
Db 53 RVVARPCPDFINGVKYNSTRSAYRECLNENGFWAFKINYSCEPTELEEKRYPVHYKIALI 112
Qy 121 INYLGHCSIALVIAFLFLCLRSICLRNIHWNLTITFILRNIMWFLQMDHNIHE 180
Db 113 INYLGHCSIVGALVIAFLFLCLRSICLRNIHWNLTITFILRNIMWLLQLLDHNIHE 172
Qy 181 SNEVWCRCITTIYNYFVVTNFFWMEVGCYLHTAIVMTYSTDKLRKWVFLFIGWCIPSP 240
Db 173 RNEPWCRLITTVNYFVVTNFFWMEVGCYLHTAIVMTYSTDKLRKWVFLFIGWCIPCV 232
Qy 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVFLNIVRILMTKLRAS 300
Db 233 IIAWAVGKLYNENEQWFGKEPGKYDYIYQGPVIVVLLINFLVFLNIVRILMTKLRAS 292
Qy 301 TSETIOYRKAVKATLVLLPLLGITTYMLFFVNPGEDDVSQIVFIYFNSFLOSFOGFFVSFV 360
Db 293 TSETIOYRKAVKATLVLLPLLGITTYMLFFVNPGEDDVSQIVFIYFNSFLOSFOGFFVSFV 352
Qy 361 YCFLNGEVRSAARKRWHRWQDHHSLRVRVARAMSIPSPTRISFHSIKQTAAV 413
Db 353 YCFLNGEVRSAARKRWHRWQDHHSLRVRVARAMSIPSPTRISFHSIKHTTAV 405
RESULT 4
US-10-649-852-38
; Sequence 38, Application US/10649852
; Publication No. US20040101911A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or F
; TITLE OF INVENTION: Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448R
; CURRENT APPLICATION NUMBER: US/10/649,852
; CURRENT FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: US 09/799,978
; PRIOR FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 38
; LENGTH: 405
; TYPE: PRT
; ORGANISM: Ameiurus nebulosus
US-10-649-852-38

Query Match      81.1%; Score 1807; DB 16; Length 405;
Best Local Similarity 79.9%; Pred. No. 1.1e-159;
Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;

QY 1 MDSTFEIIDEFDANCILLDAFQDSFLHSSSSFFGPEGYCSATIDQIGTCWPRSLAG 60
Db 1 MEVSLELL--SVEVNCSLADAFGDPAYGNASDAL-----YCNATADEIGTCWPRSGAG 52

QY 61 ELVERPCDPSFNGIRYNTNRVYRECFENGWTWASWMTYSQCVPILDNKRKYALHYKI 120
Db 53 RVVARPCDFINGVKYNSTRSAYRECLNGTWAFKINYSSEPILEEKRYPVHYKIALI 112

QY 121 INYLGHCSILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMMFLQMDIHNIE 180
Db 113 INYLGHCSIVGALVIAFLFLCLRSIRCLRNVIHWNLTITFILRNIMMFLQMDIHNIE 172

QY 181 SNEVWCRCITTYINYYVVTNFFMVEGCVLHTAIVMTYSTDKLRKWVFLFGWCIPSP 240
Db 173 RNEPCRLITTYINYYVVTNFFMVEGCVLHTAIVMTYSTDKLRKWVFLFGWCIPCPV 232

QY 241 IVTWAICKLFYENECQWIKGPKYIDYIQGRVILVLLINFLVFNILMTKRLAST 300
Db 233 ILAWAVGKLYNEQECWFKGPKYVDYIQGPVILVLLINFLVFNILMTKRLAST 292

QY 301 TSETTIQYRKAVKATLVLLPLLGITVYMLFPVNPGEDDVSQIVFIYFNSFLOSGQGFV 360
Db 293 TSETTIQYRKAVKATLVLLPLLGITVYMLFPVNPGEDDVSQIVFIYFNSFLOSGQGFV 352

QY 361 YCFLNGEVRSAARKRWQDHHSRLVRVARAMSPTSPTRISFHSIKQTAAV 413
Db 353 YCFLNGEVRSAVRKRWQDHHSRLVRVARAMSPTSPTRISFHSIKHTTAV 405

RESULT 5
US-10-292-798-636
; Sequence 636, Application US/10292798
; Publication No. US20030235833A1
; GENERAL INFORMATION:
; APPLICANT: SUWA, MAKIKO
; APPLICANT: ASAI, KIYOSHI
; APPLICANT: AKIYAMA, YUTAKA
; APPLICANT: ABURATANI, HIROYUKI
; TITLE OF INVENTION: GUANOSINE TRIPHOSPHATE-BINDING PROTEIN COUPLED RECEPTORS
; FILE REFERENCE: 084335/166
; CURRENT APPLICATION NUMBER: US/10/292,798
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: 10/017,161
; PRIOR FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: JP 2001-246789
; PRIOR FILING DATE: 2001-06-18
; NUMBER OF SEQ ID NOS: 2070
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 636
; LENGTH: 411
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-292-798-636

Query Match      80.9%; Score 1804; DB 15; Length 411;
Best Local Similarity 80.0%; Pred. No. 2.1e-159;
Matches 333; Conservative 33; Mismatches 42; Indels 8; Gaps 4;

QY 1 MDSTFEIIDEFDANCILLDAFQDSFLHSSSSFFGPEGP--YCSATIDQIGTCWPRSL 58
Db 1 MDAALLHSLI---EANCSL--ALAEELLDDGCGPFLDPGPGYSYCNLTLDQIGTCWPRSA 55

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 39
; LENGTH: 405
; TYPE: PRT
; ORGANISM: Ameiurus nebulosus
US-10-649-852-39

Query Match      81.1%; Score 1807; DB 16; Length 405;
Best Local Similarity 79.9%; Pred. No. 1.1e-159;
Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;

QY 1 MDSTFEIIDEFDANCILLDAFQDSFLHSSSSFFGPEGYCSATIDQIGTCWPRSLAG 60
Db 1 MEVSLELL--SVEVNCSLADAFGDPAYGNASDAL-----YCNATADEIGTCWPRSGAG 52

QY 61 ELVERPCDPSFNGIRYNTNRVYRECFENGWTWASWMTYSQCVPILDNKRKYALHYKI 120
Db 53 RVVARPCDFINGVKYNSTRSAYRECLNGTWAFKINYSSEPILEEKRYPVHYKIALI 112

QY 121 INYLGHCSILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMMFLQMDIHNIE 180
Db 113 INYLGHCSIVGALVIAFLFLCLRSIRCLRNVIHWNLTITFILRNIMMFLQMDIHNIE 172

QY 181 SNEVWCRCITTYINYYVVTNFFMVEGCVLHTAIVMTYSTDKLRKWVFLFGWCIPSP 240
Db 173 RNEPCRLITTYINYYVVTNFFMVEGCVLHTAIVMTYSTDKLRKWVFLFGWCIPCPV 232

QY 241 IVTWAICKLFYENECQWIKGPKYIDYIQGRVILVLLINFLVFNILMTKRLAST 300
Db 233 ILAWAVGKLYNEQECWFKGPKYVDYIQGPVILVLLINFLVFNILMTKRLAST 292

QY 301 TSETTIQYRKAVKATLVLLPLLGITVYMLFPVNPGEDDVSQIVFIYFNSFLOSGQGFV 360
Db 293 TSETTIQYRKAVKATLVLLPLLGITVYMLFPVNPGEDDVSQIVFIYFNSFLOSGQGFV 352

QY 361 YCFLNGEVRSAARKRWQDHHSRLVRVARAMSPTSPTRISFHSIKQTAAV 413
Db 353 YCFLNGEVRSAVRKRWQDHHSRLVRVARAMSPTSPTRISFHSIKHTTAV 405

RESULT 6
US-09-881-401-8
; Sequence 8, Application US/09881401
; Patent No. US20020077468A1
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; Lovensdorf, Tilman
; Liaw, Chen
; Grigoriadis, Dimitri E.
; Chalmers, Derek T.
; DeSouza, Errol B.
; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
; RECEPTORS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed Intellectual Property Law Group
; STREET: 701 Fifth Avenue, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/881,401
; FILING DATE: 13-Jun-2001
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Christiansen, William T.
; REGISTRATION NUMBER: 44,614
; REFERENCE/POCKET NUMBER: 690068.401C4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 411 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-881-401-8

Query Match      80.7%; Score 1799; DB 9; Length 411;
Best Local Similarity 79.8%; Pred. No. 6.2e-159;
```



```
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or R
; TITLE OF INVENTION: Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448R
; CURRENT APPLICATION NUMBER: US/10/649,852
; PRIOR FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: US 09/799,978
; PRIOR FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 10
; LENGTH: 411
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-649-852-10

Query Match      80.7%; Score 1799; DB 16; Length 411;
Best Local Similarity 79.8%; Pred. No. 6.2e-159;
Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

QY 1 MDSTFEIILDFDANCSLLDFAQDSFLHSSSSFFGEGP--YCSATIDQIGTCWPRSL 58
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 1 MDAALLHSL--EANCSL--ALABELLDGWPPLDPEGYSYCNVTTLDQIGTCWPRSA 55

QY 59 AGEIVERPCDSENGIRYNTNRYVRECFTWASWNYSCVPILDNK-RKYALHYKI 117
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 56 AGALVERPCPEYFNGKYNTTNRAYRECLNENGTWASKINYSQCEPILDDKQKDYDLHYRI 115

QY 118 ALIINYLGHCISIALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMWFLQMDHN 177
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 116 ALVNYLGHCVSAALVAALFLFLALRSIRCLRNVIHWNLTITFILRNWVWFLQLVDHE 175

QY 178 IHESNEVWCRCITTIYNYFVVTNFFMWVEGCVLHTAIWMTYSTDKLRKWFLEFGWCIP 237
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 176 VHESNEVWCHCITTIYNYFVVTNFFMWVEGCVLHTAIWMTYSTDLKCLFLFEGWCIP 235

QY 238 SPIIVTWAICKLFYENECWIGKEPGKYDIYIOGRVILVLLINFLVFNIVRIIMTKLR 297
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 236 FBIIVAMAIGKLYENECWFGKPGDLVDYIOGPILVLLINFLVFNIVRIIMTKLR 295

QY 298 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLQSQGFV 357
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 296 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDLQIMFIYFNSFLQSQGFV 355

QY 358 SVFYCFNLGEVRSAAKRHRWQDHHSLRVVARAMS IPTSPTRISFHSIKQTAAV 413
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 356 SVFYCFNCEVRSVAKRHRWQDHHSLRVVPMARAMS IPTSPTRISFHSIKQTAAV 411

RESULT 10
US-10-821-502-8
; Sequence 8, Application US/10821502
; Publication No. US20040185533A1
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; Altersdorf, Tilman
; Liaw, Chen Wang
; Grigoriadis, Dimitri E.
; Chalmers, Derek T.
; DeSouza, Errol B.
; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
; RECEPTORS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed Intellectual Property Law Group
; STREET: 701 Fifth Avenue, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
```

```
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/821,502
; FILING DATE: 09-Apr-2004
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Christiansen, William T.
; REGISTRATION NUMBER: 44,614
; REFERENCE/DOCKET NUMBER: 690068.401C5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 411 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
; US-10-821-502-8

Query Match      80.7%; Score 1799; DB 16; Length 411;
Best Local Similarity 79.8%; Pred. No. 6.2e-159;
Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

QY 1 MDSTFEIILDFDANCSLLDFAQDSFLHSSSSFFGEGP--YCSATIDQIGTCWPRSL 58
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 1 MDAALLHSL--EANCSL--ALABELLDGWPPLDPEGYSYCNVTTLDQIGTCWPRSA 55

QY 59 AGEIVERPCDSENGIRYNTNRYVRECFTWASWNYSCVPILDNK-RKYALHYKI 117
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 56 AGALVERPCPEYFNGKYNTTNRAYRECLNENGTWASKINYSQCEPILDDKQKDYDLHYRI 115

QY 118 ALIINYLGHCISIALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMWFLQMDHN 177
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 116 ALVNYLGHCVSAALVAALFLFLALRSIRCLRNVIHWNLTITFILRNWVWFLQLVDHE 175

QY 178 IHESNEVWCRCITTIYNYFVVTNFFMWVEGCVLHTAIWMTYSTDKLRKWFLEFGWCIP 237
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 176 VHESNEVWCHCITTIYNYFVVTNFFMWVEGCVLHTAIWMTYSTDLKCLFLFEGWCIP 235

QY 238 SPIIVTWAICKLFYENECWIGKEPGKYDIYIOGRVILVLLINFLVFNIVRIIMTKLR 297
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 236 FBIIVAMAIGKLYENECWFGKPGDLVDYIOGPILVLLINFLVFNIVRIIMTKLR 295

QY 298 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLQSQGFV 357
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 296 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDLQIMFIYFNSFLQSQGFV 355

QY 358 SVFYCFNLGEVRSAAKRHRWQDHHSLRVVARAMS IPTSPTRISFHSIKQTAAV 413
||: : : : ||||| : ||||| ||||| ||||| |||||
Db 356 SVFYCFNCEVRSVAKRHRWQDHHSLRVVPMARAMS IPTSPTRISFHSIKQTAAV 411

RESULT 11
US-10-757-262-120
; Sequence 120, Application US/10757262
; Publication No. US20040197825A1
; GENERAL INFORMATION:
; APPLICANT: Karicheti, Venkateswarlu
; APPLICANT: Silos-Santiago, Inmaculada
; APPLICANT: Eliasof, Scott D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING
; TITLE OF INVENTION: UROLOGICAL DISORDERS USING 44390, 54181, 211, 5687, 884,
; TITLE OF INVENTION: 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047,
; TITLE OF INVENTION: 33751, 52872, 14083, 20739, 32544, 43239, 44373, 51164,
; TITLE OF INVENTION: 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990,
; TITLE OF INVENTION: 18547, 115, 579, 15985, 15625, 760, 18603, 2395, 2554, 8675,
; TITLE OF INVENTION: 32720, 4809, 14303, 16816, 17827, 32620, 577, 619, 1423,
; TITLE OF INVENTION: 2158, 8263, 15402, 16209, 16386, 21165, 30911, 41897, 1643,
```

;; TITLE OF INVENTION: 2543, 9626, 13231, 32409, 84260, 2882, 8203, 32678 OR
;; TITLE OF INVENTION: 55053
;; FILE REFERENCE: MEI03-007P1RNMNIM
;; CURRENT APPLICATION NUMBER: US/10/757,262
;; CURRENT FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 60/440,318
;; PRIOR FILING DATE: 2003-01-15
;; PRIOR APPLICATION NUMBER: US 60/444,783
;; PRIOR FILING DATE: 2003-02-04
;; PRIOR APPLICATION NUMBER: US 60/457,901
;; PRIOR FILING DATE: 2003-03-27
;; PRIOR APPLICATION NUMBER: US 60/468,775
;; PRIOR FILING DATE: 2003-05-08
;; PRIOR APPLICATION NUMBER: US 60/471,614
;; PRIOR FILING DATE: 2003-05-19
;; PRIOR APPLICATION NUMBER: US 60/478,742
;; PRIOR FILING DATE: 2003-06-16
;; PRIOR APPLICATION NUMBER: US 60/488,529
;; PRIOR FILING DATE: 2003-07-18
;; PRIOR APPLICATION NUMBER: US 60/491,156
;; PRIOR FILING DATE: 2003-07-30
;; PRIOR APPLICATION NUMBER: US 60/499,594
;; PRIOR FILING DATE: 2003-09-02
;; PRIOR APPLICATION NUMBER: US 60/506,332
;; PRIOR FILING DATE: 2003-09-26
;; NUMBER OF SEQ ID NOS: 136
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 120
;; LENGTH: 411
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-10-757-262-120

Query Match 80.7%; Score 1799; DB 16; Length 411;
Best Local Similarity 79.8%; Pred. No. 6.2e-159;
Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;
Qy 1 MDSTIFEIIDEFDANCSLLDPAQDSFLHSESSFFGFEGP--YCSATIDQIGTCWPSRL 58
Db 1 MDALLHSL---FANCSL--ALAEELLDDGWGPDPPEGYSYCNITLDDQIGTCWPSRA 55
Qy 59 AGELVERPCDPSFNGIRYNTNRVYRCFENGWTWASWMNYSCQVPILDNK-RKYALHYKI 117
Db 56 AGALVERPCPYFNGVKYNTNRNAYRECLNGTWASKINSQCFPIILDDKQKDYDLHYRI 115
Qy 118 ALIINYLGHCISIALVALTAFLLFLCLRSIRCLRNIIHWNLTTFILRNIMWFLLOMDHN 177
Db 116 ALVNYLGHCVSVAALVAFLFLALRSIRCLRNVIHWNLTTFILRNVMWFLQLVDHE 175
Qy 178 IHESNEVWCRCITTYNYFVVTNFFWVVEGCVLHTAIVMTYSTDKLRKWVFLFGWCIP 237
Db 176 VHESNEVWCRCITTYNFYFVVTNFFWVVEGCVLHTAIVMTYSTRLRKCLFLFGWCIP 235
Qy 238 SPIIVTWAICKLFYENECQWKGPKYIDYIYQGRVILVLLINFLVFNILNVRILMTKLR 297
Db 236 PPIIVAMAIGKLYFENECQWKGPKGLVDYIYQGPPIILVLLINFLVFNILNVRILMTKLR 295
Qy 298 ASTTSETIQRKAVKATVLLPLLGITYMLFFVNPBGDDVSQIVFIYFNSFLOSFGFFV 357
Db 296 ASTTSETIQRKAVKATVLLPLLGITYMLFFVNPBGDDLSQIMFIYFNSFLOSFGFFV 355
Qy 358 SVFYCFNLGNGEVRSAARKRWQDHSLSURVVARAMSIPSPTRISPHSIKQTAAV 413
Db 356 SVFYCFNNGEVRSAVRKEWRWQDHSLSURVPMARAMSIPSPTRISPHSIKQTAAV 411

RESULT 12

US-09-881-401-4
; Sequence 4, Application US/09881401
; Patent No. US20020077468A1
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; Olterdord, Tilman

Liaw, Chen
Grigoriadis, Dimitri E.
Chalmers, Derek T.
DeSouza, Errol B.
TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Seed Intellectual Property Law Group
STREET: 701 Fifth Avenue, Suite 6300
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/881,401
FILING DATE: 13-Jun-2001
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Christiansen, William T.
REGISTRATION NUMBER: 44,614
REFERENCE/DOCKET NUMBER: 690068.401C4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-881-401-4

Query Match 80.4%; Score 1793; DB 9; Length 411;
Best Local Similarity 80.0%; Pred. No. 2.3e-158;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;
Qy 1 MDSTIFEIIDEFDANCSLLDPAQDSFLHSESSFFGFEGP--YCSATIDQIGTCWPSRL 58
Db 1 MDAA---LLSLSEANCSL--ALAEELLDDGWGEPPDPEGYSYCNITLDDQIGTCWPSA 55
Qy 59 AGELVERPCDPSFNGIRYNTNRVYRCFENGWTWASWMNYSCQVPILDNK-RKYALHYKI 117
Db 56 PGALVERPCPEYFNGIKYNTNRNAYRECLNGTWASRINYSHCEPILDDKQKDYDLHYRI 115
Qy 118 ALIINYLGHCISIALVALTAFLLFLCLRSIRCLRNIIHWNLTTFILRNIMWFLLOMDHN 177
Db 116 ALIINYLGHCVSVAALVAFLFLVLSIRCLRNVIHWNLTTFILRNITWFLQLDHE 175
Qy 178 IHESNEVWCRCITTYNYFVVTNFFWVVEGCVLHTAIVMTYSTDKLRKWVFLFGWCIP 237
Db 176 VHESNEVWCRCITTYNFYFVVTNFFWVVEGCVLHTAIVMTYSTELRKCLFLFGWCIP 235
Qy 238 SPIIVTWAICKLFYENECQWKGPKYIDYIYQGRVILVLLINFLVFNILNVRILMTKLR 297
Db 236 CPIIVAWAVGKLYYENECQWKGPKGLVDYIYQGPPIILVLLINFLVFNILNVRILMTKLR 295
Qy 298 ASTTSETIQRKAVKATVLLPLLGITYMLFFVNPBGDDVSQIVFIYFNSFLOSFGFFV 357
Db 296 ASTTSETIQRKAVKATVLLPLLGITYMLFFVNPBGDDLSQIVFIYFNSFLOSFGFFV 355
Qy 358 SVFYCFNLGNGEVRSAARKRWQDHSLSURVVARAMSIPSPTRISPHSIKQTAAV 413
Db 356 SVFYCFNNGEVRSAIRKRWQDHSLSURVVARAMSIPSPTRISPHSIKQTAAV 411

RESULT 13

US-09-818-009-12

GENERAL INFORMATION:
APPLICANT: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
TITLE OF INVENTION: UROCORTIN PEPTIDES
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: FITCH, EVEN, TABIN & FLANNERY
STREET: 120 S. LaSalle Street, Suite 1600
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60603

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/818,009
FILING DATE: 26-Mar-2001

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/981,189
FILING DATE: 10-DEC-1997
APPLICATION NUMBER: US 60/028,144
FILING DATE: 13-JUN-1995
APPLICATION NUMBER: US 60/002,223
FILING DATE: 11-AUG-1995

ATTORNEY/AGENT INFORMATION:
NAME: Schumann, James J.
REGISTRATION NUMBER: 20,856
REFERENCE/DOCKET NUMBER: 57611

TELECOMMUNICATION INFORMATION:
TELEPHONE: 858-552-1311
TELEFAX: 858-552-0095

SEQUENCE DESCRIPTION: SEQ ID NO: 12:

US-09-818-009-12

Query Match 80.4%; Score 1793; DB 10; Length 411;
Best Local Similarity 80.0%; Pred. No. 2.3e-158;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

QY 1 MDSTFEIIDFDANCSLDADFOSFLHSESSFFGEGP--YCSATIDQIGTCWPSL 58
DB 1 MDAA---LLLSLEANCSL--ALAEELLDGEGPPDEGPGSYSCNTTLDQIGTCWPSA 55
QY 59 AGELVERPCDPSFNGIRYNTNRVRECFENGWTWASWNNYSQCVPIIDNK-RKYALHYKI 117
DB 56 PGALVERPCPEYFNGIKYNTNRNAYRECLENGTWASRINYSHCEPILDDKQKDYDLHYRI 115
QY 118 ALIINYLGHCSILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMFWLLQMDHN 177
DB 116 ALIINYLGHCSVVALVAFLFLVLSIRCLRNVIHWNLTITFILRNITWELLQIDHE 175
QY 178 IHESNEVWCRCITTIYNYFVNTNFMFVEGCVLHTAIWMTYSTDKLRKWFLFGWCIP 237
DB 176 VHEGNEVWCRCVTIIFNYFVNTNFMFVEGCVLHTAIWMTYSTHLRKLWFLFGWCIP 235
QY 238 SPIIVTWAICKLFYENEQWCKGPKYIDYIQGRVILVLLINFFVFNIVRIILMTKLR 297
DB 236 CPIIVAWAGKLYYENEQWCKGPKGDLVDYIQGPILVLLINFFVFNIVRIILMTKLR 295
QY 298 ASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLSQSGPFV 357
DB 296 ASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPGEDDLSQIVFIYFNSFLSQSGPFV 355
QY 358 SVFYCFNGEVRSAARKWHRWQDHSRLVRVARAMSIPSPTRISFHSIKQTAAV 413
DB 356 SVFYCFNGEVRSAARKWHRWQDHSRLVRVARAMSIPSPTRISFHSIKQTAAV 411

RESULT 14

US-09-799-978-18
Sequence 18, Application US/09799978

Publication No. US20030165807A1

GENERAL INFORMATION:
APPLICANT: The Procter & Gamble Company

APPLICANT: Isfort, Robert
APPLICANT: Sheldon, Russell

TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or
Function Using Corticotropin Releasing Factor Receptors
FILE REFERENCE: 8448

CURRENT APPLICATION NUMBER: US/09/799,978
CURRENT FILING DATE: 2001-03-06

NUMBER OF SEQ ID NOS: 44
SOFTWARE: Patent in version 3.0

SEQ ID NO 18
LENGTH: 411

TYPE: PRT
ORGANISM: Rattus norvegicus

US-09-799-978-18

Query Match 80.4%; Score 1793; DB 10; Length 411;
Best Local Similarity 80.0%; Pred. No. 2.3e-158;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

QY 1 MDSTFEIIDFDANCSLDADFOSFLHSESSFFGEGP--YCSATIDQIGTCWPSL 58
DB 1 MDAA---LLLSLEANCSL--ALAEELLDGEGPPDEGPGSYSCNTTLDQIGTCWPSA 55
QY 59 AGELVERPCDPSFNGIRYNTNRVRECFENGWTWASWNNYSQCVPIIDNK-RKYALHYKI 117
DB 56 PGALVERPCPEYFNGIKYNTNRNAYRECLENGTWASRINYSHCEPILDDKQKDYDLHYRI 115
QY 118 ALIINYLGHCSILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMFWLLQMDHN 177
DB 116 ALIINYLGHCSVVALVAFLFLVLSIRCLRNVIHWNLTITFILRNITWELLQIDHE 175
QY 178 IHESNEVWCRCITTIYNYFVNTNFMFVEGCVLHTAIWMTYSTDKLRKWFLFGWCIP 237
DB 176 VHEGNEVWCRCVTIIFNYFVNTNFMFVEGCVLHTAIWMTYSTHLRKLWFLFGWCIP 235
QY 238 SPIIVTWAICKLFYENEQWCKGPKYIDYIQGRVILVLLINFFVFNIVRIILMTKLR 297
DB 236 CPIIVAWAGKLYYENEQWCKGPKGDLVDYIQGPILVLLINFFVFNIVRIILMTKLR 295
QY 298 ASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLSQSGPFV 357
DB 296 ASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPGEDDLSQIVFIYFNSFLSQSGPFV 355
QY 358 SVFYCFNGEVRSAARKWHRWQDHSRLVRVARAMSIPSPTRISFHSIKQTAAV 413
DB 356 SVFYCFNGEVRSAARKWHRWQDHSRLVRVARAMSIPSPTRISFHSIKQTAAV 411

RESULT 15

US-10-649-852-18
Sequence 18, Application US/10649852

Publication No. US20040101911A1
GENERAL INFORMATION:

APPLICANT: The Procter & Gamble Company
APPLICANT: Isfort, Robert

APPLICANT: Sheldon, Russell
TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or

Function Using Corticotropin Releasing Factor Receptors
FILE REFERENCE: 8448R

CURRENT APPLICATION NUMBER: US/10/649,852
CURRENT FILING DATE: 2003-08-27

PRIOR APPLICATION NUMBER: US 09/799,978
PRIOR FILING DATE: 2001-03-06

NUMBER OF SEQ ID NOS: 44
SOFTWARE: Patent in version 3.0

SEQ ID NO 18
LENGTH: 411

TYPE: PRT
ORGANISM: Rattus norvegicus

US-10-649-852-18

```
Query Match      80.4%; Score 1793; DB 16; Length 411;
Best Local Similarity 80.0%; Pred. No. 2.3e-158;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

Qy 1 MDSIFRIIDDEFDANCGLLDADFODSFLHSSSSFFGEGP--YCSATIDQIGTCWPRSL 58
Db 1 MDAA---LLLSLLBANCSL--ALAEELLDCGWGPPDPGEGYSYCNITLDOIGTCWQPSA 55

Qy 59 AGELVERPCPDSPFNGIRYNTTRNYRECENGFWASWNNYSQCVPILDNK-RKYALHYKI 117
Db 56 PGALVERPCPEYFNGIKYNTTRNAYRECLENGTWASRINYSHCEPILDDKORKYDLYRI 115

Qy 118 ALIINYLGHCISIALVIAFLFLCLRSIRCLRNIIHWNLTTFILRNIMWFLLOMIDHN 177
Db 116 ALIINYLGHCVSVALVAAFLFLVLRISIRCLRNVIHWNLTTFILRNITWFLQLIDHE 175

Qy 178 IHESNEVWCRCITTIYNYFVVTFNFFMFWVEGCVLHTALVMTYSTDKLRKWVFLFGWCIP 237
Db 176 VHEGNEVWCRCVTTFIYNYFVVTFNFFMFWVEGCVLHTALVMTYSTEHLRKLWFLFGWCIP 235

Qy 238 SPIITVWAICKLFYENECWIGKEPGKYIDYIQGRVILVLLINFLVFLNIVRILMTKLR 297
Db 236 CPIIVANAVGKLYYENECWFGKEPGDLVDYIYQGPILVLLINFLVFLNIVRILMTKLR 295

Qy 298 ASTTSETIQYRKAVKATLVLLPLLGITYMLPFVNPGEDDVSQIVFIYFNSFLQSFQGFV 357
Db 296 ASTTSETIQYRKAVKATLVLLPLLGITYMLPFVNPGEDDLQSIYFIYFNSFLQSFQGFV 355

Qy 358 SVFYCFNGEVRSAARKRHWQDHSLRVVRVARAMSIPTSPTRISPHSIKQTAAV 413
Db 356 SVFYCFNGEVRSAALKRHWQDHHLRVVPARAMSIPTSPTRISPHSIKQTAAV 411
```

Search completed: August 20, 2005, 00:42:16
Job time : 165 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 20, 2005, 00:23:03 ; Search time 43 Seconds
(without alignments)
716.978 Million cell updates/sec

Title: US-10-649-852-32
Perfect score: 2229
Sequence: 1 MDSITFEIIDEFDANCSLL.....SIPTSPTRISPHSIKQTAHV 413

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/ptodata/1/iaa/5A-COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/5B-COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/6A-COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/6B-COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/PCTUS-COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2229	100.0	413	4	US-09-799-978-32
2	1807	81.1	405	4	US-09-799-978-38
3	1804	80.9	411	4	US-09-631-603-12
4	1799	80.7	411	1	US-08-381-433A-8
5	1799	80.7	411	4	US-09-799-978-10
6	1799	80.7	411	4	US-09-881-401-8
7	1793	80.4	411	1	US-08-381-433A-4
8	1793	80.4	411	3	US-08-981-189B-12
9	1793	80.4	411	4	US-09-799-978-18
10	1793	80.4	411	4	US-09-881-401-4
11	1787.5	80.2	397	4	US-09-799-978-14
12	1786	80.1	438	4	US-09-799-978-12
13	1784.5	80.1	431	3	US-08-981-189B-13
14	1784.5	80.1	431	4	US-09-881-401-2
15	1778.5	79.8	431	1	US-08-381-433A-2
16	1776.5	79.7	431	4	US-09-799-978-20
17	1770.5	79.4	431	3	US-08-981-189B-11
18	1770.5	79.4	431	3	US-08-482-746-10
19	1770.5	79.4	431	4	US-09-580-734-10
20	1770.5	79.4	431	4	US-08-374-009-10
21	1770.5	79.4	431	4	US-09-191-724-10
22	1770.5	79.4	431	4	US-09-799-978-24
23	1769	79.4	430	4	US-09-799-978-26
24	1582.5	71.0	428	4	US-09-799-978-36
25	1582	71.0	420	4	US-09-799-978-42
26	1578.5	70.8	445	4	US-09-799-978-34
27	1566	70.3	415	1	US-08-110-286A-2

28	1566	70.3	415	3	US-08-482-746-2	Sequence 2, Appli
29	1566	70.3	415	4	US-09-580-734-2	Sequence 2, Appli
30	1566	70.3	415	4	US-08-374-009-2	Sequence 2, Appli
31	1566	70.3	415	4	US-09-191-724-2	Sequence 2, Appli
32	1566	70.3	415	4	US-09-799-978-2	Sequence 2, Appli
33	1566	70.3	415	4	US-09-799-978-4	Sequence 4, Appli
34	1564.5	70.2	415	4	US-09-799-978-30	Sequence 30, Appli
35	1560	70.0	415	4	US-09-826-509-483	Sequence 483, App
36	1556.5	69.8	415	3	US-08-482-746-13	Sequence 13, Appl
37	1556.5	69.8	415	4	US-09-580-734-13	Sequence 13, Appl
38	1556.5	69.8	415	4	US-08-374-009-13	Sequence 13, Appl
39	1556.5	69.8	415	4	US-09-799-978-22	Sequence 22, Appl
40	1553	69.7	415	4	US-09-799-978-40	Sequence 40, Appl
41	1551.5	69.6	415	1	US-08-110-286A-6	Sequence 6, Appli
42	1551.5	69.6	415	3	US-08-981-189B-10	Sequence 10, Appl
43	1551.5	69.6	415	3	US-08-482-746-6	Sequence 6, Appli
44	1551.5	69.6	415	4	US-09-580-734-6	Sequence 6, Appli
45	1551.5	69.6	415	4	US-09-580-734-6	Sequence 6, Appli

ALIGNMENTS

RESULT 1

US-09-799-978-32
; Sequence 32, Application US/09799978
; Patent No. 6670140
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass Or
; TITLE OF INVENTION: Function Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799,978
; CURRENT FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 32
; LENGTH: 413
; TYPE: PRT
; ORGANISM: Xenopus laevis
US-09-799-978-32

Query Match	100.0%	Score	2229;	DB	4;	Length	413;
Best Local Similarity	100.0%	Pred. No.	1.2e-200;				
Matches	413;	Conservative	0;	Mismatches	0;	Indels	0;
Gaps	0;						
Qy	1	MDSITFEIIDEFDANCSLLDAFQDSPFLHSESSSPFGFEGPYCSATIDQIGTCWPRSLAG	60				
Db	1	MDSITFEIIDEFDANCSLLDAFQDSPFLHSESSSPFGFEGPYCSATIDQIGTCWPRSLAG	60				
Qy	61	ELVERPCDPSNGIRYNTNRVYRCFENGWASWNNYSQCVPILDNRKRYALHYKIALI	120				
Db	61	ELVERPCDPSNGIRYNTNRVYRCFENGWASWNNYSQCVPILDNRKRYALHYKIALI	120				
Qy	121	INYLGHCSILALVAFLLFLCLRSICRLNIHNLITTFILRNIMFLLQMDHNIHE	180				
Db	121	INYLGHCSILALVAFLLFLCLRSICRLNIHNLITTFILRNIMFLLQMDHNIHE	180				
Qy	181	SNEVWCRCITTYNYFVVTNFFWMEVEGCYLHTAIVMTYSTDKLRKWFLFGWCIPSP	240				
Db	181	SNEVWCRCITTYNYFVVTNFFWMEVEGCYLHTAIVMTYSTDKLRKWFLFGWCIPSP	240				
Qy	241	IVTWAICKLFVNEQCWIKGPKGYIDYIQGRVILVLLINVFILNIVRIILMTKLRAS	300				
Db	241	IVTWAICKLFVNEQCWIKGPKGYIDYIQGRVILVLLINVFILNIVRIILMTKLRAS	300				
Qy	301	TSETTOYRKAVKATVLLPLLGITTYMLFPVNPGEDDVSQIVFIYFNSFLQSQFGFVSVF	360				
Db	301	TSETTOYRKAVKATVLLPLLGITTYMLFPVNPGEDDVSQIVFIYFNSFLQSQFGFVSVF	360				
Qy	361	YCFNLNGEVRSAARKRWHRWQDHHSLRVRVARAMSIPSPTRISFHSIKQTAHV	413				

NAME: McMASTERS, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 690068.401C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
TELEX: 3723836 SEEDANDBERRY
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 411 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-381-433A-8

Query Match 80.7%; Score 1799; DB 1; Length 411;
Best Local Similarity 79.8%; Pred. No. 2.3e-160;
Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

QY 1 MDSTIFEIIDFPDANCSSLDAFQDSFLHSSSSFFGPEGP--YCSATIDQIGTCWPRSL 58
DB 1 MDAALLHSL--EANCSL--ALABELLDGWPDPDPGYPYSCNTTLDQIGTCWPRSA 55
QY 59 AGELVERPCDPSFNGIRYNTTRNVYRECFTWASWNNYSQCVPIIDNK-RKYALHYKI 117
DB 56 AGALVERPCPEYFNGVKYNTTRNAYRECLNGTWASKINYSQCEPILDDKQKRYDLHYRI 115
QY 118 ALIINYLGHICISILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMFWLQWIDHN 177
DB 116 ALVNYLGHCVSVAALVAFLFLALRSIRCLRNVIHWNLTITFILRNIMFWLQWIDHN 175
QY 178 IHESNEVWCRCITTIYNYFVNTFMMFVEGCVLHTAIYMTYSTDKLRKWFVLTGWCIP 237
DB 176 VHSNEVWCRCITTIYNYFVNTFMMFVEGCVLHTAIYMTYSTDKLRKWFVLTGWCIP 235
QY 238 SPIIIVTWAICKLFYENECWIGKEPKGYIDYIYQGRVILVLLINFLVFLNIVRIILMTKLR 297
DB 236 PFIIVAWAIGKLYYENECWIGKEPKGYIDYIYQGRVILVLLINFLVFLNIVRIILMTKLR 295
QY 298 ASTTSETIOYRKAVKATVLLPLGITYMLFFVNPGEDDVSQIVFIYFNSFLQSQGFV 357
DB 296 ASTTSETIOYRKAVKATVLLPLGITYMLFFVNPGEDDVSQIVFIYFNSFLQSQGFV 355
QY 358 SVFYCFNGEVSAAKRWQDHHSLRVVARAMSIPTRISFHSIKOTAUV 413
DB 356 SVFYCFNGEVSAAKRWQDHHSLRVVARAMSIPTRISFHSIKOTAUV 411

RESULT 5
US-09-799-978-10
Sequence 10, Application US/09799978
Patent No. 6670140
GENERAL INFORMATION:
APPLICANT: The Procter & Gamble Company
APPLICANT: Isfort, Robert
APPLICANT: Sheldon, Russell
TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or
TITLE OF INVENTION: Function Using Corticotropin Releasing Factor Receptors
FILE REFERENCE: 8448
CURRENT APPLICATION NUMBER: US/09/799,978
CURRENT FILING DATE: 2001-03-06
NUMBER OF SEQ ID NOS: 44
SOFTWARE: Patent in version 3.0
SEQ ID NO 10
LENGTH: 411
TYPE: PRT
ORGANISM: Homo sapiens
US-09-799-978-10

Query Match 80.7%; Score 1799; DB 4; Length 411;
Best Local Similarity 79.8%; Pred. No. 2.3e-160;
Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

QY 1 MDSTIFEIIDFPDANCSSLDAFQDSFLHSSSSFFGPEGP--YCSATIDQIGTCWPRSL 58
DB 1 MDAALLHSL--EANCSL--ALABELLDGWPDPDPGYPYSCNTTLDQIGTCWPRSA 55
QY 59 AGELVERPCDPSFNGIRYNTTRNVYRECFTWASWNNYSQCVPIIDNK-RKYALHYKI 117
DB 56 AGALVERPCPEYFNGVKYNTTRNAYRECLNGTWASKINYSQCEPILDDKQKRYDLHYRI 115
QY 118 ALIINYLGHICISILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMFWLQWIDHN 177
DB 116 ALVNYLGHCVSVAALVAFLFLALRSIRCLRNVIHWNLTITFILRNIMFWLQWIDHN 175
QY 178 IHESNEVWCRCITTIYNYFVNTFMMFVEGCVLHTAIYMTYSTDKLRKWFVLTGWCIP 237
DB 176 VHSNEVWCRCITTIYNYFVNTFMMFVEGCVLHTAIYMTYSTDKLRKWFVLTGWCIP 235
QY 238 SPIIIVTWAICKLFYENECWIGKEPKGYIDYIYQGRVILVLLINFLVFLNIVRIILMTKLR 297
DB 236 PFIIVAWAIGKLYYENECWIGKEPKGYIDYIYQGRVILVLLINFLVFLNIVRIILMTKLR 295
QY 298 ASTTSETIOYRKAVKATVLLPLGITYMLFFVNPGEDDVSQIVFIYFNSFLQSQGFV 357
DB 296 ASTTSETIOYRKAVKATVLLPLGITYMLFFVNPGEDDVSQIVFIYFNSFLQSQGFV 355
QY 358 SVFYCFNGEVSAAKRWQDHHSLRVVARAMSIPTRISFHSIKOTAUV 413
DB 356 SVFYCFNGEVSAAKRWQDHHSLRVVARAMSIPTRISFHSIKOTAUV 411

RESULT 6
US-09-881-401-8
Sequence 8, Application US/09881401
Patent No. 6723841
GENERAL INFORMATION:
APPLICANT: Lovenberg, Timothy W.
Oltersdorf, Tilman
Liw, Chen
Grigoriadis, Dimitri E.
Chalmers, Derek T.
DeSouza, Errol B.
TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
RECEPTORS
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Seed Intellectual Property Law Group
STREET: 701 Fifth Avenue, Suite 6300
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/881,401
FILING DATE: 13-Jun-2001
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Christiansen, William T.
REGISTRATION NUMBER: 44,614
REFERENCE/DOCKET NUMBER: 690068.401C4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 411 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 8:

```
US-09-881-401-8
Query Match      80.7%; Score 1799; DB 4; Length 411;
Best Local Similarity 79.8%; Pred. No. 2.3e-160;
Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

QY 1 MDSITFEIIDEFDANGSLDADFQDSFLHSESSFFGEGP--YCSATIDQIGTCWPRSL 58
DB 1 MDAALLHSL--BANCSL--ALAEELLDDGWGPDPDEGYSYCNITLQDQIGTCWPRSA 55
QY 59 AGELVERPCDPSFNGIRYNTNRNYRECFNGTWASWMTYSQCVPILDNK-RKYALHYKI 117
DB 56 AGALVERPCPEYFNGYKYNTRNAYRECLENGTWASKINYSQCEPILDDKQKRYDLHYRI 115
QY 118 ALIINYLGHCISIALVIAFLFLCLRSIRCLRNIIHWNLTITPILRNIMWFLQMDHN 177
DB 116 ALVNYLGHCVSAALVAALFLFLALRSIRCLRNVIHWNLTITPILRNVMWFLQLVDHE 175
QY 178 IHESNEVWCRCITTYNYFVVTNFFWVFGCYLHTALVMTYSTDKLRKWVFLFGWCIP 237
DB 176 VHESNEVWCRCITTYNYFVVTNFFWVFGCYLHTALVMTYSTDKLRKWVFLFGWCIP 235
QY 238 SPIIIVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVFLNIVRLMTKLR 297
DB 236 FPIIIVAWAIGKLYYENECQWIFGKPGDLVDYIYQGPILVLLINFLVFLNIVRLMTKLR 295
QY 298 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSFGFFV 357
DB 296 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDLQIMFIYFNSFLOSFGFFV 355
QY 358 SVFYCFNLGEVRSAAKRWHRWODHSLRVVRVARAMSIPSPTRISFHSIKQTAAV 413
DB 356 SVFYCFNGEVRSALKRWHRWODHSLRVVRVARAMSIPSPTRISFHSIKQTAAV 411

RESULT 7
US-08-381-433A-4
; Sequence 4, Application US/08381433A
; Patent No. 5786203
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; APPLICANT: Oltersdorf, Tilman
; APPLICANT: Liaw, Chen
; APPLICANT: Grigoriadis, Dimitri E.
; APPLICANT: Desouza, Errol B.
; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED AND BERRY
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/381,433A
; FILING DATE: 31-JAN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 690068.401C1
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; TELEX: 3723836 SEEDANDBERRY
; INFORMATION FOR SEQ ID NO: 4:
```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 411 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-381-433A-4

Query Match      80.4%; Score 1793; DB 1; Length 411;
Best Local Similarity 80.0%; Pred. No. 8.3e-160;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

QY 1 MDSITFEIIDEFDANGSLDADFQDSFLHSESSFFGEGP--YCSATIDQIGTCWPRSL 58
DB 1 MDA--L--LLSLLEANCSL--ALAEELLDDGWGEPPDPEGPYSYCNITLQDQIGTCWPQSA 55
QY 59 AGELVERPCDPSFNGIRYNTNRNYRECFNGTWASWMTYSQCVPILDNK-RKYALHYKI 117
DB 56 PGALVERPCPEYFNGIKYNTRNAYRECLENGTWASRINYSHCEPILDDKQKRYDLHYRI 115
QY 118 ALIINYLGHCISIALVIAFLFLCLRSIRCLRNIIHWNLTITPILRNIMWFLQMDHN 177
DB 116 ALIINYLGHCVSVALVAALFLFLVLSIRCLRNVIHWNLTITPILRNITWFLQLLDHE 175
QY 178 IHESNEVWCRCITTYNYFVVTNFFWVFGCYLHTALVMTYSTDKLRKWVFLFGWCIP 237
DB 176 VHESNEVWCRCITTYNYFVVTNFFWVFGCYLHTALVMTYSTDKLRKWVFLFGWCIP 235
QY 238 SPIIIVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFLVFLNIVRLMTKLR 297
DB 236 CPIIIVAWAIGKLYYENECQWIFGKPGDLVDYIYQGPILVLLINFLVFLNIVRLMTKLR 295
QY 298 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSFGFFV 357
DB 296 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDLQIVFIYFNSFLOSFGFFV 355
QY 358 SVFYCFNLGEVRSAAKRWHRWODHSLRVVRVARAMSIPSPTRISFHSIKQTAAV 413
DB 356 SVFYCFNGEVRSALKRWHRWODHSLRVVRVARAMSIPSPTRISFHSIKQTAAV 411

RESULT 8
US-08-981-189B-12
; Sequence 12, Application US/08981189B
; Patent No. 6214797
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: UROCORTIN PEPTIDES
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FITCH, EVEN, TABIN & FLANNERY
; STREET: 120 S. LaSalle Street, Suite 1600
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/981,189B
; FILING DATE: 10-DEC-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/028,144
; FILING DATE: 13-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/002,223
; FILING DATE: 11-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Schumann, James J.
; REGISTRATION NUMBER: 20,856
; REFERENCE/DOCKET NUMBER: 57611
```



```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 858-552-1311
; FAX: 858-552-0095
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 411 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..411
; OTHER INFORMATION: /note= "Rat CRF-R2 Short Form"
; PUBLICATION INFORMATION:
; AUTHORS: Lovenberg, Timothy W
; AUTHORS: Liaw, Chen W
; AUTHORS: Grigoriadis, Dimitri E
; AUTHORS: Chalmers, Derek T
; AUTHORS: Desouza, Errol B
; AUTHORS: Oltersdorf, Tilman
; TITLE: Cloning and characterization of a
; TITLE: functionally distinct corticotropin-releasing
; TITLE: factor receptor subtype from rat brain
; JOURNAL: Proc. Natl. Acad. Sci. U.S.A.
; VOLUME: 92
; PAGES: 836-840
; DATE: January-1995
; US-08-981-189B-12

Query Match 80.4%; Score 1793; DB 3; Length 411;
Best Local Similarity 80.0%; Pred. No. 8.3e-160;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

QY 1 MDSTIFEIIDEFDANGSLDADFOSFLHSESSFFGEGP--YCSATIDQIGTCWPRSL 58
Db 1 MDAA---LLLSLEANCSL--ALAEELLDDGWGPPDPPEGYSYCNVTLDDQIGTCWQPSA 55

QY 59 AGELVERPCDPSFNGIRYNTTRNVYRECFTNGTWSMNYSCQVPILDNK-RKVALHYKI 117
Db 56 PGALVERPCPEYFNGIKYNTTRNAYRECLNGTWASRINYSCHCEPILDDKQKDYDLHYRI 115

QY 118 ALIINYLGHCISIALVALFLLCLRSIRCLRNIIHWNLTITFILRNIMFLLQMDHN 177
Db 116 ALIINYLGHCVSVALVAFLFLVLSIRCLRNVIHWNLTITFILRNITWFLQLQIDHE 175

QY 178 IHESNEVWCRCITTIYNYFVVTNFFMFWVEGCVLHTAIVMTYSTDKLRKWVFLFGWCIP 237
Db 176 VHEGNEVWCRCVTITFYNYFVVTNFFMFWVEGCVLHTAIVMTYSTEHRLKWLFLFGWCIP 235

QY 238 SPIIVTWAICKLFLYNEQCWIGKEPGKYDIYIYQGRVILVLLINFLVFNIVRIILMTKLR 297
Db 236 CPIIVAVAGKLYYNEQCWFGKPGDLVDYIYQGPILVLLINFLVFNIVRIILMTKLR 295

QY 298 ASTTSETIYRKAVKATLVLLPLGITVYMLFFVNPGEEDVDSQIVFIYFNSFLOSQGFV 357
Db 296 ASTTSETIYRKAVKATLVLLPLGITVYMLFFVNPGEEDLSQIVFIYFNSFLOSQGFV 355

QY 358 SVFYCFNGEVSRAARKHWRQDHSRVRVARAMSIPSPTRISFHSIKQTAAV 413
Db 356 SVFYCFNGEVSRAARKHWRQDHSRVRVARAMSIPSPTRISFHSIKQTAAV 411

RESULT 10
US-09-881-401-4
; Sequence 4, Application US/09881401
; Patent No. 6723841
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; Oltsersdorf, Tilman
; Liaw, Chen
; Grigoriadis, Dimitri E.
; Chalmers, Derek T.
; Desouza, Errol B.
; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
; RECEPTORS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESS: Seed Intellectual Property Law Group
; STREET: 701 Fifth Avenue, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/881,401
; FILING DATE: 13-Jun-2001
```

```
;
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
;   NAME: Christiansen, William T.
;   REGISTRATION NUMBER: 44,614
;   REFERENCE/DOCKET NUMBER: 690068.401C4
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (206) 622-4900
;   TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 4:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 411 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-881-401-4

      Query Match      80.4%; Score 1793; DB 4; Length 411;
      Best Local Similarity 80.0%; Pred. No. 8.3e-160;
      Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

Qy 1 MDSTFIIFIIIDFANGSLDADFODSFLHSESSSFFGFEGP--YCSATIDQIGTCWPRSL 58
Db 1 MDAA--LLLSLLEANCSL--ALAEELLDCGWGPPDPPEGPYSYCNNTLTDQIGTCWPQSA 55

Qy 59 AGEIVRCPDPSFNGIRYNTNRVYRCFNGTWSWMNYSQCVPILDNK-RKYALHYKI 117
Db 56 PGALVERPCPEYFNGIKYNTNRAYRECLNGTWSRINYSHCPEPIILDDKQKYDLHYRI 115

Qy 118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLTTFILRNIMFWLLQMDIHN 177
Db 116 ALIINYLGHCVSVALVAAPLLFLVLSIRCLRNVIHWNLTTFILRNITWFLQLQIDHE 175

Qy 178 IHESNEVWCRCITTIYNYFVVTNFMFVVEGCYLHTAIWMTYSTDKLRKWVFLFGWCIP 237
Db 176 VHEGNEVWCRCVTTFINFYFVTNFMFVVEGCYLHTAIWMTYSTELRKLWFLFGWCIP 235

Qy 238 SPIITWAIKCLFYENECQWIGKPGKYDIIYQGRVILVLLINVFVFLNIVRILMTKLR 297
Db 236 CPIIWAAGVGLVYENECQWFGKPGDLVDYIQGPILVLLINVFVFLNIVRILMTKLR 295

Qy 298 ASTTSETIQYRKAVKATILVLLPLIGITVMLFFVNPGEDDVSQIVFIYFNSFLQSGQFFV 357
Db 296 ASTTSETIQYRKAVKATILVLLPLIGITVMLFFVNPGEDDLVSQIVFIYFNSFLQSGQFFV 355

Qy 358 SVFYCFNLGGEVRSAAKRWHRWQDHHSLRVRVARAMSIPTSPTRISFHSIKQTAAV 413
Db 356 SVFYCFNGEVRSALRKRWHRWQDHHALRVVPARAMSIPTSPTRISFHSIKQTAAV 411

RESULT 11
US-09-799-978-14
; Sequence 14, Application US/09799978
; Patent No. 6670140
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799,978
; CURRENT FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 14
; LENGTH: 397
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-799-978-14

      Query Match      80.2%; Score 1787.5; DB 4; Length 397;
      Best Local Similarity 85.4%; Pred. No. 2.6e-159;

; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799,978
; CURRENT FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 14
; LENGTH: 397
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-799-978-14
```

```
Matches 323; Conservative 28; Mismatches 24; Indels 3; Gaps 2;

Qy 39 EGP--YCSATIDQIGTCWPRSLAGELVERPCDPSFNGIRYNTNRVYRCFNGTWSWM 96
Db 20 QGFSYCNNTLTDQIGTCWPRSAAGALVERPCPEYFNGVKYNTNRNAYRECLNGTWSKI 79

Qy 97 NYSQCVPIILDNK-RKYALHYKIALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHW 155
Db 80 NYSQCEPIILDDKQKYDLHYRIALVYNYLGHCVSVALVAAPLLFLALRSIRCLRNIIHW 139

Qy 156 NLITTFILRNIMFWLLQMDIHNIIHESNEVWCRCITTIYNYFVVTNFMFVVEGCYLHTAI 215
Db 140 NLITTFILRNIMFWLLQMDIHNIIHESNEVWCRCITTIYNYFVVTNFMFVVEGCYLHTAI 199

Qy 216 VMTYSTDKLRKWVFLFGICWIPSPITWAIKCLFYENECQWIGKPGKYDIIYQGRVI 275
Db 200 VMTYSTELRKLCLFLFGICWIPSPITWAIKCLFYENECQWIGKPGKYDIIYQGPIL 259

Qy 276 LVLLINVFVFLNIVRILMTKLRASITSETIQYRKAVKATILVLLPLIGITVMLFFVNPGE 335
Db 260 LVLLINVFVFLNIVRILMTKLRASITSETIQYRKAVKATILVLLPLIGITVMLFFVNPGE 319

Qy 336 DVSQIVFIYFNSFLQSGQFFVSVFYCFNLGGEVRSAAKRWHRWQDHHSLRVRVARAMSI 395
Db 320 DLSQIMFIYFNSFLQSGQFFVSVFYCFNGEVRSAAKRWHRWQDHHSLRVPDARAMSI 379

Qy 396 PTPSTRISFHSIKQTAAV 413
Db 380 PTPSTRISFHSIKQTAAV 397

RESULT 12
US-09-799-978-12
; Sequence 12, Application US/09799978
; Patent No. 6670140
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799,978
; CURRENT FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 12
; LENGTH: 438
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-799-978-12

      Query Match      80.1%; Score 1786; DB 4; Length 438;
      Best Local Similarity 82.3%; Pred. No. 4.1e-159;
      Matches 325; Conservative 31; Mismatches 35; Indels 4; Gaps 3;

Qy 22 AFQDSFLHSESSSFFGFEGP--YCSATIDQIGTCWPRSLAGELVERPCDPSFNGIRYNTT 79
Db 45 ALLEQYCHT-IMTLTNLGYSYCNNTLTDQIGTCWPRSAAGALVERPCPEYFNGVKYNTT 103

Qy 80 RNVYRCFNGTWSWMNYSQCVPIILDNK-RKYALHYKIALIINYLGHCISILALVIAFL 138
Db 104 RNAYRECLNGTWSKINSQCEPIILDDKQKYDLHYRIALVYNYLGHCVSVALVAAPL 163

Qy 139 LFLCLRSIRCLRNIIHWNLTTFILRNIMFWLLQMDIHNIIHESNEVWCRCITTIYNYFV 198
Db 164 LFLALRSIRCLRNVIHWNLTTFILRNIMFWLLQMDIHNIIHESNEVWCRCITTIYNYFV 223

Qy 199 TNFFWVVEGCYLHTAIWMTYSTDKLRKWVFLFGICWIPSPITWAIKCLFYENECWI 258
Db 224 TNFFWVVEGCYLHTAIWMTYSTELRKLCLFLFGICWIPSPITWAIKCLFYENECWF 283

Qy 259 GKBPQKYDIIYQGRVILVLLINVFVFLNIVRILMTKLRASITSETIQYRKAVKATILVLL 318
```

Db 284 GKEPGDLVDYIYQGPILVLLINFLVFNIVRLMTKLRASITSETIOYRKAVKATLVLL 343
Qy 319 PLLGITTYMLFFVNPGEEDVQIVFIYFNSFLQSQFGFFVSVFYCFELNGEVSAAARKWHR 378
Db 344 PLLGITTYMLFFVNPGEEDLSQIMFIYFNSFLQSQFGFFVSVFYCFELNGEVSAAARKWHR 403
Qy 379 WODHSLRVRVARMSIPTSPTRISFHSIKQTAAV 413
Db 404 WODHSLRVRVARMSIPTSPTRISFHSIKQTAAV 438
RESULT 13
US-08-981-189B-13
; Sequence 13, Application US/08981189B
; Patent No. 6214797
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: UROCORTIN PEPTIDES
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FITCH, EVEN, TABIN & FLANNERY
; STREET: 120 S. LaSalle Street, Suite 1600
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 10-DEC-1997
; APPLICATION NUMBER: US/08/981,189B
; PRIOR APPLICATION DATA:
; FILING DATE: 13-JUN-1995
; APPLICATION NUMBER: US 60/028,144
; PRIOR APPLICATION DATA:
; FILING DATE: 11-AUG-1995
; APPLICATION NUMBER: US 60/002,223
; FILING DATE: 11-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Schumann, James J.
; REGISTRATION NUMBER: 20,856
; REFERENCE/DOCKET NUMBER: 57611
; TELEPHONE: 858-552-1311
; TELEFAX: 858-552-0095
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 431 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..431
; OTHER INFORMATION: /note= "Rat CRF-R2 Long Form"
; PUBLICATION INFORMATION:
; AUTHORS: Lovenberg, Timothy W
; AUTHORS: Liaw, Chen W
; AUTHORS: Grigoriadis, Dimitri E
; AUTHORS: Clevenger, William
; AUTHORS: Chalmers, Derek T
; AUTHORS: DeSouza, Errol B
; AUTHORS: Oltersdorf, Tilman
; TITLE: Cloning and characterization of a
; TITLE: functionally distinct corticotropin-releasing
; TITLE: factor receptor subtype from rat brain
; JOURNAL: Proc. Natl. Acad. Sci. U.S.A.
; VOLUME: 92
; PAGES: 836-840
; DATE: January-1995

US-08-981-189B-13
Query Match 80.1%; Score 1784.5; DB 3; Length 431;
Best Local Similarity 85.5%; Pred. No. 5.5e-159;
Matches 324; Conservative 24; Mismatches 28; Indels 3; Gaps 2;
Qy 38 FEGP--YCSATIDQIGTCWPSRLAGELVPRPCPSDFNGIRYNTRNRYVRECFENGWTWASW 95
Db 53 FSGPYSYCNNTLDQIGTCWPSAPGALVPRPCPEYFNGIKYNTTRNAYRECLENGTWSAR 112
Qy 96 MNYSCQVPIIDNK-RKYALHYKIALIINYLGHGCSILALVIAFLFLCLRSIRCLNIIH 154
Db 113 INYSHCEPIIDDKQKQYDLHYRIALIINYLGHCVSVVALVAFLFLVLRIRCLRNVIH 172
Qy 155 WNLITTFILRNIMWFLQIMIDHNIHESNEVMCRITTIYNYFVVTNFFMVEGCLHTA 214
Db 173 WNLITTFILRNITWFLQLDHEVHEGNEVMWCRCVTTIFNYFVVTNFFMVEGCLHTA 232
Qy 215 IVMTYSTDKLRKRVFLFIGWCIPSPPIIVTWAICKLFYENECWIGKPGKIDYIYQGRV 274
Db 233 IVMTYSTHLRKWLFLFIGWCIPCIIVAVAGKLYYENECWFCGKPGDLVDYIYQGP 292
Qy 275 ILVLLINFLVFNIVRLMTKLRASITSETIOYRKAVKATLVLLPLLGITTYMLFFVNPGE 334
Db 293 ILVLLINFLVFNIVRLMTKLRASITSETIOYRKAVKATLVLLPLLGITTYMLFFVNPGE 352
Qy 335 DDVSOIVFIYFNSFLQSQFGFFVSVFYCFELNGEVSAAARKWHRQDHHSLRVRVARMS 394
Db 353 DDLSQIVFIYFNSFLQSQFGFFVSVFYCFELNGEVSAAARKWHRQDHHSLRVRVARMS 412
Qy 395 IPTSPTRISFHSIKQTAAV 413
Db 413 IPTSPTRISFHSIKQTAAV 431
RESULT 14
US-09-881-401-2
; Sequence 2, Application US/09881401
; Patent No. 6723841
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; Oltersdorf, Tilman
; Liaw, Chen
; Grigoriadis, Dimitri E.
; Chalmers, Derek T.
; DeSouza, Errol B.
; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
; RECEPTORS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed Intellectual Property Law Group
; STREET: 701 Fifth Avenue, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/881,401
; FILING DATE: 13-Jun-2001
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Christiansen, William T.
; REGISTRATION NUMBER: 44,614
; REFERENCE/DOCKET NUMBER: 690068.401C4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 2:

```
;
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 431 amino acids
;   TYPE: amino acid
;   TOPOLOGY: linear
;   MOLECULE TYPE: protein
;   SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-881-401-2

Query Match      80.1%; Score 1784.5; DB 4; Length 431;
Best Local Similarity 85.5%; Pred. No. 5.5e-159;
Matches 324; Conservative 24; Mismatches 28; Indels 3; Gaps 2;

Qy 38 FEGP--YCSATIDQIGTCWPSLAGELVERPCPDSENGIRYNTTRNVYRECFFENGWASW 95
Db 53 FSGPYSYCVNTLQIGTCWPSAGALVERPCPEYFNGIKYNTTRNAYRECLENGTWASR 112
Qy 96 MNYSCQVPILDNK-RKVALHYKIALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIH 154
Db 113 INYSCEPILDDKQKYDLHYRIALIINYLGHCVSVALVAFLFLVLSIRCLRNVIH 172
Qy 155 WNLITTFILRNIMFLLQIDHNIHESNEVWCRCITTIYNYFVVTNFFWPFVGCYLHTA 214
Db 173 WNLITTFILRNITWELLQIDHNIHESNEVWCRCITTIYNYFVVTNFFWPFVGCYLHTA 232
Qy 215 IVMTYSTDKLRKWFVLFIGWCIPSPPIIVTWAICKLFYENECWIGKBPQKVIDYIYQGRV 274
Db 233 IVMTYSTHLRKLWLFVIGWCIPCPPIIVAVAGKLYYENECWFGKPGDLVDYIYQGP 292
Qy 275 ILVLLINVFVLFNIVRIILMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGE 334
Db 293 ILVLLINVFVLFNIVRIILMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGE 352
Qy 335 DDVSOQVPIYFNSFLOSFGPFVSFYCFNGEVRSAARKRWQDHHSLRVVRVARAMS 394
Db 353 DDLSQIVFIYFNSFLOSFGPFVSFYCFNGEVRSAARKRWQDHHSLRVVRVARAMS 412
Qy 395 IPTSPTRISPHSIKQTAAV 413
Db 413 IPTSPTRISPHSIKQTAAV 431

RESULT 15
US-08-381-433A-2
; Sequence 2, Application US/08381433A
; Patent No. 5786203
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; APPLICANT: Oltersdorf, Tilman
; APPLICANT: Liaw, Chen
; APPLICANT: Grigoriadis, Dimitri E.
; APPLICANT: Desouza, Errol B.
; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
; TITLE OF INVENTION: RECEPTORS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/381,433A
; FILING DATE: 31-JAN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McMaisters, David D.
; REGISTRATION NUMBER: 33,963

;
; REFERENCE/DOCKET NUMBER: 690068.401C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; TELEX: 3723836 SEEDANDBERRY
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 431 amino acids
;   TYPE: amino acid
;   TOPOLOGY: linear
;   MOLECULE TYPE: protein
;   US-08-381-433A-2

Query Match      79.8%; Score 1778.5; DB 1; Length 431;
Best Local Similarity 85.2%; Pred. No. 2e-158;
Matches 323; Conservative 24; Mismatches 29; Indels 3; Gaps 2;

Qy 38 FEGP--YCSATIDQIGTCWPSLAGELVERPCPDSENGIRYNTTRNVYRECFFENGWASW 95
Db 53 FSGPYSYCVNTLQIGTCWPSAGALVERPCPEYFNGIKYNTTRNAYRECLENGTWASR 112
Qy 96 MNYSCQVPILDNK-RKVALHYKIALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIH 154
Db 113 INYSCEPILDDKQKYDLHYRIALIINYLGHCVSVALVAFLFLVLSIRCLRNVIH 172
Qy 155 WNLITTFILRNIMFLLQIDHNIHESNEVWCRCITTIYNYFVVTNFFWPFVGCYLHTA 214
Db 173 WNLITTFILRNITWELLQIDHNIHESNEVWCRCITTIYNYFVVTNFFWPFVGCYLHTA 232
Qy 215 IVMTYSTDKLRKWFVLFIGWCIPSPPIIVTWAICKLFYENECWIGKBPQKVIDYIYQGRV 274
Db 233 IVMTYSTHLRKLWLFVIGWCIPCPPIIVAVAGKLYYENECWFGKPGDLVDYIYQGP 292
Qy 275 ILVLLINVFVLFNIVRIILMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGE 334
Db 293 ILVLLINVFVLFNIVRIILMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGE 352
Qy 335 DDVSOQVPIYFNSFLOSFGPFVSFYCFNGEVRSAARKRWQDHHSLRVVRVARAMS 394
Db 353 DDLSQIVFIYFNSFLOSFGPFVSFYCFNGEVRSAARKRWQDHHSLRVVRVARAMS 412
Qy 395 IPTSPTRISPHSIKQTAAV 413
Db 413 IPTSPTRISPHSIKQTAAV 431

Search completed: August 20, 2005, 00:38:08
Job time : 45 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 20, 2005, 00:09:52 ; Search time 166 Seconds
(without alignments)
962.241 Million cell updates/sec

Title: US-10-649-852-32
Perfect score: 2229
Sequence: 1 MDSITFEIIBDFANCSSL.....SIPSPTRISPHSIKQTAAV 413

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Geneseq 16Dec04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2229	100.0	413	5	AAO19435 Xenopus c
2	2229	100.0	413	8	Ado50813 Frog cort
3	1807	81.1	405	5	AAO19438 Fish cort
4	1807	81.1	405	8	Ado50819 Brown bul
5	1804	80.9	411	2	AAWI6481 Human cor
6	1804	80.9	411	4	AAW16481 Human cor
7	1804	80.9	411	7	Adc86183 Human GPC
8	1804	80.9	411	8	Ado29267 Human GPC
9	1799	80.7	411	2	AAW16481 Human cor
10	1799	80.7	411	5	AAO19424 Human cor
11	1799	80.7	411	6	ABP81806 Human cor
12	1799	80.7	411	8	Ado50791 Human cor
13	1799	80.7	411	8	Ado89168 Human uro
14	1793	80.4	411	2	ABU62363 Rat corti
15	1793	80.4	411	5	AAO19428 Rat corti
16	1793	80.4	411	8	Ado50799 Rat corti
17	1790	80.3	411	2	AAW16481 Human cor
18	1787.5	80.2	397	5	AAO19426 Human cor
19	1787.5	80.2	397	8	Ado50795 Human cor
20	1786	80.1	438	5	AAO19425 Human cor
21	1786	80.1	438	8	Ado50793 Human cor
22	1784.5	80.1	431	2	ABU62364 Rat corti
23	1776.5	79.7	431	2	AAW16481 Human cor
24	1776.5	79.7	431	5	AAO19429 Rat corti
25	1776.5	79.7	431	8	Ado50801 Rat corti

26	1770.5	79.4	431	2	AAW16481 Human cor
27	1770.5	79.4	431	2	AAW16481 Human cor
28	1770.5	79.4	431	5	AAE26683 Mouse cor
29	1770.5	79.4	431	5	AAO19431 Murine co
30	1770.5	79.4	431	6	ABU08079 Mouse cor
31	1770.5	79.4	431	6	ABG76050 Mouse cor
32	1770.5	79.4	431	8	ADJ65805 Mouse cor
33	1770.5	79.4	431	8	ADO29268 Mouse GPC
34	1770.5	79.4	431	8	ADO50805 mouse cor
35	1769	79.4	430	5	AAO19432 Murine co
36	1769	79.4	430	8	Ado50807 mouse cor
37	1582.5	71.0	428	5	AAO19437 Fish cort
38	1582.5	71.0	428	8	Ado50817 Catfish c
39	1582	71.0	420	5	AAO19440 Chicken c
40	1582	71.0	420	8	Ado50823 Chicken c
41	1578.5	70.8	445	5	AAO19436 Fish cort
42	1578.5	70.8	445	8	Ado50815 Catfish c
43	1566	70.3	415	2	AAW16481 Human cor
44	1566	70.3	415	2	AAW16481 Human cor
45	1566	70.3	415	2	AAW00159 Human cor

ALIGNMENTS

RESULT 1
AAO19435
ID AAO19435 standard; protein; 413 AA.
XX
AC AAO19435;
XX
DT 10-DEC-2002 (first entry)
XX
DE Xenopus corticotrophin releasing factor receptor CRF2R.
XX
KW Human; rat; mouse; sheep; cow; chicken; CRF1R; CRF2R;
KW skeletal muscle atrophy; corticotrophin releasing factor-2 receptor;
KW muscular dystrophy; corticotrophin releasing factor-1 receptor;
KW gene therapy.
XX
OS Xenopus laevis.
XX
PN WO200269908-A2.
XX
PD 12-SEP-2002.
XX
PF 06-MAR-2002; 2002WO-US007476.
XX
PR 06-MAR-2001; 2001US-00799978.
XX
PA (PROC) PROCTER & GAMBLE CO.
XX
PI Isfort RJ, Sheldon RJ;
XX
DR WPI; 2002-713413/77.
DR N-PSDB; AAL49986.
XX
PT Identifying candidate compounds for regulating skeletal muscle mass or
PT treating skeletal muscle atrophy by identifying test compounds that bind
PT to, or activate, the corticotrophin releasing factor-2 receptor.
XX
PS Claim 7; Page 142-143; 167pp; English.
XX
CC The present invention relates to a method of identifying candidate
CC compounds for regulating skeletal muscle mass or function, and comprises
CC contacting a test compound with a corticotrophin releasing factor-2
CC receptor (CRF2R) or with a cell expressing a functional CRF2R,
CC determining whether the test compound binds to, or activates, the CRF2R
CC and identifying the test compounds that bind to, or activates, the CRF2R
CC as candidate compounds for regulating skeletal muscle mass or function.
CC The method is useful for preparing a medicament for treating skeletal
CC muscle atrophy or for prophylactic treatment of muscular dystrophies. The
CC present sequence is a corticotrophin releasing factor receptor

```

XX SQ Sequence 413 AA;
Query Match 100.0%; Score 2229; DB 5; Length 413;
Best Local Similarity 100.0%; Pred. No. 6.9e-217;
Matches 413; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MDSTIFEIIDEFDANCSLLDAFQDSFLHSESSFFGFGPGYCSATIDQIGTCWPRSLAG 60
Db 1 MDSTIFEIIDEFDANCSLLDAFQDSFLHSESSFFGFGPGYCSATIDQIGTCWPRSLAG 60

Qy 61 ELVERPCDPSNGIRYNTNRVYRECENGWTWASWNNYSOCVPLDNKRKYALHYKIALI 120
Db 61 ELVERPCDPSNGIRYNTNRVYRECENGWTWASWNNYSOCVPLDNKRKYALHYKIALI 120

Qy 121 INYLGHGISILALVIAFLFLCLRSIRCLRNIIHWNLTITPILRNIMWFLQMDHNHIE 180
Db 121 INYLGHGISILALVIAFLFLCLRSIRCLRNIIHWNLTITPILRNIMWFLQMDHNHIE 180

Qy 181 SNEVWCRCITTIYNYFVVTNFFWVFGCYLHTAI VMTYSTDKLRKWVFLFGWCIPSPI 240
Db 181 SNEVWCRCITTIYNYFVVTNFFWVFGCYLHTAI VMTYSTDKLRKWVFLFGWCIPSPI 240

Qy 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFVFLNIVRLMTKLRAS 300
Db 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFVFLNIVRLMTKLRAS 300

Qy 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSGFQFFVSFV 360
Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSGFQFFVSFV 360

Qy 361 YCFINGEVRSAARKRWHRWQDHSLSLRVRVARAMSIPTSPTRISPHSIKQTA 413
Db 361 YCFINGEVRSAARKRWHRWQDHSLSLRVRVARAMSIPTSPTRISPHSIKQTA 413

RESULT 2
AD050813
ID AD050813 standard; protein; 413 AA.
XX AC AD050813;
XX DT 12-AUG-2004 (first entry)
XX DE Frog corticotropin releasing factor receptor 2, CRF2R.
XX KW Frog; receptor; corticotropin releasing factor receptor; CRF1R; CRF2R;
XX KW skeletal muscle; muscle atrophy; skeletal muscle dystrophy;
XX KW skeletal muscle hypertrophy; surgery; bed rest; broken bone;
XX KW infectious disease; AIDS cachexia.
XX OS Xenopus laevis.
XX PN US2004101911-A1.
XX FD 27-MAY-2004.
XX PF 27-AUG-2003; 2003US-00649852.
XX PR 06-MAR-2001; 2001US-00799978.
XX PA (PROC ) PROCTER & GAMBLE CO.
XX PT Isfort RJ, Sheldon RJ;
XX DR WPI; 2004-459890/43.
XX DR N-PSDB; AD050812.
XX PT Identifying compounds for regulating skeletal muscle mass or function, by
XX PT contacting test compound with vertebrate corticotropin releasing factor2
XX PT receptors (CRF2R), selecting compounds that bind or activate CRF2R.
XX CS Claim 3; SEQ ID NO 32; 100pp; English.

```

```

XX CC The invention relates to identifying candidate compounds for regulating
XX CC skeletal muscle mass or function, comprising contacting a test compound
XX CC with vertebrate corticotropin releasing factor 2 receptors (CRF 2 R),
XX CC determining if the compound binds to or activates CRF2R, selecting
XX CC compounds that bind or activate CRF 2 R, and determining if compound
XX CC increases muscle mass or function in muscle atrophy model. Also included
XX CC are identifying candidate therapeutic compounds from a group of one or
XX CC more candidate compounds which have been previously determined to bind to
XX CC or activate a vertebrate CRF 2 R (comprising administering the candidate
XX CC compound to a non-human animal and determining whether the candidate
XX CC compound regulates skeletal muscle mass or function in the treated
XX CC animal), increasing skeletal muscle mass or function in a subject in
XX CC which such an increase is desirable (comprising identifying a subject in
XX CC which an increase in muscle mass or function is desirable and
XX CC administering to the subject a safe and effective amount of a CRF 2 R
XX CC agonist), a purified antibody specific for a CRF2R (where the antibody is
XX CC a chimaeric or human antibody), and a pharmaceutical composition
XX CC comprising a safe and effective amount of a CRF2R agonist and carrier.
XX CC The methods are useful for identifying candidate compounds for regulating
XX CC skeletal muscle mass or function, for increasing skeletal muscle mass or
XX CC function (in a subject in which an increase is desirable), for
XX CC identifying candidate compounds that are potentially useful in the
XX CC treatment of skeletal muscle dystrophy and for identifying compounds that
XX CC prolong or augment the agonist-induced activation of CRF2R or of a CRF2R
XX CC signal transduction pathway. The compound is useful for treating skeletal
XX CC muscle hypertrophy and for modulating skeletal muscle atrophy induced by
XX CC e.g. surgery, bed rest, broken bones, infectious disease or AIDS
XX CC cachexia. The present sequence represents a corticotropin releasing
XX CC factor receptor.
XX SQ Sequence 413 AA;

Query Match 100.0%; Score 2229; DB 8; Length 413;
Best Local Similarity 100.0%; Pred. No. 6.9e-217;
Matches 413; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MDSTIFEIIDEFDANCSLLDAFQDSFLHSESSFFGFGPGYCSATIDQIGTCWPRSLAG 60
Db 1 MDSTIFEIIDEFDANCSLLDAFQDSFLHSESSFFGFGPGYCSATIDQIGTCWPRSLAG 60

Qy 61 ELVERPCDPSNGIRYNTNRVYRECENGWTWASWNNYSOCVPLDNKRKYALHYKIALI 120
Db 61 ELVERPCDPSNGIRYNTNRVYRECENGWTWASWNNYSOCVPLDNKRKYALHYKIALI 120

Qy 121 INYLGHGISILALVIAFLFLCLRSIRCLRNIIHWNLTITPILRNIMWFLQMDHNHIE 180
Db 121 INYLGHGISILALVIAFLFLCLRSIRCLRNIIHWNLTITPILRNIMWFLQMDHNHIE 180

Qy 181 SNEVWCRCITTIYNYFVVTNFFWVFGCYLHTAI VMTYSTDKLRKWVFLFGWCIPSPI 240
Db 181 SNEVWCRCITTIYNYFVVTNFFWVFGCYLHTAI VMTYSTDKLRKWVFLFGWCIPSPI 240

Qy 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFVFLNIVRLMTKLRAS 300
Db 241 IVTWAICKLFYENECQWIGKEPGKYIDYIYQGRVILVLLINFVFLNIVRLMTKLRAS 300

Qy 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSGFQFFVSFV 360
Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSGFQFFVSFV 360

Qy 361 YCFINGEVRSAARKRWHRWQDHSLSLRVRVARAMSIPTSPTRISPHSIKQTA 413
Db 361 YCFINGEVRSAARKRWHRWQDHSLSLRVRVARAMSIPTSPTRISPHSIKQTA 413

RESULT 3
AA019438
ID AA019438 standard; protein; 405 AA.
XX AC AA019438;
XX DT 10-DEC-2002 (first entry)

```

XX Fish corticotrophin releasing factor receptor CRF2R.
DE Human; rat; mouse; sheep; cow; chicken; CRF1R; CRF2R;
XX skeletal muscle atrophy; corticotrophin releasing factor-2 receptor;
KW muscular dystrophy; corticotrophin releasing factor-1 receptor;
KW gene therapy.
XX
OS Ameiurus nebulosus.
XX WO200269908-A2.
PN
PD 12-SEP-2002.
XX
XX 06-MAR-2002; 2002WO-US007476.
PF
XX 06-MAR-2001; 2001US-00799978.
PR
XX (PROC) PROCTER & GAMBLE CO.
PA
XX Isfort RJ, Sheldon RJ;
PI
XX WPI; 2002-713413/77.
DR N-PSDB; AAL49989.
XX
XX Identifying candidate compounds for regulating skeletal muscle mass or
PT treating skeletal muscle atrophy by identifying test compounds that bind
PT to, or activate, the corticotrophin releasing factor-2 receptor.
XX
XX Claim 7; Page 154-156; 167pp; English.
PS
XX The present invention relates to a method of identifying candidate
XX compounds for regulating skeletal muscle mass or function, and comprises
CC contacting a test compound with a corticotrophin releasing factor-2
CC receptor (CRF2R) or with a cell expressing a functional CRF2R,
CC determining whether the test compound binds to, or activates, the CRF2R
CC and identifying the test compounds that bind to, or activate, the CRF2R
CC as candidate compounds for regulating skeletal muscle mass or function.
CC The method is useful for preparing a medicament for treating skeletal
CC muscle atrophy or for prophylactic treatment of muscular dystrophies. The
CC present sequence is a corticotrophin releasing factor receptor
XX
XX Sequence 405 AA;
SQ
Query Match 81.1%; Score 1807; DB 5; Length 405;
Best Local Similarity 79.9%; Pred. No. 4e-174;
Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;
QY 1 MDSTIFEIIDEFDANCSLDAFQDSFLHSESSFFGEGPYCSATIDQIGTCWPRSLAG 60
DB 1 MEVSLELL--SVEVNCSLADAFGDPAYGNVADAL-----YCNATADEIGTCWPRSGN 52
QY 61 ELVERPCPSDFNGIRNTYTRNVYRECFENGTSWAMNYSQCVPIIDNKRKYALHYKIALI 120
DB 53 RVVARPCPDFINGVKYNSRYSARECLENGTWAFKINYSCEPILEKKRYPVHYKIALI 112
QY 121 INVLGHCISILALVIAFLFLCLRSIRCLRNIIHNLITTFILRNIMFWLLOWIDHNIHE 180
DB 113 INVLGHCISVAGVIAFLFLCLRSIRCLRNIIHNLITTFILRNIMFWLLOWIDHNIHE 172
QY 181 SNEVWCRCITTYNYFVNTNFFMVEGCVLHTAIWMTYSTDKLRKWFLEFGWCIPSP 240
DB 173 RNEPWCRLITVNYFVNTNFFMVEGCVLHTAIWMTYSTDKLRKWFLEFGWCIPSP 232
QY 241 IYVTAICLKYENEQWCKEKGKIDYIYQGRVILVLLINFLNFIIVRLMTKLRAST 300
DB 233 IIAWAVGKLYENEQWCKEKGKIDYIYQGRVILVLLINFLNFIIVRLMTKLRAST 292
QY 301 TSETIYQKAVKATVLLPGLITMYLFFWNGCEDVDVSIYFIYFNSFLQSGGFVSVP 360
DB 293 TSETIYQKAVKATVLLPGLITMYLFFWNGCEDVDVSIYFIYFNSFLQSGGFVSVP 352
QY 361 YCFLNGEVSRAARKRHRWQDHHSLRVVARAMS IPTSPTRISFHSIKQTAAV 413

DB 353 YCFLNGEVSRAARKRHRWQDHHSLRVVARAMS IPTSPTRISFHSIKHTAV 405
RESULT 4
ADOS0819
ID ADOS0819 standard; protein; 405 AA.
XX
AC ADOS0819;
XX
DT 12-AUG-2004 (first entry)
XX
DE Brown bullhead catfish corticotrophin releasing factor receptor 2, CRF2R.
XX
KW Brown bullhead catfish; receptor;
KW corticotrophin releasing factor receptor; CRF1R; CRF2R; skeletal muscle;
KW muscle atrophy; skeletal muscle dystrophy; skeletal muscle hypertrophy;
KW surgery; bed rest; broken bone; infectious disease; AIDS cachexia.
XX
OS Ameiurus nebulosus.
XX
PN US2004101911-A1.
XX
PD 27-MAY-2004.
XX
XX 27-AUG-2003; 2003US-00649852.
PF
XX 06-MAR-2001; 2001US-00799978.
PR
XX (PROC) PROCTER & GAMBLE CO.
PA
XX Isfort RJ, Sheldon RJ;
PI
XX WPI; 2004-459890/43.
DR N-PSDB; ADOS0818.
XX
XX Identifying compounds for regulating skeletal muscle mass or function, by
PT contacting test compound with vertebrate corticotrophin releasing factor-2
PT receptors (CRF2R), selecting compounds that bind or activate CRF2R.
XX
XX Claim 3; SEQ ID NO 38; 100pp; English.
PS
XX The invention relates to identifying candidate compounds for regulating
CC skeletal muscle mass or function, comprising contacting a test compound
CC with vertebrate corticotrophin releasing factor 2 receptors (CRF 2 R),
CC determining if the compound binds to or activates CRF2R, selecting
CC compounds that bind or activate CRF 2 R, and determining if compound
CC increases muscle mass or function in muscle atrophy model. Also included
CC are identifying candidate therapeutic compounds from a group of one or
CC more candidate compounds which have been previously determined to bind to
CC or activate a vertebrate CRF 2 R (comprising administering the candidate
CC compound to a non-human animal and determining whether the candidate
CC compound regulates skeletal muscle mass or function in the treated
CC animal), increasing skeletal muscle mass or function in a subject in
CC which such an increase is desirable (comprising identifying a subject in
CC which an increase in muscle mass or function is desirable and
CC administering to the subject a safe and effective amount of a CRF 2 R
CC agonist), a purified antibody specific for a CRF2R (where the antibody is
CC comprising a safe and effective amount of a CRF2R agonist and carrier.
CC The methods are useful for identifying candidate compounds for regulating
CC skeletal muscle mass or function, for increasing skeletal muscle mass or
CC function (in a subject in which an increase is desirable), for
CC identifying candidate compounds that are potentially useful in the
CC treatment of skeletal muscle dystrophy and for identifying compounds that
CC prolong or augment the agonist-induced activation of CRF2R or of a CRF2R
CC signal transduction pathway. The compound is useful for treating skeletal
CC muscle hypertrophy and for modulating skeletal muscle atrophy induced by
CC e.g. surgery, bed rest, broken bones, infectious disease or AIDS
CC cachexia. The present sequence represents a corticotrophin releasing
CC factor receptor.
XX
XX Sequence 405 AA;

```

Query Match      81.1%; Score 1807; DB 8; Length 405;
Best Local Similarity 79.9%; Pred. No. 4e-174;
Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;

QY 1 MDSTFEIIDEFANCSSLIDAFQDSFLHSESSSFFGFEQGYCSATIDQIGTCWPRSLAG 60
DB 1 MEVSLLELL--SVEVNSCLADAFQDPAYGNASDAL-----YCNATADEIGTCWPRSGAG 52

QY 61 ELVERPCPDSPNGIRYNTNRVYRECFENGFWASWMNYSQCVPILDNKRKYALHYKIALI 120
DB 53 RVVARPCPDFINGVKYNSTRSAYRECLENGFWAKINYSCEPILEKRYKYPVHYKIALI 112

QY 121 INYLGHICISILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMWFLQLMDHNIHE 180
DB 113 INYLGHICISVALVIAFLFLCLRSIRCLRNVIHWNLTITFILRNIMWLLQLLDHNIHE 172

QY 181 SNEVWCRCITTIYNYFVVTNFFWFMVEGCVLHTAI VMTYSTDKLRKQVFLFIGWCIPSP 240
DB 173 RNEVWCRLITTYNYFVVTNFFWFMVEGCVLHTAI VMTYSTDKLRKQVFLFIGWCIPCV 232

QY 241 IVTWAICLFLYENECQWIGKEPGKYIDYIYQGRVILVLLINVFELFNIVRLMTKLRAS 300
DB 233 IIAWAVGKLYENECQWFGKEPGKYVDYIYQGPVIVLLINVFELFNIVRLMTKLRAS 292

QY 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFYFNSFLOSFGQFFVSUF 360
DB 293 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDISQIVFYFNSFLOSFGQFFVSUF 352

QY 361 YCFLNGEVRSAARKRWHQDHSRLVRVARAMSIPSPTRISPHSIKQTAAV 413
DB 353 YCFLNGEVRSAVRKRWHQDHNHALRVVARAMSIPSPTRISPHSIKHTTAV 405

RESULT 5
AAW16481
ID AAW16481 standard; protein; 411 AA.
XX
AC AAW16481;
XX
DT 20-JUN-1997 (first entry)
XX
DE Human corticotrophin releasing factor 2 receptor protein.
XX
KW Human; corticotrophin; corticotropin; releasing factor 2; CRF2; receptor;
KW screen; agonist; antagonist; activation; inhibition; prevention;
KW treatment; dementia; obesity; acceleration; stress adaptation;
KW melancholia; anxiety; stress headache; AIDS;
KW acquired immunodeficiency syndrome; Alzheimer's disease;
KW gastrointestinal disorder.
XX
OS Homo sapiens.
XX
PN JP09070289-A.
XX
PD 18-MAR-1997.
XX
PF 14-SEP-1995; 95JP-00237081.
XX
PR 27-JUN-1995; 95JP-00161213.
XX
PA (TAKE ) TAKEDA CHEM IND LTD.
XX
DR WPI; 1997-230023/21.
XX
DR N-PSDB; AAT66508.
XX
PT PCR primer for G protein conjugate type receptor protein DNA - and human
PT corticotrophin releasing factor 2 receptor protein, useful to screen for
PT agonists and antagonists to treat dementia and anxiety.
XX
*PS Claim 8; Page 39-40; 46pp; Japanese.
XX
XX The present sequence is the human corticotrophin releasing factor 2
CC

```

```

CC (CRF2) receptor protein, which can be used to screen for an agonist or
CC antagonist which activates the receptor, or competitively inhibits the
CC binding of the receptor to CRF. The agonist can be used to prevent or
CC treat dementia and obesity, or accelerate stress adaptation. The
CC antagonist can be used to prevent or treat melancholia, anxiety, stress
CC headaches, AIDS, Alzheimer's disease or gastrointestinal disorders
XX
SQ Sequence 411 AA;

Query Match      80.9%; Score 1804; DB 2; Length 411;
Best Local Similarity 80.0%; Pred. No. 8.3e-174;
Matches 333; Conservative 33; Mismatches 42; Indels 8; Gaps 4;

QY 1 MDSTFEIIDEFANCSSLIDAFQDSFLHSESSSFFGFEQ--YCSATIDQIGTCWPRSL 58
DB 1 MDAAALLSL--EANCSL--ALABELLDDGWGPPIDPEGPYSYCNLTLDQIGTCWPRSA 55

QY 59 AGEVVERPCPDSPNGIRYNTNRVYRECFENGFWASWMNYSQCVPILDNK-RKYALHYKI 117
DB 56 AGEVVERPCPEYNGVKYNTNRNAYRECLENGFWASKINYSQCEPILDDKQKYDLHYRI 115

QY 118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNIMWFLQLMDHNI 177
DB 116 ALVNVYLGHCVSVAALVAAPFLFLALRSIRCLRNVIHWNLTITFILRNVMWFLQLVDHE 175

QY 178 IHESNEVWCRCITTIYNYFVVTNFFWFMVEGCVLHTAI VMTYSTDKLRKQVFLFIGWCIP 237
DB 176 VHSNEVWCRCITTIYNYFVVTNFFWFMVEGCVLHTAI VMTYSTERLKRCLFLFIGWCIP 235

QY 238 SPIIVTWAICLFLYENECQWIGKEPGKYIDYIYQGRVILVLLINVFELFNIVRLMTKLR 297
DB 236 FPIIWAIGKLYENECQWFGKEPGDLVDYIYQGPILLVLLINVFELFNIVRLMTKLR 295

QY 298 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFYFNSFLOSFGQFFV 357
DB 296 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDLSQLMFYFNSFLOSFGQFFV 355

QY 358 SVFYCFNGEVRSAARKRWHQDHSRLVRVARAMSIPSPTRISPHSIKQTAAV 413
DB 356 SVFYCFNGEVRSAVRKRWHQDHSRLVRVARAMSIPSPTRISPHSIKQTAAV 411

RESULT 6
AAB71867
ID AAB71867 standard; protein; 411 AA.
XX
AC AAB71867;
XX
DT 03-MAY-2001 (first entry)
XX
DE Human CRF2 seven transmembrane domain.
XX
KW Human; CRF2; corticotropin releasing factor receptor 2; h15571;
KW immunomodulatory; vascular; hepatic; antiasthma; antimicrobial;
KW antiinflammatory; immunosuppressive; gene therapy; vaccine;
KW G-protein coupled receptor; GPCR; liver fibrosis; respiratory disorder;
KW infection; chronic inflammatory disease; organ-specific autoimmunity;
KW graft rejection; cystic fibrosis.
XX
OS Homo sapiens.
XX
PN WO200109328-A1.
XX
PD 08-FEB-2001.
XX
PF 03-AUG-2000; 2000WO-US021278.
XX
PR 03-AUG-1999; 99US-0146916P.
XX
PR 29-FEB-2000; 2000US-00515781.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Hodge MR, Lloyd C, Weich NS;

```


XX WPI; 2001-138653/14.
 XX Nucleic acids encoding a G-prot. coupled receptor polypeptides, useful
 PT for preventing, diagnosing and treating, e.g. liver fibrosis and asthma.
 XX
 XX Disclosure; Fig 2; 145pp; English.
 XX
 CC The present sequence is a human G-protein coupled receptor (GPCR) used
 CC for comparison with the seven transmembrane domain of a novel GPCR
 CC designated h15571. h15571 GPCR polynucleotides and polypeptides may be
 CC used in the prevention, treatment and diagnosis of diseases associated
 CC with inappropriate GPCR expression. Such diseases includes immune,
 CC haematological, fibrotic, hepatic and respiratory disorders including
 CC asthma, allergies (e.g. allergic rhinitis and psoriasis), pathogenic
 CC infections, chronic inflammatory diseases, organ-specific autoimmunity,
 CC graft rejection, graft versus host disease, cystic fibrosis and, in
 CC particular, liver fibrosis. The GPCR polypeptides may be used as antigens
 CC in the production of antibodies against GPCR and in assays to identify
 CC modulators (agonists and antagonists) of GPCR expression and activity.
 CC The anti-GPCR antibodies and GPCR antagonists may also be used to down
 CC regulate GPCR expression and activity. The anti-GPCR antibodies may be
 CC used as diagnostic agents for detecting the presence of GPCR polypeptides
 CC in samples
 XX
 SQ Sequence 411 AA;
 Query Match 80.9%; Score 1804; DB 4; Length 411;
 Best Local Similarity 80.0%; Pred. No. 8.3e-174;
 Matches 333; Conservative 33; Mismatches 42; Indels 8; Gaps 4;
 QY 1 MDSTFEIILDFDANCSSLDAFODSFLHSSSSFFGPEGP--YCSATIDQIGTCWPSRL 58
 DB 1 MDAALLHSL--EANCSSL--ALABELLDGWPPLDPGYSYCNITLDQIGTCWPSRA 55
 QY 59 AGELVERPCPSDFNGIRYNTTNRVYRECENGFTWASMMYSCVPILDNK-RKYALHYKI 117
 DB 56 AGALVERPCPEYFNGVKYNTTNRAYRECLNGTWASKINYSQCEPILDDKQKYDLHYRI 115
 QY 118 ALIINYLGHCSILALVIAFLFLCLRSIRCLRNIIHWNLIITFTILRNIMWFLQMDHN 177
 DB 116 ALVNVYLGHCVSVAALVAFLFLALRSIRCLRNVIHWNLIITFTILRNIMWFLQMDHN 175
 QY 178 IHESNEVWCRCITTIYNYFVNTNFMFVEGCVLHTAIWMTYSTDKLRKWFLFGWCIP 237
 DB 176 VHSNEVWCRCITTIYNYFVNTNFMFVEGCVLHTAIWMTYSTDLRKLKFLFGWCIP 235
 QY 238 SPIIVTWAICKLIFYNEQCWIGKEPGKYIDYIQGRVILVLLINVFVLFNIVRIILMTKLR 297
 DB 236 FPIIIVAWAIGKLYYENEQWCFGKPGDLVDYIQGPILVLLINVFVLFNIVRIILMTKLR 295
 QY 298 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVIFYNFSFLOSGQGFV 357
 DB 296 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNSFLOSGQGFV 355
 QY 358 SVFYCFNGEVSRAARKHWRQDHSLSRVVARAMSIPTSPTSRISFHSIKOTAUV 413
 DB 356 SVFYCFNGEVSRAVRKRWHRQDHSLSRVVPARAMSIPTSPTSRISFHSIKOTAUV 411
 RESULT 7
 ADC86183
 ID ADC86183 standard; protein; 411 AA.
 XX
 AC ADC86183;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human GPCR protein SEQ ID NO:636.
 XX
 KW human; GPCR; guanosine triphosphate-binding protein coupled receptor;
 KW gene therapy.
 XX

OS Homo sapiens.
 XX
 PN EPI270724-A2.
 XX
 XX 02-JAN-2003.
 PD
 XX 18-JUN-2002; 2002EP-00013517.
 PF
 XX 18-JUN-2001; 2001JP-00246789.
 PR
 XX (NNAAD-) NAT INST ADVANCED IND SCI & TECHNOLOGY.
 PA (ADSC-) CENT ADVANCED SCI & TECHNOLOGY INCUBATIO.
 XX
 PI Suwa M, Asai K, Akiyama Y, Aburatani H;
 XX
 XX WPI; 2003-315783/31.
 DR N-PSDB; ADC86182.
 DR
 XX New polynucleotide, useful for preparing a composition for treating a
 PT patient in need of increased or suppressed activity or expression of the
 PT guanosine triphosphate-binding protein coupled receptor.
 PT
 XX Claim 2; SEQ ID NO 636; 28pp; English.
 PS
 XX The invention relates to a novel polynucleotide encoding a guanosine
 CC triphosphate-binding protein coupled receptor (GPCR). A polynucleotide of
 CC the invention may have a use in gene therapy. The polynucleotide and
 CC polypeptide are useful for preparing a composition for treating a patient
 CC in need of increased or suppressed activity or expression of the
 CC guanosine triphosphate-binding protein coupled receptor. The protein
 CC sequences shown in ADC85549-ADC87617 represent GPCR's of the invention.
 XX
 SQ Sequence 411 AA;
 Query Match 80.9%; Score 1804; DB 7; Length 411;
 Best Local Similarity 80.0%; Pred. No. 8.3e-174;
 Matches 333; Conservative 33; Mismatches 42; Indels 8; Gaps 4;
 QY 1 MDSTFEIILDFDANCSSLDAFODSFLHSSSSFFGPEGP--YCSATIDQIGTCWPSRL 58
 DB 1 MDAALLHSL--EANCSSL--ALABELLDGWPPLDPGYSYCNITLDQIGTCWPSRA 55
 QY 59 AGELVERPCPSDFNGIRYNTTNRVYRECENGFTWASMMYSCVPILDNK-RKYALHYKI 117
 DB 56 AGALVERPCPEYFNGVKYNTTNRAYRECLNGTWASKINYSQCEPILDDKQKYDLHYRI 115
 QY 118 ALIINYLGHCSILALVIAFLFLCLRSIRCLRNIIHWNLIITFTILRNIMWFLQMDHN 177
 DB 116 ALVNVYLGHCVSVAALVAFLFLALRSIRCLRNVIHWNLIITFTILRNIMWFLQMDHN 175
 QY 178 IHESNEVWCRCITTIYNYFVNTNFMFVEGCVLHTAIWMTYSTDKLRKWFLFGWCIP 237
 DB 176 VHSNEVWCRCITTIYNYFVNTNFMFVEGCVLHTAIWMTYSTDLRKLKFLFGWCIP 235
 QY 238 SPIIVTWAICKLIFYNEQCWIGKEPGKYIDYIQGRVILVLLINVFVLFNIVRIILMTKLR 297
 DB 236 FPIIIVAWAIGKLYYENEQWCFGKPGDLVDYIQGPILVLLINVFVLFNIVRIILMTKLR 295
 QY 298 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVIFYNFSFLOSGQGFV 357
 DB 296 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNSFLOSGQGFV 355
 QY 358 SVFYCFNGEVSRAARKHWRQDHSLSRVVARAMSIPTSPTSRISFHSIKOTAUV 413
 DB 356 SVFYCFNGEVSRAVRKRWHRQDHSLSRVVPARAMSIPTSPTSRISFHSIKOTAUV 411
 RESULT 8
 ADO29267
 ID ADO29267 standard; protein; 411 AA.
 XX
 AC ADO29267;
 XX

DT 29-JUL-2004 (first entry)
 XX Human GPCR CRHR2, SEQ ID NO:368.
 DE
 XX G protein-coupled receptor; GPCR; drug screening; diagnosis;
 KW transgenic mouse; neurological disorder; adrenal gland disorder;
 KW colon disorder; intestinal disorder; cardiovascular disorder;
 KW muscular disorder; blood disorder; immune disorder; bone disorder;
 KW joint disorder; metabolic disorder; nutritive disorder; cancer;
 KW kidney disorder; liver disorder; lung disorder; breast disorder;
 KW ovary disorder; uterus disorder; prostate disorder; testis disorder;
 KW skin disorder; stomach disorder; pancreas disorder; spleen disorder;
 KW thymus disorder; thyroid disorder; antiparkinsonian; antimanic;
 KW cystostatic; antiinflammatory; vasotropic; antitanginal; antiarrhythmic;
 KW CNS; central nervous system; respiratory; antidiarrhoeic; antidiabetic;
 KW virucide; hepatotropic; antibacterial; antianaemic; antiseborrhoeic;
 KW dermatological; antitumor; antithyroid; antiallergic; anorectic;
 KW immunosuppressive; nephrotropic; gene therapy; GPCR modulator; human;
 KW receptor.
 XX
 OS Homo sapiens.
 XX
 PN WO2004040000-A2.
 XX
 XX 13-MAY-2004.
 XX
 PD 09-SEP-2003; 2003WO-US028226.
 PF
 XX 09-SEP-2002; 2002US-0409303P.
 PR 09-APR-2003; 2003US-0461329P.
 XX
 XX (PRIM-) PRIMAL INC.
 PA
 XX Gaitanaris GA, Bergmann JF, Gragerov A, Hohmann J, Li F;
 PI Madisen L, McIlwain KL, Pavlova MN, Vassilatis D, Zeng H;
 XX
 DR WPI; 2004-390329/36.
 DR N-PSDB; ADO29852.
 XX
 PT Novel mammalian G protein coupled receptors, useful for identifying
 PT compounds that modulates diagnosing and treating disease condition
 PT associated with GPCR dysfunction e.g. autoimmune diseases, angina
 PT pectoris, Parkinson's disease.
 XX
 PS Claim 151; SEQ ID NO 368; 542pp; English.
 XX
 CC The invention relates to human and mouse G protein-coupled receptors
 CC (GPCRs) and nucleic acids encoding them. The invention also relates to
 CC sequences at least 90% identical to the GPCR proteins and nucleic acids
 CC of the invention; methods of treating, preventing or diagnosing diseases
 CC associated with GPCRs of the invention; methods of screening for
 CC compounds useful in the treatment of GPCR-related diseases; a transgenic
 CC mouse comprising a GPCR gene of the invention; a mouse comprising a
 CC mutation in a GPCR transgene or in an endogenous GPCR gene; cells derived
 CC from the transgenic mice; kits comprising several mice, each of which has
 CC a mutation in a different GPCR gene of the invention; and kits comprising
 CC probes which hybridise to GPCR polynucleotides of the invention. The
 CC invention further discloses variants of the GPCR polypeptides and vectors
 CC comprising a GPCR nucleic acid. The GPCR nucleic acids and proteins may
 CC be used in the diagnosis, treatment or prevention of a wide variety of
 CC diseases including neurological disorders (e.g., Alzheimer's disease,
 CC depression, diabetic neuropathy, Parkinson's disease or schizophrenia);
 CC disorders of the adrenal gland; disorders of the colon or intestine
 CC (e.g., Crohn's disease, diarrhoea, food poisoning or irritable bowel
 CC syndrome); cardiovascular disorders (e.g., angina, cardiac arrhythmia or
 CC myocardial infarction); muscular disorders; blood disorders (e.g.,
 CC anaemia or leukaemia); immune disorders (e.g., autoimmune disorders or
 CC AIDS); bone and joint disorders (e.g., osteoarthritis, rheumatoid
 CC arthritis, gout or osteoporosis); metabolic or nutritive disorders (e.g.,
 CC obesity, enzyme deficiency-related diseases or vitamin deficiency-related
 CC diseases); and disorders of the kidney, liver, lung, breast, ovary,
 CC uterus, prostate, testis, skin, stomach, pancreas, spleen, thymus and
 CC thyroid (e.g., cancers). The present sequence represents a GPCR of the

CC invention. Note: The full sequence data for this patent did not form part
 CC of the printed specification; those sequences not shown were obtained in
 CC electronic format directly from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 411 AA;

Query Match 80.9%; Score 1804; DB 8; Length 411;
 Best Local Similarity 80.0%; Pred. No. 8.3e-174;
 Matches 333; Conservative 33; Mismatches 42; Indels 8; Gaps 4;
 Qy 1 MDSTFPIIIIDPDANGSLLDADFQDSFLHSESSFFCFEGP--YCSATIDQIGTCWPRSL 58
 Db 1 MDAALLHSLI--EANGSL--ALAELLLDGWPPLDPEGYSVCNTLDDQIGTCWPRSA 55
 Qy 59 AGELVERPCDPSFNGIRYNTRNVYRECFNGTWSMMNYSQCVPLDNK-RKYALHYKI 117
 Db AGALVERPCPEYFNGVKYNTNRNAVRECLENGTWASKINYSQCEPILDDKQKYDLHYRI 115
 Qy 118 ALIINYLGHCISILALVIAELLFLCLRSIRCLNIHWNLTTFILRNIMWELLOMDHN 177
 Db 116 ALVNVYLGHCVSVAALVAEFLFLALRSIRCLRNVIHWNLTTFILRNVMWELLQVLDHE 175
 Qy 178 IHESNEVWCRCITTYNYFVVTNFFWMFVGGCYLHTAIVMTYSTDKLRKWVFLFIGWCIIP 237
 Db 176 VHSNEVWCRCITTYFNYFVVTNFFWMFVGGCYLHTAIVMTYSTERLARKCLFLFIGWCIIP 235
 Qy 238 SPIIVTWAICKLFYENBQCWIGKEPGKYIDYIYQGRVILVLLINVFELFNVIRILMTKLR 297
 Db 236 FPIIWAIAIGLYVENEQCFWKEPGDLVDYIYQGPILVLLINVFELFNVIRILMTKLR 295
 Qy 298 ASTTSETIOYRKAVKATLVLLPLGLTYMLFFVNPGEDDYDQIVFIYFNSFLOSFGQFFV 357
 Db 296 ASTTSETIOYRKAVKATLVLLPLGLTYMLFFVNPGEDDYDQIVFIYFNSFLOSFGQFFV 355
 Qy 358 SVFYCFNLGGEVRSAAARKRHRWQDHSLSLRVRVARMSIPTSPTRISPHSIKQTAAV 413
 Db 356 SVFYCFNNGEVRSAVRKRWHRWQDHSLSLRVRVARMSIPTSPTRISPHSIKQTAAV 411

RESULT 9
 AAR90576
 ID AAR90576 standard; protein; 411 AA.
 XX
 AC AAR90576;
 XX
 DT 08-APR-1996 (first entry)
 XX
 DE Human CRF2 receptor.
 XX
 KW CRF2 receptor; corticotropin-releasing factor-2 receptor;
 KW cerebrovascular disorder; memory disorder; Alzheimer disease.
 XX
 OS Homo sapiens.
 XX
 PN WO9534651-A2.
 XX
 PD 21-DEC-1995.
 XX
 PF 14-JUN-1995; 95WO-US007757.
 PR 14-JUN-1994; 94US-00259959.
 PR 31-JAN-1995; 95US-00381433.
 PR 07-JUN-1995; 95US-00485984.
 XX
 PA (NEUR-) NEUROCRINE BIOSCIENCES INC.
 XX
 PI Chalmers D, Lovenberg TW, Oltersdorf T, Liaw CW, Grigoriadis DE;
 PI De Souza EB;
 XX
 DR WPI; 1996-049680/05.
 DR N-PSDB; AAT12247.
 XX

PT Corticotropin-releasing factor-2 receptor, and DNA encoding it - used to
 PT isolate CRF-2 receptor antagonists for the treatment of cerebrovascular
 PT disorders, memory disorders and Alzheimer's disease.

XX Disclosure; Page 80-82; 109pp; English.

PS Human corticotropin-releasing factor-2 (CRF2) receptor (AAR90576) is a
 CC membrane-bound G-coupled protein receptor involved in signal
 CC transduction. It can be produced by expression of encoding cDNA
 CC (AA11247) in prokaryotic or eucaryotic host cells. Recombinant CRF2
 CC receptor is used to screen CRF2 receptor agonists and antagonists of
 CC therapeutic appln., and to prepare antibodies which specifically bind to
 CC CRF2 receptors.

XX Sequence 411 AA;

Query Match 80.7%; Score 1799; DB 2; Length 411;
 Best Local Similarity 79.8%; Pred. No. 2.7e-173;
 Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;
 QY 1 MDSTFEIILDEFDANGSLLDFAQDSFLHSSSSFFGEGP--YCSATIDQIGTCWPSL 58
 DB 1 MDALLHSL--EANCSL--ALAEELLDGWGPPLDPEGYSYCNLTLDQIGTCWPSA 55
 QY 59 AGELVERPCDSFNGIRYNTTRNRYRECFENGWASWNYSCVPILDNK-RKYALHYKI 117
 DB 56 AGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDQKQYDLHYRI 115
 QY 118 ALIINYLGHCSILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNMMFLQMDHN 177
 DB 116 ALVNYLGHCVSAALVAALFLFLALRSIRCLRNVIHWNLTITFILRNMMFLQLVDHE 175
 QY 178 IHESNEVWCRCITTIYNYFVVTNFFWVEGCVLHTAIVMTYSTDKLRKWFLFGWCIP 237
 DB 176 VHSNEVWCHCITTIYNYFVVTNFFWVEGCVLHTAIVMTYSTERLRKCLFLFGWCIP 235
 QY 238 SPLIIVTWAICKLFYENECWICKGPKYIDYIQGRVILVLLINVFLENIVRIILMTKLR 297
 DB 236 PFIIVAMAIGKLYYENECWCFKEPGDLVDYIQGPILVLLINVFLENIVRIILMTKLR 295
 QY 298 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSGPFV 357
 DB 296 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDLQIMFIYFNSFLOSGPFV 355
 QY 358 SVFYCFNLGEVRSAAKRWQDHHSLRVVARAMSIPSPTRISPHSIKQTAAV 413
 DB 356 SVFYCFNGEVRSVAKRWQDHHSLRVVPARAMSIPSPTRISPHSIKQTAAV 411

RESULT 10

AAO19424
 ID AAO19424 standard; protein; 411 AA.

XX AAO19424;

XX 10-DEC-2002 (first entry)

DE Human corticotropin releasing factor receptor CRF2Ralpha.

XX Human; rat; mouse; sheep; cow; chicken; CRF1R; CRF2R;
 KW skeletal muscle atrophy; corticotropin releasing factor-2 receptor;
 KW muscular dystrophy; corticotropin releasing factor-1 receptor;
 KW gene therapy.

XX Homo sapiens.

XX WO200269908-A2.

XX 12-SEP-2002.

XX 06-MAR-2002; 2002WO-US007476.

XX 06-MAR-2001; 2001US-00799978.

XX (PROC) PROCTER & GAMBLE CO.

XX Isfort RJ, Sheldon RJ;

XX WPI; 2002-713413/77.

XX N-PSDB; AAL49975.

XX Identifying candidate compounds for regulating skeletal muscle mass or
 PT treating skeletal muscle atrophy by identifying test compounds that bind
 PT to, or activate, the corticotropin releasing factor-2 receptor.

XX Claim 7; Page 95-97; 167pp; English.

XX The present invention relates to a method of identifying candidate
 CC compounds for regulating skeletal muscle mass or function, and comprises
 CC contacting a test compound with a corticotropin releasing factor-2
 CC receptor (CRF2R) or with a cell expressing a functional CRF2R, the CRF2R
 CC determining whether the test compound binds to, or activates, the CRF2R
 CC and identifying the test compounds that bind to, or activates, the CRF2R
 CC as candidate compounds for regulating skeletal muscle mass or function.
 CC The method is useful for preparing a medicament for treating skeletal
 CC muscle atrophy or for prophylactic treatment of muscular dystrophies. The
 CC present sequence is a corticotropin releasing factor receptor

XX Sequence 411 AA;

Query Match 80.7%; Score 1799; DB 5; Length 411;
 Best Local Similarity 79.8%; Pred. No. 2.7e-173;
 Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;
 QY 1 MDSTFEIILDEFDANGSLLDFAQDSFLHSSSSFFGEGP--YCSATIDQIGTCWPSL 58
 DB 1 MDALLHSL--EANCSL--ALAEELLDGWGPPLDPEGYSYCNLTLDQIGTCWPSA 55
 QY 59 AGELVERPCDSFNGIRYNTTRNRYRECFENGWASWNYSCVPILDNK-RKYALHYKI 117
 DB 56 AGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDQKQYDLHYRI 115
 QY 118 ALIINYLGHCSILALVIAFLFLCLRSIRCLRNIIHWNLTITFILRNMMFLQMDHN 177
 DB 116 ALVNYLGHCVSAALVAALFLFLALRSIRCLRNVIHWNLTITFILRNMMFLQLVDHE 175
 QY 178 IHESNEVWCRCITTIYNYFVVTNFFWVEGCVLHTAIVMTYSTDKLRKWFLFGWCIP 237
 DB 176 VHSNEVWCHCITTIYNYFVVTNFFWVEGCVLHTAIVMTYSTERLRKCLFLFGWCIP 235
 QY 238 SPLIIVTWAICKLFYENECWICKGPKYIDYIQGRVILVLLINVFLENIVRIILMTKLR 297
 DB 236 PFIIVAMAIGKLYYENECWCFKEPGDLVDYIQGPILVLLINVFLENIVRIILMTKLR 295
 QY 298 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLOSGPFV 357
 DB 296 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDLQIMFIYFNSFLOSGPFV 355
 QY 358 SVFYCFNLGEVRSAAKRWQDHHSLRVVARAMSIPSPTRISPHSIKQTAAV 413
 DB 356 SVFYCFNGEVRSVAKRWQDHHSLRVVPARAMSIPSPTRISPHSIKQTAAV 411

RESULT 11

ABP81806

ID ABP81806 standard; protein; 411 AA.

XX ABP81806;

XX 04-MAR-2003 (first entry)

XX Human corticotropin releasing factor receptor 2 protein SEQ ID NO:96.

XX G protein-coupled receptor; GPCR; antigenic peptide; gene therapy;

KW G protein-coupled receptor modulator; antibody; immune-related disease;
 KW growth-related disease; cell regeneration-related disease; AIDS; cancer;

immunological-related cell proliferative disease; autoimmune disease; Alzheimer's disease; atherosclerosis; infection; osteoarthritis; allergy; osteoporosis; cardiomyopathy; inflammation; Crohn's disease; diabetes; graft versus host disease; Parkinson's disease; multiple sclerosis; pain; psoriasis; anxiety; depression; schizophrenia; dementia; memory loss; mental retardation; epilepsy; asthma; tuberculosis; obesity; nausea; hypertension; hypotension; renal disorder; rheumatoid arthritis; trauma; ulcer.

OS Homo sapiens.

PN WO200261087-A2

08-AUG-2002.

19-DEC-2001: 2001WO-IIS050107.

19-DEC-2000: 2000US-0257144P-

XX PA (LIFE-) LIFESPAN BIOSCIENCES INC.

XX	PI	Burmer GC.	Rough CL.	Brown JP.
----	----	------------	-----------	-----------

AA
DR
WPI: 2003-046718/04.

PT New isolated antigenic peptides e.g., for G protein-coupled receptors
PT (GPCR), useful for diagnosing and designing drugs for treating conditions
PT in which GPCRs are involved, e.g. AIDS, Alzheimer's disease, cancer or
PT autoimmune diseases.

PS Disclosure: Fig 1: 523pp: English.

The present invention describes antigenic peptides (I) comprising: (a) any one of 1601 sequences (see ABP82019 to ABP83619) of 12-24 amino acids. Also described: (1) an assay for the detection of a particular G protein-coupled receptor (GPCR) or a candidate polypeptide in a sample; and (2) an isolated antibody having high specificity and high affinity or avidity for a particular GPCR. (I) can be used as GPCR modulators and in gene therapy. The antigenic peptides for GPCRs are useful in detecting an antibody against a particular GPCR, and in the production of specific antibodies. The peptides and antibodies are also useful for detecting the presence or absence of corresponding GPCRs. The antigenic peptides for GPCRs and antibodies are useful for diagnosing and designing drugs for treating immune-related diseases, growth-related diseases, cell regeneration-related disease, immunological-related cell proliferative diseases, or autoimmune diseases, e.g. AIDS, Alzheimer's disease, atherosclerosis, bacterial, fungal, protozoan or viral infections, osteoarthritis, osteoporosis, cancer, cardiomyopathy, chronic and acute inflammation, allergies, Crohn's disease, diabetes, graft versus host disease, Parkinson's disease, multiple sclerosis, pain, psoriasis, anxiety, depression, schizophrenia, dementia, mental retardation, memory loss, epilepsy, asthma, tuberculosis, obesity, nausea, hypertension, hypotension, renal disorders, rheumatoid arthritis, trauma, ulcers, or any other disorder in which GPCRs are involved. The antibodies may be used in immunoassays and immunodiagnosis. ABP242523 to ABP242869 encode GPCR proteins given in ABP81675 to ABP82018, which are used in the exemplification of the present invention

Sequence 411 AA:

Query Match	80.7%	Score 1799;	DB 6;
Best Local Similarity	79.8%	Pred. No. 2.7e-173;	
Matches 332;	Conservative	33;	Mismatches 43;
			Indels 8;
			Gaps 4;

1 MDSTIFEIIDEFDANCSLDAFQDSFLHSESSFFGFEQP--YCSATIDQIGTCWPRSL 58

Db 1 MDAALLHSL--EANCSL--ALAEELLDGWGPPLDPEGPYSYCNLTLDQIGTCWPSA 55

QY 59 AGELVERPCDSFNGIRYNTTRNVYRECFCENGTSWWMNYSQCVPILDNK-RKYALHYKI 117

```
db
56 AGALVERPCPEYFNGVKVNTTRNAYRECLENGTWASKINYSQCEPILDDKQKDYDLHYRI 115
```

[illegible]

RESULT 12

RESOL. I.
ADO50791

ID ADO50791 standard; protein; 411 AA.

AC ADO50791;

DT 12-AUG-2004 (first entry)

Human corticotropin releasing factor receptor 2 alpha.

Human; receptor; corticotropin releasing factor receptor; CRF1R; CRF2R;
skeletal muscle; muscle atrophy; skeletal muscle dystrophy;
skeletal muscle hypertrophy; surgery; bed rest; broken bone;
infectious disease; AIDS cachexia.

XX Homo sapiens.

XX
PN
US2004101911-A1.

27-MAY-2004

XX
PF 27-AUG-2003: 2003US-00649852.XX
PR 06-MAR-2001: 2001US-00799978-XX
PA (PROC) PROCTER & GAMBLE CO-XX
PT
Tsfort RJ.
Sheldon RJ:XX
DR
WPT: 2004-459890/43.DR N-PSDB; ADO50790.
XX

PT contacting test compound with vertebrate corticotropin releasing factor2
PT receptors (CRF2R), selecting compounds that bind or activate CRF2R.
PT Identifying compounds for regulating skeletal muscle mass or function, by
PT contacting test compound with vertebrate corticotropin releasing factor2
PT receptors (CRF2R), selecting compounds that bind or activate CRF2R.

PS Claim 3; SEQ ID NO 10; 100pp; English.

The invention relates to identifying candidate compounds for regulating skeletal muscle mass or function, comprising contacting a test compound with vertebrate corticotropin releasing factor 2 receptors (CRF 2 R), determining if the compound binds to or activates CRF2R, selecting compounds that bind or activate CRF 2 R, and determining if compound increases muscle mass or function in muscle atrophy model. Also included are identifying candidate therapeutic compounds from a group of one or more candidate compounds which have been previously determined to bind to or activate a vertebrate CRF 2 R (comprising administering the candidate compound to a non-human animal and determining whether the candidate compound regulates skeletal muscle mass or function in the treated animal), increasing skeletal muscle mass or function in a subject in which such an increase is desirable (comprising identifying a subject in which an increase in muscle mass or function is desirable and

CC administering to the subject a safe and effective amount of a CRF 2 R
 CC agonist), a purified antibody specific for a CRF2R (where the antibody is
 CC a chimeric or human antibody), and a pharmaceutical composition
 CC comprising a safe and effective amount of a CRF2R agonist and carrier.
 CC The methods are useful for identifying candidate compounds for regulating
 CC skeletal muscle mass or function, for increasing skeletal muscle mass or
 CC function (in a subject in which an increase is desirable), for
 CC identifying candidate compounds that are potentially useful in the
 CC treatment of skeletal muscle dystrophy and for identifying compounds that
 CC prolong or augment the agonist-induced activation of CRF2R or of a CRF2R
 CC signal transduction pathway. The compound is useful for treating skeletal
 CC muscle hypertrophy and for modulating skeletal muscle atrophy induced by
 CC e.g. surgery, bed rest, broken bones, infectious disease or AIDS
 CC cachexia. The present sequence represents a corticotropin releasing
 CC factor receptor.

XX SQ Sequence 411 AA;

Query Match 80.7%; Score 1799; DB 8; Length 411;
 Best Local Similarity 79.8%; Pred. No. 2.7e-173;
 Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

QY 1 MDSTIFEIIDEFANDCSLLDFAQDSFLHSSSSFFGEGP--YCSATIDQIGTCWPRSL 58
 DB 1 MDAALLHSL--EANCSL--ALAEELLDGWPPLDPEGPYSYCNVTLTDLQIGTCWPRSA 55
 QY 59 AGELVERPCDPSNGIRYNTTNNVRECFENGTSWNNYSQCVPLDNK-RKYALHYKI 117
 DB 56 AGALVERPCPEYFNGVKYNTTNNAYRECLNKTWASKINYSQCEPILDDKQKYLHYRI 115
 QY 118 ALIINYLGHICISILALVIAFLFLCLRSICRLNIIHWNLTITFILRNMFLQMDHN 177
 DB 116 ALUVNYLGHCVSAALVAALFLFLALRSICRLNIIHWNLTITFILRNMFLQMDVHE 175
 QY 178 IHSENEVWCRCITTIYNYFVNTFFMFWVEGCVLHTAIWMTYSTDKLRWFLFGWCIP 237
 DB 176 VHSENEVWCRCITTIYNYFVNTFFMFWVEGCVLHTAIWMTYSTDLRKLFLFGWCIP 235
 QY 238 SPIIWTWAIKLFYNEQCWIGKPGKYIDYIYQGRVLLVLLINVFLENVIRIILMTKLR 297
 DB 236 FPIIVAMAIGKLYYENECWFGKPGDLDVYIYQGPPIILVLLINVFLENVIRIILMTKLR 295
 QY 298 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLQSQGFV 357
 DB 296 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNSFLQSQGFV 355
 QY 358 SVFYCFNLGEVRSAAKRWHRQDHHSLRVVRVARAMSIPTSPTRISFHSIKQTAAV 413
 DB 356 SVFYCFNCEVRSVAKRWHRQDHHSLRVVARAMSIPTSPTRISFHSIKQTAAV 411

RESULT 13
 ID ADQ89168
 XX ADQ89168 standard; protein; 411 AA.
 XX ADQ89168;
 AC ADQ89168;
 DT 21-OCT-2004 (first entry)
 XX Human urological disorder related protein 2543 SEQ:120.
 DE urological disorder; uropathic; cytostatic; urinary incontinence;
 KW benign prostatic hyperplasia; human.
 XX Homo sapiens.
 XX WO2004065576-A2.
 XX 05-AUG-2004.
 XX 14-JAN-2004; 2004WO-US0000750.
 XX 15-JAN-2003; 2003US-0440318P.
 PR

PR 04-FEB-2003; 2003US-0444783P.
 PR 27-MAR-2003; 2003US-0457901P.
 PR 08-MAY-2003; 2003US-0468775P.
 PR 19-MAY-2003; 2003US-0471614P.
 PR 16-JUN-2003; 2003US-0478742P.
 PR 18-JUL-2003; 2003US-0488529P.
 PR 30-JUL-2003; 2003US-0491156P.
 PR 02-SEP-2003; 2003US-0499594P.
 PR 26-SEP-2003; 2003US-0506332P.
 XX (MILL-) MILLENNIUM PHARM INC.
 PA Karicheti V, Silos-Santiago I, Eliasof SD;
 XX WPI; 2004-562167/54.
 DR N-PSDB; ADQ89167.
 XX

PT Use of polypeptides related to urological disorders, e.g. 44390, 54181,
 PT 211 or for identifying a compound capable of treating a urological
 PT disorder or identifying and treating a subject having a urological
 PT disorder.

PS Claim 1; SEQ ID NO 120; 542pp; English.

XX The present invention describes the use of polypeptides related to
 CC urological disorders for identifying a compound capable of treating a
 CC urological disorder, identifying a subject having a urological disorder,
 CC or treating a subject having a urological disorder. Also described: (1) a
 CC method for identifying a compound capable of treating a urological
 CC disorder; and (3) a method for treating a subject having a urological
 CC disorder. The compound has uropathic and cytostatic activities. The
 CC polypeptides related to urological disorders are useful for identifying a
 CC compound capable of treating a urological disorder, identifying a subject
 CC having a urological disorder, or treating a subject having a urological
 CC disorder. Disorders include urinary incontinence and benign prostatic
 CC hyperplasia. The present sequence represents a human urological disorder
 CC related protein, which is used in the exemplification of the present
 CC invention.

XX SQ Sequence 411 AA;

Query Match 80.7%; Score 1799; DB 8; Length 411;
 Best Local Similarity 79.8%; Pred. No. 2.7e-173;
 Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

QY 1 MDSTIFEIIDEFANDCSLLDFAQDSFLHSSSSFFGEGP--YCSATIDQIGTCWPRSL 58
 DB 1 MDAALLHSL--EANCSL--ALAEELLDGWPPLDPEGPYSYCNVTLTDLQIGTCWPRSA 55
 QY 59 AGELVERPCDPSNGIRYNTTNNVRECFENGTSWNNYSQCVPLDNK-RKYALHYKI 117
 DB 56 AGALVERPCPEYFNGVKYNTTNNAYRECLNKTWASKINYSQCEPILDDKQKYLHYRI 115
 QY 118 ALIINYLGHICISILALVIAFLFLCLRSICRLNIIHWNLTITFILRNMFLQMDHN 177
 DB 116 ALUVNYLGHCVSAALVAALFLFLALRSICRLNIIHWNLTITFILRNMFLQMDVHE 175
 QY 178 IHSENEVWCRCITTIYNYFVNTFFMFWVEGCVLHTAIWMTYSTDKLRWFLFGWCIP 237
 DB 176 VHSENEVWCRCITTIYNYFVNTFFMFWVEGCVLHTAIWMTYSTDLRKLFLFGWCIP 235
 QY 238 SPIIWTWAIKLFYNEQCWIGKPGKYIDYIYQGRVLLVLLINVFLENVIRIILMTKLR 297
 DB 236 FPIIVAMAIGKLYYENECWFGKPGDLDVYIYQGPPIILVLLINVFLENVIRIILMTKLR 295
 QY 298 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFLQSQGFV 357
 DB 296 ASTTSETIOYRKAVKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNSFLQSQGFV 355
 QY 358 SVFYCFNLGEVRSAAKRWHRQDHHSLRVVRVARAMSIPTSPTRISFHSIKQTAAV 413
 DB 356 SVFYCFNCEVRSVAKRWHRQDHHSLRVVARAMSIPTSPTRISFHSIKQTAAV 411

RESULT 14
ABU62363
ID ABU62363 standard; protein; 411 AA.
AC ABU62363;
XX
DT 29-AUG-2003 (first entry)
XX
DE Rat corticotropin release factor receptor, rCRF-R2alpha.
XX
KW Corticotropin release factor; receptor; adrenocorticotrophic hormone;
KW ACTH; blood flow; blood pressure; vascular bed; coronary blood flow;
KW inflammation; vascular permeability; CRF-binding protein; parturition;
KW Alzheimer's disease; chronic fatigue syndrome; depression; anxiety; memory;
KW respiratory system; learning performance; endocrine disorder; swelling;
KW hypothalamic pituitary adrenal function; endocrine disorder; swelling;
KW central nervous system disorder; CRF; rCRF-R2alpha.
XX
OS Rattus sp.
XX
PN US2003032587-A1.
XX
PD 13-FEB-2003.
XX
XX 26-MAR-2001; 2001US-00818009.
XX
XX 13-JUN-1995; 95US-0028444P.
XX
PR 11-AUG-1995; 95US-0022223P.
XX
PR 12-JUN-1996; 96WO-US010240.
XX
PR 10-DEC-1997; 97US-00981189.
XX
XX (SALK) SALK INST BIOLOGICAL STUDIES.
XX
XX Vale WM, Vaughan J, Donaldson CJ, Lewis KA, Sawchenko P;
XX Rivier JEF, Perrin MH;
XX WPI; 1997-077344/07.
XX
XX Urocortin peptide(s) related to urotensin and corticotropin-releasing
XX factor - for increasing ACTH and beta-endorphin levels, lowering blood
XX pressure and improving mood, memory and learning performance.
XX
XX Disclosure; Page 27-28; 34pp; English.
XX
XX The invention relates to a human urocortin (Ucn) peptide or an analogous
XX sequence having only conservative substitutions to the amino acid
XX residues in it, or an N-terminally shortened fragment of either which is
XX biologically active to increase adrenocorticotrophic hormone (ACTH)
XX production. Human urocortin or its N-terminally shortened antagonist
XX peptide are useful for modifying blood flow and/or blood pressure and is
XX further useful for modulating blood flow in a desired vascular bed. Human
XX urocortin is also useful for increasing coronary blood flow and for
XX decreasing swelling and/or inflammation and/or vascular permeability. A
XX CRF-binding protein blocking compound is useful for increasing the in
XX vivo level of CRF and/or Ucn. The amount of CRF-binding protein blocking
XX compound is sufficient to promote parturition in a pregnant female. The
XX amount of the compound administered is effective so as to result in an
XX increase in free endogenous CRF and/or Ucn in the brain which causes
XX improvement in short to medium term memory in a subject afflicted with
XX Alzheimer's disease, relief from chronic fatigue syndrome, suppression of
XX appetite, stimulation of the respiratory system, improvement in learning
XX performance, improvement in memory, improvement in alertness, reduction
XX of depression and/or lessening of anxiety. The compound is administered
XX so that it reaches the brain. Human urocortin is useful for evaluating
XX hypothalamic pituitary adrenal function in mammals with suspected
XX endocrine or central nervous system pathology. Human urocortin antibodies
XX are useful in diagnostic methods and systems for detecting the level of
XX Ucn polypeptide, for immunofluorescence or affinity chromatography
XX purification of Ucn, and also in human therapeutic methods. The present
XX sequence represents the amino acid sequence of the rat corticotropin
XX release factor receptor, rCTF-R2alpha

XX SQ Sequence 411 AA;
Query Match 80.4%; Score 1793; DB 2; Length 411;
Best Local Similarity 80.0%; Pred. No. 1.1e-172;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;
QY 1 MDSTFEIIDIIEFDANCSLLDAFQDSFLHSSESSPFGEPP--YCSATIDQIGTCWPRSL 58
DB 1 MDAA---LLLSLLEANCSL--ALAEILLDDGHWGPDPEGPYSYCNITLDQIGTCWPQA 55
QY 59 AGELVERPCPSDFNGIRYNTTRNVYRECFCENGFWASMMNYSQCVPLDNK-RYALHYKI 117
DB 56 PGALVERPCPEYFNGIKYNTTRNAYRECLENGFWASRINYSHCPEILLDKQRYDLHYRI 115
QY 118 ALIINYLGHICISIALVIAFLFLCLRSIRCLRNIIHWNLTTFILRNIMWELLOMDHN 177
DB 116 ALIINYLGHICISVALVAAFLFLVLRSLRCLRNVIHWNLTTFILRNITWFLQLIDHE 175
QY 178 IHESNEVWCRCITTYINYVVTNFFWVFEGCVLHTAIWMTYSTDKLRKWVFLFIGWCI 237
DB 176 VHEGNEVWCRCVTIYNYFVTNFFWVFEGCVLHTAIWMTYSTELRKLWFLFIGWCI 235
QY 238 SPIIVTWAICKLFYENEQCMIGKEPKYIDYIQGRVILVLLINFLVFLNIVRILMTKLR 297
DB 236 CPIIVAVAVGKLYENEQCMWFGKPGDLVDYIQGPILVLLINFLVFLNIVRILMTKLR 295
QY 298 ASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPGEDDVSQIVFIYFNSFQSGFFV 357
DB 296 ASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPGEDDLQSQIVFIYFNSFQSGFFV 355
QY 358 SVFYCFNGEVRSAARKRWHRQDHHSLRVVARAMSIPSPTRISFHSIKQTA 413
DB 356 SVFYCFNGEVRSAARKRWHRQDHHSLRVVARAMSIPSPTRISFHSIKQTA 411
RESULT 15
AAO19428
ID AAO19428 standard; protein; 411 AA.
XX
AC AAO19428;
XX
DT 10-DEC-2002 (first entry)
XX
DE Rat corticotropin releasing factor receptor CRP2Ralpha.
XX
KW Human; rat; mouse; sheep; cow; chicken; CRF1R; CRF2R;
KW skeletal muscle atrophy; corticotropin releasing factor-2 receptor;
KW muscular dystrophy; corticotropin releasing factor-1 receptor;
KW gene therapy.
XX
OS Rattus norvegicus.
XX
PN WO200269908-A2.
XX
PD 12-SEP-2002.
XX
XX 06-MAR-2002; 2002WO-US0007476.
XX
XX 06-MAR-2001; 2001US-00799978.
XX
XX (PROC) PROCTER & GAMBLE CO.
XX
XX Isfort RJ, Sheldon RJ;
XX WPI; 2002-713413/77.
XX
XX N-PSDB; AAL49979.
XX
XX Identifying candidate compounds for regulating skeletal muscle mass or
XX treating skeletal muscle atrophy by identifying test compounds that bind
XX to, or activate, the corticotropin releasing factor-2 receptor.
XX
XX Claim 7; Page 112-113; 167pp; English.
PS

XX The present invention relates to a method of identifying candidate
CC compounds for regulating skeletal muscle mass or function, and comprises
CC contacting a test compound with a corticotropin releasing factor-2
CC receptor (CRF2R) or with a cell expressing a functional CRF2R,
CC determining whether the test compound binds to, or activates, the CRF2R
CC and identifying the test compounds that bind to, or activates, the CRF2R
CC as candidate compounds for regulating skeletal muscle mass or function.
CC The method is useful for preparing a medicament for treating skeletal
CC muscle atrophy or for propylactic treatment of muscular dystrophies. The
CC present sequence is a corticotropin releasing factor receptor
XX Sequence 411 AA;
SQ
Query Match 80.4%; Score 1793; DB 5; Length 411;
Best Local Similarity 80.0%; Pred. No. 1.1e-172; Indels 8; Gaps 4;
Matches 333; Conservative 30; Mismatches 45;
QY 1 MDSTIFEIIDFDANCILLDAFQDSFLHSESSSPFGEFP--YCSATIDQIGTCWPRSL 58
DB 1 MDAA---LLLSLENCSL--ALAEELLDGWEPPDPGPYSYCNITLDQIGTCWQSA 55
QY 59 AGELVERPCPSFNGIRYNTTENVRECFENGTSWMMYSCVPILDNK-RKYALHYKI 117
DB 56 PGALVERPCPEYFNGIKYNTTRNAVRECLENGTSWASRINYSCEPILDDKQKDYDLHYRI 115
QY 118 ALIINYLGHCSILALVIAFLFLCLRSIRCLRNIIHWNLIITFTILRNIMHLLQMDHN 177
DB 116 ALIINYLGHCVSVAALVAFLFLVLSIRCLRNVIHWNLIITFTILRNITWFLQLIDHE 175
QY 178 IHSENEVWCRCITTYNYFVTVTFWFMFVEGCGYLHTAIVMTYSTDKLRKWFLFGWCIP 237
DB 176 VHEGNEVWCRCVTITTFNFVTVTFWFMFVEGCGYLHTAIVMTYSTELRKLWFLFGWCIP 235
QY 238 SPIIVTWAICKLFYENEQCGWKEPKYIDYIYQGRVILVLLINFLVFLFNIVRIILMTKLR 297
DB 236 CPIIVAVAGKLYYENEQCGWKEPGDLVDYIYQGPILVLLINFLVFLFNIVRIILMTKLR 295
QY 298 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNFGEDDVSQIVFIYFNSFLSQGFV 357
DB 296 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNFGEDDLSQIVFIYFNSFLSQGFV 355
QY 358 SVFYCFNGEVSAAKRWRHWDHSLRVVRAMSIPTSPTRISFHSIKOTA 413
DB 356 SVFYCFNGEVSALRKWRHWDHSLRVVRAMSIPTSPTRISFHSIKOTA 411

Search completed: August 20, 2005, 00:25:30
Job time : 168 secs

This Page Blank (uspto)